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ABSTRACT

UNDERSTANDING THE SOLID STATE, SOLUBILITY AND DISSOLUTION
BEHAVIOR OF CEFUROXIME AXETIL DIASTEREOMERS IN INTERACTIVE
MIXTURE FORMULATIONS

By
Namita Dalal
December 2015

Dissertation supervised by Ira S. Buckner, Ph.D.
The objective of the first part of this work was to understand the solid-state and
solution behavior of a cephalosporin antibiotic prodrug, cefuroxime axetil (CFA). CFA is
present in commercial products as a mixture of diastereomers, which commonly form
eutectic mixtures. A phase diagram was constructed utilizing differential scanning
calorimetry. It was observed that the diastereomers formed a eutectic mixture with a
composition of 75 % isomer B and a melting temperature of 124.8±0.5 °C. Phase
solubility studies on diastereomer mixtures of various compositions showed that the
diastereomers interacted to form a complex in solution. This interaction resulted in a
solubility increase upon use of certain diastereomer combinations over any individual
diastereomer.

iv

A second major objective of this project was to study the dissolution behavior of
interactive mixtures containing CFA. Mechanically stable interactive mixtures were
prepared utilizing the amorphous and crystalline forms of the drug with hydrophilic
carrier particles. The dissolution rate of CFA was significantly higher from interactive
mixtures compared to both physical mixtures and pure drug agglomerates. The
enhancement in dissolution rate by interactive mixing was attributed to a decrease in
fraction of agglomerated drug particles and agglomerate particle size. Both these factors
produced an increase in effective surface area of drug available for interaction with the
dissolution medium.
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Chapter 1: Introduction

1.1 Background to Solid-State Chemistry of Chiral Drugs
More than half of commercialized Active Pharmaceutical Ingredients (APIs) are
chiral. API chirality may be essential for the biological activity of the compound. The
stereoselectivity of chiral drugs in pharmacology and toxicology has been studied
extensively. Stereoselectivity is based on differences in interactions between different
enantiomers and diastereomers of drugs having receptors and enzymes in the body, which
are themselves chiral.1, 2 In addition to the differences in the pharmacological effects of
chiral drugs, the physical properties of enantiomers, racemates, and diastereomers differ.
These differences can potentially affect the pharmacokinetic profile of the administered
drug and the development of a reliable and efficacious formulation and manufacturing
process. The following section provides an overview of the different solid-state structures
of chiral drugs and their analysis by commonly used techniques in literature.
1.1.1 Enantiomers, Racemates, and Diastereomers
Compounds with the same molecular formula but different chemical structures are
known as isomers. Unlike constitutional isomers that differ in the order in which the
atoms are connected (or functional groups), stereoisomers contain the same functional
groups; however, differ only in the arrangement of atoms in space. Optical isomerism is a
type of stereoisomerism which arises from differences in the three-dimensional
relationship of substituents around one or more atoms. Enantiomers are optical isomers
that are non-superimposable mirror images of each other. An equimolar mixture of
enantiomers is known as a racemic mixture or racemate. Diastereomers are pairs of
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compounds that contain more than one chiral center, all of which are not
superimposable.3 Unlike enantiomers, diastereomers do not differ in configuration around
all of the asymmetric carbon atoms. Consequently, the distances between non-bonded
atoms are different, causing changes in the overall conformation and polarities of
diastereomers. Each diastereomer molecule packs differently in a crystal lattice;
therefore, their crystals differ in physical properties such as solubility and melting
points.4 Conversely, enantiomers have the same physical properties and behave
differently when exposed to polarized light or when participating in a chemical reaction
catalyzed using a chiral compound, such as enzymes in the body.5, 6
Enantiomers and diastereomers may differ considerably in their pharmacological
and toxicological effects because they commonly interact with stereoselective biological
macromolecules such as enzymes and receptors. However, synthesizing chiral drugs in an
achiral environment leads to the formation of a racemic mixture. Unless a considerable
disadvantage is associated with the use of a particular enantiomer over a racemic mixture,
the mixture is most commonly employed because of the difficulty in resolving a racemic
mixture into single enantiomers.1 Because diastereomers have different solubilities, they
can be separated using solvent extraction methods. Diastereomeric salt formation, chiral
chromatography, and enzymatic separation are used to separate and resolve enantiomers.1
Differences between enantiomers and diastereomers influence how they pack in a
crystalline lattice. Although an understanding of the solid-state behavior of diastereomers
of cefuroxime axetil (CFA) is relevant to this project, a detailed description of phase
diagrams and the solid-state packing behavior of enantiomer systems is also presented
(Section 1.1.2 and 1.1.3). Because crystallization of diastereomers from an equimolar
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mixture can potentially produce one of several solid-state structures, a thorough
knowledge of the possible types of binary solid-liquid phase diagrams and the solid-state
structure they represent is essential when considering the crystallization of chiral drugs
from their mixtures.
1.1.2 Molecular Interactions and Solid-State Structures of Chiral Drugs
Differences in the strength and type of interactions between molecules with same
chirality and those between molecules with opposite chirality can have a significant effect
on the physical properties, namely solubility, of crystalline structures of chiral
compounds. Homochiral interactions are defined as intermolecular, non-bonded
attractions or repulsions in assemblies of molecules with same chirality, whereas
heterochiral interactions are those between molecules with different chirality. Homochiral
and heterochiral interactions are unlikely to be equivalent (∆Ghomo ≠ ∆Ghet, where G is the
Gibbs free energy) because they are diastereomeric in nature. This difference is
negligible in the gaseous or liquid state, or in an achiral solvent. However, these
differences are substantial to result in different physical properties of pure enantiomers or
diastereomers and racemates in a chiral medium or in the crystalline state.1, 5, 7
Mostly, crystallization from a racemic mixture yields a mixture of homochiral
(racemic conglomerate) or heterochiral (racemic compound) crystals (Figure 1.1a and
Figure 1.1b, respectively). A racemic conglomerate is an equimolar physical mixture of
homochiral crystals of two enantiomers that is mechanically separable. A racemic
compound is a heterochiral crystal (contains opposite enantiomers in the crystal lattice).
In some cases, the opposite enantiomers are arranged randomly in a crystal lattice as a
solid solution (also known as pseudoracemate) (Figure 1.1c). Racemic compounds are
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generally more abundant (90–95 % of crystalline racemates) than racemic conglomerates
(5–10 % of crystalline racemates). A higher occurrence of mixed crystals is due to their
higher entropy than their homochiral counterparts.1

Figure 1.1. Solid-state packing of chiral drugs (a) Racemic conglomerate (mixture of homochiral
crystals) (b) Racemic compound (heterochiral or paired enantiomers) (c) Solid solution
(pseudoracemate or randomly arranged enantiomers).

Unlike racemic mixtures that generally yield heterochiral crystals, diastereomers
usually crystallize from an equimolar solution as a conglomerate. Solvent extraction
methods can be used to further separate the individual diastereomers forming the
conglomerate based on the differing polarities of the diastereomers.
To ascertain the type of crystalline structure that chiral drugs can form on
crystallization, phase diagrams are constructed. The next section describes in detail the
use of phase diagrams for investigating the solid-state structure of chiral drugs.
1.1.3 Phase Diagrams of Chiral Drugs
The melting point phase diagram (solid-liquid phase diagram), which is
determined using thermal methods, can be used to ascertain the solid-state structure of
chiral drugs on crystallization. A solid-liquid phase diagram graphically represents the
thermodynamic conditions (temperature and composition) at which solid and liquid
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phases can exist in equilibrium. It consists of two equilibrium lines: (i) the liquidus line
marking the equilibrium temperature at which a liquid of a given composition starts to
crystallize; (ii) the solidus line reflecting the temperature below which a liquid cannot
exist in equilibrium.2
Various thermal methods, such as differential scanning calorimetry (DSC),
differential thermal analysis (DTA), and hot-stage microscopy (HSM), are available to
determine the solid-liquid phase diagram. These methods involve detecting the solid to
liquid phase change as a function of temperature and composition. Of the thermal
methods, DSC analysis is preferred because of its small sample size requirement and
ability to use slow heating and cooling rates for better resolution of thermal events. For
DSC analysis, mixtures containing various ratios of enantiomers or diastereomers are
prepared. In DSC, for thermally stable materials, the mixtures are heated in situ to form a
fused mass and subsequently cooled. The melting points of the thermal events observed
in the second heating cycle are recorded and plotted against the mixture composition.
Although thermal methods are most widely employed to construct phase diagrams,
caution must be exercised in their use to obtain reproducible results free from the
confounding effects of polymorphism exhibited by many organic compounds. The use of
thermal methods is limited to compounds that are thermally stable and non-volatile in the
temperature range used. Furthermore, the method of sample preparation and heating and
cooling rates employed are crucial for producing an accurate equilibrium phase diagram.
Heating rate affects the temperature at which thermal transitions are observed and
thermal events are resolved. In general, an increase in the heating rate shifts melting
temperatures to higher values because of thermal lag effects and results in decreased
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resolution of thermal events. Because melting temperature is required for constructing
phase diagrams from thermal data, it must be corrected for the effects of heating rate.
This correction involves heating individual samples of each mixture composition at
different heating rates and recording the onset or peak melting temperatures. The melting
temperatures are then plotted against the heating rate, and the intercept of this plot, which
represents the extrapolated melting temperature at zero heating rate, is used to construct
the phase diagram. The phase diagram of a racemic or diastereomer conglomerate shows
typical eutectic behavior. Eutectics are intimate mixtures of two distinct crystal forms
that are miscible in the liquid state. The unique property of a eutectic is that it has a lower
melting point than pure components.8, 9 For a racemic conglomerate, the liquidus
temperature at the equimolar point lies below all other liquidus temperatures, making the
equimolar point the eutectic composition and the temperature the eutectic temperature
(Figure 1.2a). Conversely, diastereomer conglomerates also exhibit eutectic behavior;
however, the eutectic composition does not necessarily occur at the equimolar point
(Figure 1.2b).
Figure 1.2c represents the phase diagram obtained when enantiomers crystallize
from an equimolar mixture to form a racemic compound (heterochiral crystal). The shape
of the diagram can vary depending on whether the melting point of the racemic
compound is higher or lower than that of the pure enantiomers. The phase diagram is
symmetrical around a central vertical line, and the racemic compound is a new crystalline
phase that forms eutectic mixtures with the two enantiomers.8, 9 Diastereomers have
different physical properties and typically do not form heterochiral crystals. However, the
formation of a particular crystal (homochiral or heterochiral) depends on differences in
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their structures making it vital to understand the different types of phase diagrams and the
solid-state structure they represent.

Figure 1.2. Typical phase diagram of melting point versus composition: (a) Racemic
conglomerate of enantiomers; (b) Conglomerate of diastereomers; (c) Racemic compound;
D and L represent a pair of enantiomers, R and S represent a pair of diastereomers, Cconglomerate, RC-racemic compound.

1.2 Solubility and Dissolution Studies on Multicomponent Mixtures
1.2.1 Phase Solubility Analysis
When a solute is placed in a solvent, the solute molecules break away from the
solid surface. Some solute molecules redeposit on the bulk solute surface, whereas others
move randomly into the solvent to form a solution. Once sufficient solute molecules have
populated the bulk solvent, the rate of molecules leaving the solute surface becomes
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equal to the rate of deposition (dynamic equilibrium). The solute concentration in the
solvent at which this equilibrium is reached is known as the saturation solubility or
equilibrium solubility. The saturation solubility of a pure compound in a given solvent, at
a given temperature and pressure, is a characteristic physical property of the substance,
and may, therefore, be used as a criterion of purity. If a sample containing the
thermodynamically stable crystalline form of pure compound exhibits solubility in excess
of that expected, the additional quantity may be ascribed to the presence of a second
component, such as an impurity. In case of pure compounds, the experimental operation
of measuring saturation solubility consists of adding excessive solid sample to a constant
volume of solvent in which the solid is slightly soluble. The systems are brought to
equilibrium by prolonged agitation at a constant temperature. The solution phases are
then analyzed for total solute content, mostly by using spectroscopic or chromatographic
assay methods. The experimentally determined solution concentration (usually expressed
in mg/mL or M) can be plotted against time to illustrate dissolution behavior. Initially,
the solid dissolves and the concentration increases. This increase occurs until the solution
becomes saturated with respect to the compound, following which a line with a zero
slope is obtained. Extrapolation of this line to the vertical axis yields the saturation
solubility of the compound. Similarly, for a mixture of components, the solubilities of the
individual components can be determined using a method similar to that used to measure
the solubility of a pure compound, provided that the solubility of each component is not
affected by the other component(s) present. However, many systems do not exhibit this
ideal behavior and undergo molecular interactions to form complexes in solution. In case
of interaction, the differentiation between the amount of free compound dissolved and
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that dissolved in combination with the other component complicates solubility
measurements. The types of phase solubility diagrams obtained in this case are described
in detail as follows.
The general experimental operation in studying molecular interactions by means
of solubility measurements entails adding an excess amount of a slightly soluble
compound (X) to a fixed volume of solvent at a certain temperature according to the
method of Higuchi and Connors.10 Then, successively increasing portions of a relatively
soluble compound (Y) is added to the vessels, which is sealed and equilibrated at
constant temperature. The solution phase is then analyzed for the total solution
concentration of X, regardless of its molecular state. A phase diagram is constructed by
plotting the total molar concentration of X in the solution phase on the vertical axis
against the molar concentration of Y added to the system. The following phase diagrams
are commonly obtained:
(a) Type A diagrams: These show an apparent increase in the solubility of X caused
by component Y.
(b) Type B diagrams: These show a decrease in the solubility of X caused by
component Y.
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(a) Type A diagrams (Figure 1.3)

Figure 1.3. Phase-solubility diagrams of Type A systems showing an apparent increase in
solubility of X caused by Y. Adapted from Higuchi and Connors.10

Xt represents the total molar concentration of dissolved X, and Yt is the total
concentration of Y. X0 represents the equilibrium solubility of X in the absence of Y. A
linear increase in solubility is represented by line AL, whereas positive and negative
curvatures in the line are indicated by AP and AN, respectively. Type A diagrams indicate
the formation of soluble complexes between X and Y. A solid phase containing pure X is
always present; therefore, the thermodynamic activity of free X in solution is constant.
If complexes are of the first order in Y or may be written as XmY (where m is the
number of moles of X in the complex), then a Type AL diagram is observed. If they are of
a higher order in Y, such as XYn (where n is the number of moles of Y in the complex), a
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Type AP diagram is observed. The origin of a Type AN diagram is uncertain. It may be
associated with a change in the complex formation constant or self-association of Y at
high concentrations. In certain instances, Type A diagrams may exhibit a plateau level of
X that additional quantities of Y do not alter. This may be due to the disappearance of
solid X from the system by its complete solubilization. To express the solubility behavior
of a system with interacting components forming soluble complexes, the following mass
action equations are used. These equations are derived assuming 1:1 complex formation.
Suppose that a single complex, XY, is responsible for the increase in the apparent
solubility of X. The equation representing this reaction can be expressed as:
X aq  Yaq ⇄ XYaq

K

(1.1)

XY aq
X aq Y aq

(1.2)

The concentrations can then be expressed in terms of known quantities as follows:

X aq  X 0 

(1.3)

XY aq  X t   X 0 

(1.4)

Y aq  Yt   XY aq

(1.5)

where X 0 is the equilibrium solubility of X in the absence of Y, X t is the total
concentration of dissolved X regardless of the molecular state, and Yt is the total added
concentration of Y. Type AP phase diagrams may represent the formation of two
complexes, XY and XY2 ,characterized by the following constants:
K1:1 

XY 
X Y 

(1.6)
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K1:2 

XY2 
XY Y 

(1.7)

(b) Type B diagrams
Type B diagrams (Figure 1.4) are observed when insoluble complexes are
formed. In curve Bs (Figure 1.4), from point X0 to point a, the apparent solubility of X
increases because of soluble complex formation between X and Y. At point a, the
solubility of the complex is reached. Adding more Y causes more complex formation,
which precipitates keeping the concentration of uncomplexed X constant. At point b,
entire solid X is converted to a complex, and adding more Y results in the depletion of X
in the solution through complex formation and concomitant precipitation of the insoluble
complex. The curve Bl can be understood in the same manner, except that the complex
formed is so insoluble that the initial rise in the concentration of X is undetectable. These
diagrams may sometimes show an increase in solubility beyond point c, apparently due to
the formation of another complex species that is more soluble than the one responsible
for the descending portion of curve b-c.
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Figure 1.4. Phase solubility diagram of Type B systems. Adapted from Higuchi and Connors.10

1.2.2 Dissolution Model for Binary Mixtures of Non-Interacting Components
When a uniform, non-disintegrating, intimate mixture of two crystalline
components, A and B, is exposed to a solvent, both components begin to dissolve at rates
proportional to their solubilities and diffusion coefficients, according to the NoyesWhitney equation (Equation 1.8):
dW DS

(C s  Cb )
dt
h

(1.8)

where dW / dt is the dissolution rate, D is the diffusion coefficient, S is the effective
surface area and h is the hydrodynamic boundary layer thickness, C s is the saturation
solubility, and Cb is the instantaneous concentration in the bulk solution at time t .
Initially, the dissolution rate (R) of components A and B from a compact of constant
surface area under sink conditions can be expressed as:
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D C
RA  A A
h

0

D C
RB  B B
h

0

(1.9)

(1.10)

where D A and DB are the diffusion coefficients of components A and B, respectively, and
0

0

C A and C B are the saturation solubilities of components A and B, respectively.

After a short period, usually one of the components becomes depleted in the solid-liquid
0

D C
N
interface of the solid compact. This occurs when A is not equal to A A 0 , where NA
NB
DB C B
and NB represent the amount of A and B in the compact respectively. Consequently, a
surface layer is formed made up of only one of the components. Therefore, at t > 0, one
of the following cases as shown in Figure 1.5 can exist:

A
+
B

Case 1

A
+
B

A
+
B

B

Case 2

A

Case 3

Figure 1.5. Dissolution of two-component solids. Case 1: critical mixture composition where A
and B coexist at the compact surface; Case 2: component A dissolves quickly to leave a layer of
component B at the compact surface; Case 3: component B dissolves quickly to leave a layer of
component A at the compact surface.

Case 1 (Critical mixture composition): Here, components A and B coexist at the solidliquid interface. This occurs when the following condition (Equation 1.11) is met:
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0

N A D AC A

N B DB C B 0

(1.11)

In this case the dissolution rates of components A and B can be determined using
Equations 1.9 and 1.10, respectively.
Case 2: This case arises when the mass fraction of B in the solid compact is higher than
its rate of dissolution, such that a porous layer of B is formed on the compact surface.
This condition is represented by the following equation (Equation 1.12):

N A D A CA 0

N B DB C B 0

(1.12)

The dissolution rate of component B can be determined using Equation 1.10 whereas
that of component A can be calculated from Equation 1.13:

RA 

NA
RB
NB

(1.13)

Case 3: This situation case arises when the mass fraction of A in the solid compact is
higher than its rate of dissolution, such that a porous layer of A is formed on the compact
surface. This condition is represented by the following Equation 1.14:
0

N A D AC A

N B DB C B 0

(1.14)

The dissolution rate of component A can be determined using Equation 1.9 whereas that
of component B can be calculated from Equation 1.15:

RB 

NB
RA
NA

(1.15)
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The dissolution model for binary mixtures of non-interacting components is based
on two main assumptions. The first is the steady-state approximation. The equations
describing dissolution rate of each component from binary mixtures are applicable only
after the surface layer of component B or A is formed on the solid compact (Case 2 and
Case 3, respectively). If the two components have comparable solubilities (less than an
order of magnitude), then the time required to reach steady-state is short. The other
assumption, when deriving the aforementioned equations, is that the porous surface
layers do not change in any substantive manner, other than they enlarge during
dissolution. In other words, the porosity of the growing surface layer does not change as
dissolution proceeds.
Shah et al. applied the equations for dissolution rates, described earlier, to aspirinsalicylic acid mixtures and phenacetin-caffeine mixtures of various compositions. The
experimental dissolution rates were determined and compared with the theoretical values.
The experimentally measured dissolution rates were in good accordance with the
theoretically predicted rates. The results obtained with solid mixtures prepared using the
melt method deviated lesser from theory than those prepared using compression, because
of a more intimate mixing of components in the melt preparations. An increased content
of caffeine in phenacetin-caffeine mixtures led to deviations of the experimental
dissolution rates from those theoretically calculated. This was attributed to the high
solubility of caffeine that caused flaking and an increase in effective surface area of the
compact.11, 12 Therefore, the equations developed by Higuchi et al. for calculation of the
dissolution rate of each component from a binary mixture can be suitably applied to
compacts containing two materials, such as two drugs or a drug-excipient mixture.
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1.2.3 Dissolution Model for Binary Mixtures of Interacting Components
Higuchi et al. developed a model to predict the dissolution rate of mixtures of
components that interact in solution to form soluble complexes. Assuming that the only
interaction involves a solution reaction represented by: A  B  AB , the equilibrium
constant of this reaction can be written as:

K

C AB
C AC B

(1.16)

where C A , C B , and C AB are the concentrations of components A, B, and AB complex,
respectively. When phase A dissolves slower than phase B (Figure 1.5, Case 3), leaving
a layer of solid depleted of B, the dissolution rate of A ( R A ) at a steady state, can be
written as:

R A  DA

dC A
dC AB
 DAB
dX
dX

(1.17)

where D A and D AB are the diffusion coefficients for unbound A and the complex,
respectively and X is the spatial coordinate in the direction of diffusion in the liquid
diffusion layer. Accordingly the dissolution of component B can be written as:

RB  DB

dC B
dC AB
 DAB
dX
dX

(1.18)

Equations 1.17 and 1.18 may be integrated over the limits with boundary conditions:
At X = 0 (solid–liquid interface) of the solid compact:


0

C A  C A , C B  C B and C AB  C AB
At X = h (the bulk solution):
C A  CB  C AB  0

17



0
where C A is the equilibrium solubility of A, and C B and C AB are the concentrations of
free B and the complex at the solid-solution interface. Integration of Equations 1.17 and
1.18, leads to the following pair of equations:

R A h  DAC A  DAB C AB
0



(1.19)



RB h  DB C B  D AB C AB

(1.20)

At steady state, Equation 1.21 holds:
RA 

NA
RB
NB

(1.21)

Solving Equations 1.16, 1.19–1.21 results in the following:

D AC A

RAh 
1

RB h 

0

N B D AB KC A

(1.22)

0

N A ( DB  D AB KC A )
0

D AC A

0

(1.23)

0

NA
D AB KC A

N B DB  D AB KC A 0
Similarly when pure B is the surface phase, the dissolution rates of the

components can be calculated using the following equations:
0

RB h 
1

RAh 

DB C B
0
N A D AB KC B

(1.24)

N B ( DB  D AB KC B )
0

DB C B

0

(1.25)

0

NB
D AB KC B

N A D A  D AB KC B 0

For the critical mixture case:
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X = 0, C A  C A and C B  C B
0

0

X = h, C A  C B  0
Therefore,

RA h  DAC A  DAB KCB C A

0

(1.26)

RB h  DB CB  DAB KCB C A

0

(1.27)

0

0

0

0

Shah et al. applied these equations to binary mixtures of aspirin and caffeine and
Higuchi et al. applied it to benzocaine-caffeine mixtures. Both studies indicated that the
theory suitably agreed with experimental observations. Deviations were attributed to the
assumption of a 1:1 complex in the derivation of the equations.12
1.3 Background to Dissolution Rate-Limited Oral Bioavailability
The number of poorly water-soluble drug candidates in contemporary
pharmaceutical pipelines has recently increased, and this has been largely attributed to
the use of combinatorial chemistry and high-throughput screening assays in drug
discovery.13-16At present, approximately 70 % new drug candidates and approximately
40 % marketed immediate-release drugs exhibit poor aqueous solubility, posing a hurdle
for formulation scientists working on oral delivery. Several problems arise from the poor
solubility of drug candidates in research and development. The aqueous solubility of a
drug is a critical determinant of its dissolution rate. The limited dissolution rate arising
from low solubility frequently results in poor bioavailability of orally administered drugs.
This is particularly important for Biopharmaceutics Classification System (BCS) Class II
drugs (low solubility, high membrane permeability) and BCS Class IV drugs (low
solubility, low membrane permeability).14, 17 In such cases, high drug doses are generally
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given to achieve therapeutic drug concentrations. However, administering large doses can
result in toxicity and poor patient compliance making it imperative to develop
formulation strategies for dissolution rate enhancement. The drug concentration in the
gastrointestinal tract is determined by the dissolution rate, whereas the upper limit is its
solubility. Therefore, the oral absorption of BCS Class II drugs can be solubility-limited
or dissolution rate-limited. Solubility-limited absorption occurs when the dose to
solubility ratio (defined as the volume of gastrointestinal fluids required to dissolve the
administered dose) is high. In this case, the maximum achievable concentration limits
absorption such that, neither an increased dose nor particle size reduction improves oral
bioavailability. The concept of solution supersaturation using high energy solid forms,
such as metastable polymorphs or amorphous solid forms, solubilized formulations and
solid dispersions is commonly used to overcome solubility-limited bioavailability.
Dissolution rate-limited bioavailability occurs when the drug dose is soluble, but the time
required to dissolve it is greater than the time required for gastrointestinal transit.
Dissolution rate limitations can be overcome by an increased dose, particle size
reduction, or increased solubility.18, 19-21 Several methods are available to increase the
dissolution rate, which can be understood by considering the Noyes-Whitney equation as
explained below.
Noyes and Whitney studied the dissolution of two sparingly soluble compounds,
benzoic acid and lead chloride by maintaining a constant surface area.22 The dissolution
rate (mass dissolved per unit of time) was proportional to the difference between the
instantaneous concentration, Cb, at time t and the saturation solubility, Cs, according to
the following equation:
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dW
 k (C s  Cb )
dt

(1.28)

where dW/dt is the dissolution rate, and k is a constant. Nernst and Brunner modified this
equation to incorporate the diffusion layer concept and Fick’s second law of diffusion
and obtained Equation 1.8 (Section 1.2.2). It was assumed that drug diffusion across a
stagnant diffusion layer was the rate-limiting step in dissolution.23 Based on this analysis,
the main possibilities of improving dissolution rate are to increase the surface area,
enhance wetting of the solid, decrease the boundary layer thickness, ensure sink
conditions during dissolution, and improve the solubility of the drug.23, 24 Changes in
in vivo hydrodynamics are difficult to impose and the maintenance of sink conditions
depends on drug permeability and the gastrointestinal fluid volume available. Therefore,
the major factors that can be altered to improve dissolution rate are solubility and surface
area. Solubility is dependent on the crystal lattice energy and the affinity of the solute for
the solvent. Therefore, reduced intermolecular interaction in the solid-state and an
increased strength of solute-solvent interaction results in an improved dissolution
rate.24, 25 Furthermore, an increase in the surface area of the solid drug available for
dissolution by particle size reduction can also increase dissolution rate. These approaches
are discussed in the next section.
1.3.1 Formulation Strategies for Dissolution Rate Enhancement
1.3.1.1 Solubility Modification
Solubility, is a key factor in the modified Noyes–Whitney equation (Equation
1.8), as combined with the already dissolved drug concentration and the boundary layer
thickness it is used to determine the concentration gradient across the boundary layer,
which is the driving force for dissolution. Several factors influence drug solubility in the
21

gastrointestinal tract, such as the solid form of the drug, pKa of the drug (or salt form) and
solubilization by native surfactants. However, formulation strategies for solubility
modification most commonly involve using metastable polymorphs or amorphous solid
form of the drug; developing salt forms and soluble prodrugs, and crystal engineering
approaches such as co-crystals; and using solubility enhancing excipients such as
cyclodextrins.
Crystalline solids that differ only by the arrangement and packing of drug
molecules in the crystal lattice are known as polymorphs. Polymorphs differ in free
energy and exhibit different physicochemical properties such as density, melting point,
solubility, and stability.25 Solubility differences between polymorphs are due to
differences in crystal lattice energy; such that metastable polymorphs with lower lattice
energies have higher solubility than thermodynamically stable crystal forms. The
solubility difference between polymorphs is typically less than two-fold, although
occasionally higher ratios have been observed.26, 27 For example, the solubility ratio of
tolbutamide polymorphs (IV/II) and polymorph (I/II) was 1.5 and 1.1, respectively.27
Further increase in solubility can be obtained using the amorphous form of the drug, that
lacks the long-range order of molecular packing, unlike its crystalline counterpart. The
difference in solubility between the amorphous and the crystalline form has been reported
to be between 1.1to 1000 fold.27 The marked enhancement in the solubility of an
amorphous drug may lead to a significant improvement of oral bioavailability. Although
the use of high-energy solid forms is an effective approach to increase solubility and
thereby dissolution rate, these forms have the ability to convert to the thermodynamically
stable crystalline form with a lower solubility, making it necessary to monitor the
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possibility of any transformation during manufacturing, storage, and dissolution testing.
Creating amorphous solid dispersions (ASD) with suitable polymeric excipients and
surfactants is a widely used technique to stabilize the amorphous state of the drug and
lower the propensity of phase transformation to the crystalline form. Amorphous solid
dispersions facilitate in stabilizing the amorphous drug by physically intercalating the
drug molecules between the side chains of the polymeric carrier, thereby reducing
molecular mobility and lowering the tendency for recrystallization.28, 29 Drug
maintenance in the amorphous state, local increases in solubility and wettability, and
increase in the surface area as the carrier dissolves contribute to dissolution rate
enhancement from an ASD. An amorphous solid dispersion (ASD) of ER-34122 (a novel
5-lipooxygenase/cyclooxygenase inhibitor) showed an approximate 100-fold increase in
Cmax and AUC compared to the pure drug, when administered orally to beagle dogs.30
The salt formation approach is widely used to increase the solubility of ionizable
drugs due to interactions of charged ions with solvent molecules. Changes in pH at the
surface of the dissolving salt particle results in a higher dissolution rate of salts compared
to free forms.31 In one study, the mesylate salt of LY333531 (a potent protein kinase
inhibitor) had a 2.6 times higher Cmax and AUC in dogs than that with an equivalent dose
of the hydrochloride salt.32Crystal engineering approaches such as the use of co-crystals
is also a popular method for increasing dissolution rate. Co-crystals are crystalline solids
containing multiple components held together by noncovalent intermolecular forces.33, 34
Co-crystals of AMG 517 (a potent and selective VR1 antagonist) with sorbic acid showed
a higher dissolution rate in a fasted state simulated intestinal fluid and a 9.4-fold higher
AUC compared to the free base form of the drug when administered to dogs.34

23

Soluble prodrugs have been used to overcome the solubility limitation of poorly
soluble drugs. The two main strategies to produce soluble prodrugs are derivatization
with a promoiety designed to decrease the drugs melting point and/or introduction of an
ionizable functional group.35 A phosphate ester prodrug (Etopofos) of etoposide showed a
10-fold increase in Cmax compared to etoposide and an AUC twice that of the parent drug
when administered orally to rats.36, 37 This approach is valuable because the phosphate
prodrug is converted to etoposide within 5 min in plasma.
Although the approaches previously described are widely used to enhance
dissolution rate, there are limitations to the use of these techniques. For example, salt
formation is not applicable for neutral compounds and even when salts are formed, a risk
of the reconversion of the salt to the poorly soluble free form, during dissolution exists.31
High solubility of metastable polymorphs and amorphous solids makes their use in
dissolution rate enhancement popular. However, there is a risk of transformation of a
“high-energy” solid form to the stable crystalline form during storage and dissolution.
This can result in variable bioavailability of formulations containing metastable solid
forms. Furthermore, the commercial use of amorphous solid dispersions has been limited
because of manufacturing and handling difficulties, making dosage form development
and scale-up challenging. Physical instability, such as drug crystallization in dispersions
during storage is also a major problem limiting their use.29 In addition, the safety and
toxicity of co-crystal forming agents are serious drawbacks to their widespread utility.25
Particle size reduction is an attractive option for dissolution rate enhancement
because it is applicable to drugs regardless of their chemical characteristics. The next
sections (Sections 1.3.1.2 and 1.3.1.3) describe the mechanism of dissolution rate
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enhancement achieved by size reduction, methods to achieve size reduction, and
problems associated with these methods.
1.3.1.2 Particle Size Reduction
Particle size reduction leads to an increased surface area available for solvation
and thereby, an increase in dissolution rate based on the modified Noyes-Whitney
equation (Equation 1.8). Based on the inverse relationship between particle size and
specific surface area (SSA), drug micronization and nano-sizing techniques have been
widely used to improve the oral bioavailability of poorly soluble drugs. However, the
effects of particle size reduction in increasing dissolution rate cannot be solely explained
by the increase in surface area. According to the Prandtl boundary layer equation
(Equation 1.29), a decrease in particle size (below 2 µm) results in a thinner
hydrodynamic layer ( hD ) around the particles, which is attributed to their increased
curvature, thereby resulting in an increase in dissolution rate.38-41

hD  k (

L1 / 2
)
V 1/ 2

(1.29)

where k is a constant, L is the particle length on which liquid flows at constant velocity
and V is the velocity of fluid flow.
An increase in the dissolution rate upon nano-sizing (particle size < 1 µm) may
also be attributed to increased saturation solubility, as explained using the OstwaldFreundlich equation (Equation 1.30):
S  S  exp(

2M
)
rRT

(1.30)

where S is the solubility of the nanosized API, S∞ is the saturation solubility of an
infinitely large API crystal or a plane surface, γ is the crystal-medium interfacial tension,
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M is the molecular weight, r is the particle radius, ρ is the density of the crystal, R is the
gas constant, and T is the absolute temperature.42-45 The Ostwald-Freundlich equation is
derived from the Kelvin equation, according to which the vapor pressure of liquid
droplets in the gas phase increases with increasing curvature of the surface, implying a
decreasing particle size. In addition to the effects of particle curvature on size reduction,
milling techniques used for micronization and nano-sizing can cause small defects in the
crystal lattice particularly on the particle surface, which weaken the solute-solute
interactions in the lattice, resulting in an increased apparent solubility.46, 47
Particle size manipulation may be obtained using either “top-down” processes,
where large particles are fragmented into small particles, or using “bottom-up” processes
in which small particles are harvested after drug recrystallization from a supersaturated
solution. Top-down processes are usually dry impact methods that introduce considerable
shear forces and reduce the particle size of coarse drug powders, using ball mills, hammer
mills, and air-jet mills. However, some powder materials are prone to phase
transformation upon dry milling. Further the heat generated upon attrition may not be
suitable for low melting point drugs or thermolabile materials.48-50 Alternatively, topdown wet milling methods, such as pearl milling, can produce particles in the nanometer
range. In this method, an aqueous drug slurry with surfactants and/or polymers is stirred
with hard milling beads.51-53 High-pressure homogenization is another wet milling
method used to produce nanoparticles.54, 55
Bottom up approaches for particle size reduction and nanosizing involve
controlled precipitation or crystallization of the drug from a supersaturated solution. The
first step involves creating a supersaturated solution followed by nucleation and crystal
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growth; therefore, the success of this approach is dependent on a high supersaturation
level. Sonication is usually applied to prevent crystal growth and particle agglomeration,
and results in production of particles with a narrow size distribution.55-56
Based on the increase in SSA and consequently increased dissolution rate, after
particle size reduction, several studies have used micronizing and nanosizing of poorly
soluble drugs in an attempt to improve oral bioavailability. In one study, cilostazol (an
antiplatelet agent) suspensions with different particle size distributions were prepared
using hammer-milled crystals (d50 13 µm), jet-milled crystals (d50 2.4 µm), and
NanoCrystal® spray-dried powder (d50 0.22 µm). This study showed a significant effect
of particle size reduction on dissolution rate. Approximately 45 % of the drug was
dissolved in 60 min from the hammer-milled suspension, 80 % was dissolved within
15 min from the jet-milled suspension, and an almost instantaneous dissolution was
observed from the spray-dried powder. In vivo studies in beagle dogs indicated that the
AUC of the spray-dried suspension was 6-fold higher than that from the other
suspensions.57 In another study, aprepitant powder was reduced in size from 5.5 µm to
120 nm using a wet-media milling method. Compared to the micronized particles, the
surface area of the nanoparticles increased 42-fold and AUC0-72h increased 4-fold when
administered orally to beagle dogs.58
1.3.1.3 Negating Particle Size Reduction: Agglomeration Problem
Although particle size reduction resulting in surface area increase is a commonly
used approach to enhance dissolution rate, in some cases reduced rates have been
reported. This has been attributed to the agglomeration of micronized particles. It is well
established that fine particles (< 100 µm) are cohesive and tend to agglomerate as the
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magnitude of inter-particle forces exceeds the particle weight.59 Several forces are
responsible for particle agglomeration as discussed below:
Van der Waals forces: These forces occur because of electron movement to form dipoles,
which in turn are attracted to other dipoles nearby and are significant at inter-particle
distances of 0.2–1 nm. The van der Waals force ( Fvdw ) between two smooth spheres is
given by:

Fvdw 

AR
12d 2

(1.31)

where A is the Hamaker constant of the material, R is the radius of curvature of a two
particle system, and d is the distance between the spheres.60-63 This force is proportional
to the particle diameter compared to the gravitational force, which is proportional to the
cube of the particle diameter. Therefore, van der Waals forces become negligible, relative
to gravitational forces, in systems where the particle diameter exceeds a certain value of
the order of a few microns. The van der Waals force between a sphere (1) in contact with
a flat surface (2) is larger in magnitude than that between two spheres of the same radius
and is given by the following equation:

Fvdw 

AR
6d 2

(1.32)

Contact area, surface roughness, and radii of asperities also affect the magnitude
of this force. Surface roughness can cause a reduction in the area of contact on which van
der Waals forces act. The effects of surface roughness on force are dependent on the
nature of the roughness. Consider a system of two particles; if surface asperities on the
surface of one of the particles are smaller than the diameter of the other particle, then the
contact area is reduced resulting in a decrease in the magnitude of the van der Waals
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forces between the particles. The situation is reversed when the asperities are larger than
the other particle. This concept is illustrated in Figure 1.6.60, 61

Figure 1.6. Effects of surface roughness on contact area: (a) asperities smaller than particle size;
(b) asperities larger than particle size.

Electrostatic forces: Contact between particles of different materials or particles with
equipment surfaces causes’ electron exchange. Because most pharmaceutical powders are
electrical insulators, electron accumulation on particle surfaces causes the particles to
remain charged even after separation (triboelectric charging). The force acting between
two particles with charges q1and q2 is expressed as:

Fe 

q1 q 2
4 0 d 2
1

(1.33)

where ε0 is the vacuum permittivity and d is the distance between the particles.
Electrostatic forces may be several orders of magnitude smaller than van der Waals
forces particularly at higher relative humidities.60, 62
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Capillary forces: This force develops because of capillary condensation of water at the
points of contact between particles at higher relative humidities (65–80 %). The capillary
force ( Fc ) between a spherical particle (1) and a flat surface (2) can be calculated as:

Fc  2r (cos 1  cos  2 )

(1.34)

where r is the radius of the particle,  1 and  2 are the contact angles between the two
bodies in contact with a liquid and  is the surface tension of the liquid. Various factors
such as surface roughness and particle wettability influence the magnitude of this force.62
Various factors such as particle size, inter-particle distance, and atmospheric
humidity determine the magnitude of inter-particle forces. In general, a very short acting
range of these forces make them less significant as the inter-particle distance increases.
Agglomeration of micronized particles causes a fraction of the particles’ surface
area being enclosed within the agglomerates and unavailable for dissolution. This causes
the effective surface area term in the modified Noyes-Whitney equation (Equation 1.8)
to be considerably lower than the total surface area of the drug particles. The
agglomeration effect along with the poor wettability of hydrophobic drug surfaces causes
a smaller increase in dissolution rate than that theoretically expected from the specific
surface area of the solid.
Crison et al. studied the dissolution profile of two particle size fractions of a
poorly soluble drug: the bulk drug with an average diameter of 29 µm (±2.1 µm) and
micronized drug particles with an average diameter of 4 µm (±1.6 µm). They observed
that the dissolution rate from the micronized particles was significantly lower than that
predicted using the Hixson-Crowell cube root equation. This observation was attributed
to the re-agglomeration of micronized particles which was confirmed by optical
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microscopy.64 Similar effects of agglomeration on the dissolution rate was also observed
in a study involving cefuroxime axetil nanoparticles.65
Another example of agglomeration behavior was observed in nifedipine
dissolution. The percent drug dissolved at 30 min (Q30) for several size fractions with
d99 values of 233.23±18.82 µm (N1), 36.79±1.31 µm (N2), and 29.94±4.70 µm (N3)
were compared. The Q30 values increased from 13.9±2.9% to 23.1±2.7% with a decrease
in d99 from 233.23 m to 36.79 m. However, further size reduction decreased the Q30
value to 18.8±1.8% for N3. This decrease was caused by the agglomeration of the smaller
size N3 particles, resulting in low effective surface area and dissolved amount.64
1.4 Interactive Mixtures for Dissolution Rate Enhancement
1.4.1 Concept
When the difference in particle size between two components is sufficiently large
(one or two orders of magnitude), the small particles tend to adhere to the larger particles
because the inter-particle adhesion force between these two particles exceeds the weight
of the smaller particle.59, 61, 66-68 Hersey coined the term “ordered mixtures” to describe
mixtures that are expected to result from the adherence of fine particles of one constituent
to the considerably coarser particles (carrier particles) of a second constituent.69 The term
“interactive mixtures” used by Egermann described these mixtures more appropriately,
because adhesion is fundamentally a mechanism of interaction and not of order. Ordered
systems can only be achieved when an identical (or almost identical) number of
monosized fine particles (usually drug particles) adhere to each carrier particle producing
mixtures having a higher degree of homogeneity than random mixtures.64-70 Therefore,
the term “interactive,” which has no relation to the actual degree of homogeneity
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achieved, is used throughout this dissertation to describe mixtures consisting of fine
particles adhered to coarse carriers.70-72 Interactive mixtures have been used in the
pharmaceutical industry to minimize segregation, and improve flow and tableting
properties and dissolution rates of poorly soluble drugs.67, 73, 74
Interactive mixture formation occurs in three steps shown in Figure 1.7.67, 75 The
first step in this process involves breakdown of agglomerated micronized drug particles
into smaller agglomerates or primary drug particles. Agglomerate breakdown occurs
when the carrier particles impact the agglomerates during the mixing process. The high
ratio of carrier material to drug leads to a large carrier surface available to interact with
drug particles. In the next step (Step 2), the carrier and drug particles collide resulting in
the bonding of the drug particles with the carrier surface. Because of the large size
differences between the fine drug particles and the coarse carrier particles, the interparticle contact can be approximated as a sphere (drug particle) in contact with a flat
surface (carrier particle). A larger magnitude of van der Waals force between a sphere
and flat surface (Equation 1.32) than that between two spheres of the same size
(Equation 1.31) is responsible for keeping the drug particles adhered to the carrier
surface. Other inter-particle adhesive forces include capillary and electrostatic forces.
Finally, redistribution and exchange of the drug particles among the carrier particles
occurs after a uniform mixture is formed (Step 3).63
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Figure 1.7. Schematic representation of steps involved in the interactive mixing process: pinkcarrier particles; blue-micronized drug particles.

1.4.2 Methods of Preparation of Interactive Mixtures
Mechanically stable interactive mixtures are formed when the adhesive force
between the coarse carrier particles and the micronized drug particles is greater than the
cohesive force for either component. This is essential for the micronized drug particles to
adhere to the carrier surface.72 Some methods used to achieve this are discussed below.
Dry mixing: This process involves impaction and collision of the carrier particles with the
agglomerates of the micronized drug particles. Tumbling mixers such as V-blenders,
Turbula mixers, and cube mixers are used for this purpose. This method is commonly
used to produce interactive mixtures because of its simplicity and the absence of shear
forces that might affect thermolabile drugs or fragment carrier particles.74, 75
Triboelectrification: Pharmaceutical powders are prone to electrostatic charging known
as triboelectrification by colliding and sliding contacts with equipment walls and other
particles. Electron transfer occurs between the components, and the high resistivity of
pharmaceutical materials prevents the transferred charge from leaking back. Therefore,
these materials acquire a positive or negative charge depending on their electronic
properties.76, 77 This phenomenon can be used to form interactive mixtures. In this case,
carrier and drug particles can be given opposite charges through triboelectrification,
which reduces cohesion and enhances adhesion. In one study, fine potassium chloride
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particles coated with positively charged polymers adhered to negatively charged sugar
particles. The segregation tendency of the triboelectrified powder mixtures was less than
conventional mixtures.77
Dry impact blending: In this method, large impulsive forces are used to firmly attach the
fine particles on the carrier particles, for example, Mechanofusion® and Hybridizer®
equipment. The Mechanofusion® equipment uses compression and frictional forces to
cause surface fusion and embedment of the fine particles on the carrier surface.74, 78
Magnetically assisted impaction coating (MAIC): A magnetic field is used to accelerate
and spin magnetic particles mixed in with fine drug and coarse carrier particles
promoting collisions between them and leading to embedment of fine particles on the
carrier. This method has been used to coat cornstarch with fine silica particles to improve
flowability.79
Adhesion and coating: In these methods, binders and/or granulating agents may be used
to enhance the adhesion between the micronized drug and carrier particles, thereby
improving the mechanical stability of the mixtures. Supercritical fluid-based coating
techniques and deposition of drug particles dispersed in a solvent on carriers are also
used.80-82
The dry mixing method has been most commonly used for preparation of
interactive mixtures for dissolution rate enhancement. This is because all the other
methods described result in the formation of relatively strong adhesive forces between the
components. An important prerequisite for dissolution rate enhancement involves
detachment of drug particles from the carrier surface, making the dry mixing method the
most suitable method for dissolution rate enhancement.
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1.4.3 Mechanism of Dissolution Rate Enhancement of Interactive Mixtures
Most of the inter-particle forces responsible for interactive mixture formation
have reduced magnitude in liquid media as discussed below. This is important for
releasing dispersed drug particles (or small clusters) from the carrier surface. Once the
particles are released from the carrier, enhanced wetting and large effective surface area
causes faster dissolution.
Van der Waals forces are the dominant interaction forces between particles
comprising an interactive mixture, and operate both in vacuum and in liquid
environments, although in the latter case the force is considerably reduced.83, 84 Van der
Waals interaction force between a sphere of radius R (1) and flat surface (2) is given by
Equation 1.32 (Section 1.3.1.3), where the Hamaker coefficient A12 between the two
components can be obtained to a good approximation by:

A12  A11 A22

(1.35)

where A11 and A22 are the individual coefficients in a vacuum or gas environment. For a
three-component system, namely two materials (1 and 2) in a liquid environment (3), the
coefficient is written as:
(1.36)

A132  ( A11  A33 )( A22  A33 )

It is possible for the coefficient to attain a negative value, or give conditions
where the van der Waals force is negative, such as when A132 <0, or when A11 < A33<
A22.82, 83 Consequently, immersion in water leads to a substantial reduction in Fvdw. Lower
the individual value of the coefficient of the material, greater is the reduction in the
magnitude of this force.
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Electrostatic forces also have considerably reduced magnitude in a liquid
environment. The dielectric constant of water (80.4) is much larger than that of air (~1),
causing a reduction in the magnitude of electrostatic forces.82, 84
Capillary forces arise from the condensation of atmospheric moisture as a
meniscus between the particles and air. Assuming that the solid particle surface is wet
because of water, this meniscus disappears, such that capillary forces are not relevant in
liquid media.83, 85
Interactive mixtures are made using the dry mixing process where the coarse
carrier particles help to effectively deagglomerate and disperse agglomerates of the
micronized drug into dispersed drug particles or small clusters. These drug particles then
adhere to the carrier surface (Figure 1.7). As discussed previously, the magnitude of
inter-particle forces between micronized drug and carrier particles decreases in liquid
media. This can facilitate the detachment of adhered drug particles from the carrier
surface. Because the drug agglomerates are broken down into dispersed drug particles or
smaller agglomerates, it is expected that after the dissolution of the soluble carrier or the
displacement of the drug particles from the hydrophilic carrier surface, a larger surface
area of the drug will be exposed to the solvent. These processes lead to dissolution rate
enhancement.
The hydrodynamics of an agitated system of suspended particles can be used to
explain the increase in the dissolution rate obtained using interactive mixing. Solids
dispersed in liquid media, under agitation, are surrounded by zones of less movable
liquids (boundary layers) reflecting a velocity gradient between the bulk fluid and the
solid surface. From the Prandtl equation (Equation 1.29, Section 1.3.1.2), it is clear that
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a decrease in particle size corresponds to a reduced distance on which frictional forces
can act, leading to a thinner velocity gradient. This corresponds to a short diffusional
distance (hD) where liquid motion is almost absent and diffusion dominates. In case of
interactive mixtures, the carrier particle initially determines the hydrodynamic conditions
and large values for particle length on which liquid flow L and consequently hD are
obtained. When the carrier particle dissolves and drug particles are released, the fluid
around each drug particle has a high velocity (V) combined with a low particle size (low
L) resulting in a smaller value of hD. Thus, when deagglomerated drug particles are
released from the dissolving carriers, it is suggested that the reduced diffusional distance
results in rapid dissolution process comparable with well-dispersed suspension system.38
In one study, the drug surface area participating in dissolution was calculated and was
found to be in agreement with the external surface area of the primary particles
(determined by permeametry).33
Figure 1.8 depicts the dissolution processes from physical and interactive
mixtures. After interactive mixing, the drug agglomerates are broken down into dispersed
particles and smaller agglomerates. The large effective surface area of the drug particles
from interactive mixtures is responsible for dissolution rate enhancement. For physical
mixtures, the drug agglomerates are not effectively deagglomerated, causing a large
fraction of the drugs’ surface area to be enclosed in the agglomerate structure. The lower
effective surface area of the drug particles in physical mixtures is responsible for slower
drug dissolution from these mixtures than that from interactive mixtures.
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Figure 1.8. Schematic representation of dissolution process from interactive and physical
mixtures: pink-carrier particles; blue-micronized drug particles.

1.4.4 Factors affecting Dissolution Rate Enhancement from Interactive Mixtures
Surface coverage
The amount of drug that can be incorporated into interactive mixtures is limited
by the surface area of the carrier particles. The surface area ratio (Rs), which is based on
the ratio of projected area of drug particles and the external surface area of the carrier
particles, is used to describe the degree of surface coverage of the carrier. In general, the
dissolution rate decreases with an increasing surface coverage (Rs) value. It is assumed
that at high surface coverage, a film of hydrophobic drug particles formed around the
carrier impedes carrier dissolution and the release of drug particles from the carrier
surface. Because carrier dissolution is crucial to release the drug as dispersed particles,
high degrees of surface coverage are typically associated with slower dissolution rates. In
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addition, an increase in carrier surface coverage is linked to the incomplete
deagglomeration of the drug, leading to reduced dissolution rates. The effects of surface
coverage of two micronized drugs, griseofulvin and oxazepam, with lactose and mannitol
carriers on the dissolution rate was studied by Nilsson et al.86-89 The authors observed
that oxazepam mixtures, with the lowest Rs, exhibited the highest dissolution rates. The
results were expressed as a percentage of the maximum dissolution rate (kM), which was
calculated from the knowledge of the intrinsic dissolution rate and surface area of the
drug particles. For griseofulvin-lactose mixtures with Rs values 0.5 and 1, the dissolution
rates were 69 % and 46 % of kM, respectively. For the highest surface area ratio of
griseofulvin corresponding to the Rs value 1, tablets showed a higher dissolution rate of
72 % of kM than the uncompressed mixture. This was attributed to the fracture of carrier
particles, when the tablet was formed.86 Although a high degree of surface coverage is
associated with slower dissolution rates, Westerberg et al. demonstrated that interactive
mixtures dissolved rapidly even when the surface coverage was high.89 This anomalous
result was attributed to the uncertainty in estimating the coating capacity of the carrier.
As explained earlier, the surface coverage was determined based on external surface area
measurements by microscopy. In case of carrier particles with morphologies deviating
from spherical geometry, a large amount of drug was necessary to achieve complete
coverage resulting in the unexpected outcome of this study.
Mixing time
Mixing time is an important parameter that affects the rate of drug dissolution
from interactive mixtures. Selecting an optimal mixing time is necessary because
insufficient mixing can cause incomplete break down of the drug agglomerates.
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Westerberg et al. showed that an increase in mixing time produced an increase in the
dissolution rate of oxazepam-mannitol mixtures with 100 % surface coverage.86 Greater
increase in dissolution rate following longer mixing time was attributed to increased
degglomeration and consequent high effective surface area of the drug available for
dissolution. Conversely in some studies, longer mixing times were associated with
overcoating the carrier with hydrophobic drug particles. The inability of the solvent to
penetrate efficiently through the adhered drug layer was postulated to interfere with
carrier dissolution leading to a delay in the release of adhered drug particles. A decrease
in the dissolution rate with increased mixing times was observed by Nilsson et al. The
highest dissolution rates of griseofulvin were obtained for griseofulvin-lactose mixtures
mixed for 750 min; the value being 102 % of kM whereas longer mixing times reduced the
dissolution rate of griseofulvin to 69 % of kM.89
Carrier particle properties
Various carrier particle properties, namely solubility, surface texture, and
mechanical properties, have been studied to understand their effects on dissolution rate
enhancement from interactive mixtures. Of these properties, carrier solubility was the
most important factor in determining the degree of dissolution rate enhancement. The
immediate dissolution of highly soluble carriers delivered the drug in the form of
dispersed particles, with increased effective surface area and decreased diffusion layer
thickness. This was observed in a study by Westerberg et al. where griseofulvin was dry
mixed with sodium chloride carrier. The authors observed that interactive mixtures
showed rapid dissolution, independent of stirring speed and surfactant concentration,
whereas the dissolution of pure drug agglomerates increased with increase in
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theseparameters.87 This indicated that following rapid carrier particle dissolution, the drug
was delivered as well-dispersed particles. The calculated effective surface area, based on
the dissolution rate, was similar to the value for the external surface area of primary
particles measured by permeametry. Interactive mixtures prepared with insoluble carriers
possessing hydrophilic surface properties, such as Emcompress® and glass beads, had
lower drug dissolution than that in those with soluble carriers. The low dissolution rate of
mixtures containing hydrophilic carriers was attributed to the inability of the carrier to
dissolve and release the drug as dispersed particles in the medium. The drug particles
remained partly adhered to the carrier, resulting in a lower surface area available for
dissolution relative to mixtures prepared with soluble carriers.87
To study the effects of carrier surface texture on drug dissolution from interactive
mixtures, carrier materials with different surface properties were formed into interactive
mixtures with griseofulvin. Similar results for glass beads (smooth texture) and
Emcompress® (rough texture) indicated that surface texture was not a significant factor
affecting dissolution.87
Commonly, interactive mixtures are formulated into tablet dosage forms, making
it important to understand the effects of compaction on drug dissolution. Nilsson et al.
observed that tablets made from interactive mixtures containing lactose and mannitol as
carriers showed a higher dissolution rate than uncompacted interactive mixtures. The
increased dissolution rate, after compaction, was attributed to fracture of carrier particles
upon application of pressure. Consequent breakage of the carrier caused the uncoated
carrier surface to be exposed to the solvent, resulting in faster carrier dissolution and drug
release from its surface.89 In another study, Westerberg et al. studied the effects of
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mechanical properties of carrier on drug dissolution from compacted interactive mixtures.
Micronized oxazepam was formed into interactive mixtures with mannitol (brittle
material) and sodium chloride (plastic material) as carriers. Tablets prepared with both
carriers had dissolution rates comparable to that of uncompacted mixtures. However,
internal lubrication with hydrophobic magnesium stearate caused a significant reduction
in the dissolution rate of oxazepam from compacted mixtures made using sodium
chloride carrier. This was due to the low degree of fragmentation of sodium chloride
during compaction thereby providing limited, new, and clean surfaces that were not
coated with the lubricant and resulted in a decreased dissolution rate.90
Ibrahim et al. studied the effects of carrier particle size on the dissolution rate of
griseofulvin from interactive mixtures. The authors observed an 87 % drug release from
the mixtures made with carriers sized 710–850 µm compared to a 66 % drug release from
mixtures with carriers sized 1000–2000 µm. This was possibly because a reduction in
carrier particle size led to an increased number of carrier particles (and carrier surfaces)
available for interaction with the drug. In addition, the possibility of the drug being
deposited as multiple layers on the carrier surface was minimized facilitating interaction
of the carrier with the solvent.91 However, a considerable difference in the size of the
drug and carrier particles is imperative for forming interactive mixtures, because the
coarse carrier particles (together with the mixer type) help to break drug agglomerates.
Therefore, caution must be exercised when selecting the carrier particle size, because low
size ranges are prone to agglomeration and can therefore provide limited effectiveness.

42

Influence of excipients
Surfactants are known to reduce the interfacial tension between drug particles and
solvents, thereby improving the wettability and solubility of hydrophobic drugs.
Therefore, several studies have incorporated surfactants into binary drug-carrier
interactive mixtures to aid agglomerate break down and increase dissolution rate.
Westerberg et al. observed that the increased dissolution rate on surfactant addition in
oxazepam-mannitol mixtures was only significant when the degree of surface coverage
was high. Mixtures with high surface coverage (Rs > 1) are likely to contain a greater
fraction of agglomerated particles than those with a low Rs value. As surfactants promote
wetting of hydrophobic drugs and produce an increase in effective surface area by
breaking down agglomerates, they are expected to be more effective when the degree of
surface coverage is high. To understand the influence of surfactants on drug dissolution
from interactive mixtures, the dissolution data of ternary benzodiazepine-lactose-sodium
lauryl sulphate (SLS) mixtures were modeled using a multiexponential equation. The
multiexponential equation assumed drug dissolution to occur from distributions of
dispersed and aggregated particles. Addition of 5 % SLS caused a decreased aggregate
percentage and an increased dissolution rate constant for aggregated particles compared
with binary benzodiazepine-lactose mixtures. Particle size analysis of the mixtures by
laser diffraction provided evidence for a shift to lower aggregate sizes on surfactant
addition. Furthermore, the increased dissolution rate of binary interactive mixtures,
following surfactant addition directly to the solvent, was modest compared to when it was
incorporated in the powder mixture. Therefore, it was concluded that it was necessary for
the surfactant to be associated with agglomerated drug particles on the carrier surface. It

43

was hypothesized that the surfactant in the mixed drug-surfactant aggregates dissolved
and provided a high local concentration of surfactant in the aggregate microenvironment
causing the remaining drug agglomerates to diperse.92
The dissolution rate of drugs from interactive mixtures with a high degree of
surface coverage also increased on adding a disintegrant to the carrier. If the carrier
material disintegrates readily, the carrier surface area exposed to the dissolution medium
increases. An increase in the exposure of uncoated carrier surfaces to the solvent results
in faster carrier dissolution and release of the adhered drug particles from the carrier
surface. In one study, mannitol and cross-linked sodium carboxymethylcellulose granules
were used as carrier particles for oxazepam. The dissolution rate of oxazepam from
mixtures containing disintegrant, sodium carboxymethylcellulose in the carrier was
higher than that of mixtures containing mannitol particles as the carrier.87 Similar results
were reported when nifedipine was coated on the surface of superdisintegrants such as
sodium starch glycolate and croscarmellose sodium.92
Addition of micronized inorganic excipients and fine lactose to binary drugcarrier interactive mixtures has also resulted in dissolution rate enhancement. The
superior performance of mixtures containing micronized excipients relative to binary
drug-carrier mixtures was attributed to the formation of drug-excipient agglomerates on
the carrier surface. It was speculated that the mixed drug-micronized excipient
agglomerates would have a greater propensity to deagglomerate than pure drug
agglomerates, possibly because of a reduced agglomerate strength and a more porous
packing arrangement. The dissolution rate enhancement of indomethacin was observed
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by Tay et al. on adding micronized aluminum hydroxide to binary indomethacin-lactose
interactive mixtures.93, 94
1.4.5 Dissolution Models
Interactive mixtures contain micronized drug particles distributed as dispersed
particles or small agglomerates on the carrier surfaces. To model drug dissolution from
interactive mixtures, treating dissolution as if it occurs from two distinct particle
populations having different mean particle sizes is suitable. Traditional particulate
dissolution models such as the Hixson-Crowell cube root law is ideally valid for uniform
spherical particles, in other words, the solid is in the form of a single unit or all units have
identical properties regarding size, shape, surface, and volume. However, in some cases
studies have shown polydispersed powders to experimentally follow the cube root law.
The Hixson-Crowell cube root equation is also derived assuming that all particles have
the same shape.95 However, this would not be a reasonable assumption for agglomerated
particle distribution because it is more likely that agglomerates would deviate from
spherical geometry. Therefore, most studies describing drug dissolution from interactive
mixtures, treat dissolution as a two-stage process involving the rapid dissolution of
dispersed particles consequent with the slow dissolution of agglomerated particles
without making any assumptions of particle size or shape, as described below.
Multiexponential dissolution models
Alway et al. mathematically modeled diazepam dissolution from lactose
interactive mixtures. In accordance with previous studies, diazepam dissolution occurred
rapidly at low drug concentrations. To represent the dissolution profiles by rate constants,
conventional models were used to fit the dissolution data. The Hixson-Crowell model did
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not linearize the data, because the model was derived for uniform spherical particles and
isotropic dissolution, in other words, particle shape was unaltered during dissolution.
Wagner’s percent undissolved versus time model also provided a poor fit, because
theoretically it is valid only when the surface area decreases exponentially with time and
is not applicable for materials with bimodal particle distributions. Based on these
observations, the authors hypothesized that dissolution from interactive mixtures was a
two-stage process involving dissolution from dispersed particles and agglomerates of the
drug, and a biexponential model derived from Wagner’s model was proposed to fit the
dissolution data.96 The derivation of the biexponential equation from Wagner’s
dissolution model is given below. This model is valid when there are sink conditions and
the surface area varies with time. Assuming that the surface area available for dissolution
decreases exponentially with time, the following equation is obtained:

S  S 0 exp( k s t )

(1.37)

where S is the surface area available for dissolution at time t , S 0 is the surface area
available for dissolution at t  0 , and k s is the rate constant for surface area decrease.
Substituting Equation 1.37 in the Noyes-Whitney equation (Equation 1.8, Section
1.2.2) yields:
dW
 kCs S 0 exp( k s t )
dt

(1.38)

Integrating Equation 1.38 from time = 0 to time = t gives:

Wt  W0  

kCs S 0
[exp( k s t )  1]
ks

(1.39)
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where Wt is the amount of drug dissolved at time t and W0 is the amount of drug
dissolved at t  0 . Because W0  0 , Equation 1.39 can be written as:

Wt 

kCs S 0
[1  exp( k s t )]
ks

(1.40)

At time t   ,

W 

kCs S 0
ks

(1.41)

Subtracting Equation 1.40 from Equation 1.41 gives the following:

W  Wt 

kCs S 0
exp( k s t )
ks

(1.42)

Taking the logarithm of both sides of Equation 1.42 gives the Wagner model for
dissolution as follows:

log(W  Wt )  log

kCs S 0
kt
 s
ks
2.303

(1.43)

where (W  Wt ) is the amount not dissolved at time t . W (Equation 1.41) represents
the drug amount dissolved at infinite time or the initial drug amount in the formulation.
Wagner’s model can be applied to describe drug dissolution from two particle
populations of different sizes assuming exponential surface area decreases on dissolution.
Because drug dissolution from interactive mixtures is hypothesized to occur from
agglomerated and dispersed particles, Equation 1.40 can be written as:

Wt  Wa (1  exp( k a t ))  Wd (1  exp(k d t ))

(1.44)

where Wa and Wd are the initial weights of the agglomerated and dispersed particles,
respectively, and k a and k d are the dissolution rate constants describing the surface area
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changes of the agglomerated and dispersed particles, respectively. Because the term

(Wa  Wd )  Wtotal represents the total amount of drug in the mixtures, Equation 1.44 can
be written as:

Wtotal  Wt  Wa exp(ka t )  Wd exp(kd t )

(1.45)

where (Wtotal  Wt ) is the amount of undissolved drug at time t .
Therefore, a plot of amount undissolved versus time gives a biexponential plot.
The parameters representing the dissolution of agglomerated particles, namely Wa and k a
can be determined from the terminal phase of this plot. The parameters describing the
dissolution of dispersed particles, namely Wd and k d , can then be determined by
applying the method of residuals to the amount undissolved versus time data.
Alway et al. used Equation 1.45 to model drug dissolution from diazepamlactose interactive mixtures with different degrees of drug loading. Nonlinear least
squares curve fitting was applied to the amount of drug undissolved versus time data.
Modeling results showed that k d remained relatively constant across the different drug
loadings in the mixtures. Conversely, the value of k a decreased with an increase in drug
loading. In addition, increasing diazepam concentration in the mixtures also increased Wa
because of low degree of deagglomeration. The overall dissolution rate was a function of
the rate constants and of Wa and Wd. To support use of the biexponential model,
environmental scanning electron microscopy (SEM) was used to observe the drug
dissolution from interactive mixtures with small amounts of water condensed on the
carrier surface. Microscopy revealed that the carrier dissolved rapidly, releasing the drug
as agglomerates and dispersed particles. Furthermore, SEM images of the interactive
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mixtures before dissolution qualitatively showed greater evidence of agglomeration at
high drug loadings.96, 97 Increased drug agglomeration with an increase in drug loading is
caused by an incomplete agglomerate break down when mixing.
The biexponential model was also applied to study the influence of micronized
surfactants (SLS and cetrimide) on benzodiazepine dissolution from lactose interactive
mixtures. SEM showed the presence of mixed drug-surfactant agglomerates on the
lactose carrier surface. An increase in the surfactant concentration in mixtures caused a
decrease in Wa and an increase in the rate constants, k a and k d . The increase in rate
constants on surfactant addition was attributed to two factors: an increase in the intrinsic
dissolution rate of the drug caused by dissolved surfactant in the agglomerate
microenvironment and a decrease in the mean particle size of agglomerates caused by
their increased dispersion.91
Particle size analysis
Kinetic particle sizing approaches, such as laser diffraction analysis, have been
used to determine the percentage and size distributions of agglomerated and dispersed
drug particles after adding interactive mixtures to the dissolution media.91, 98, 99 To
measure particle size using laser diffraction size analysis, a laser passes through a sample
dispersed in suitable liquid media and is diffracted by the particles. In general, light
scatters at smaller angles off large particles than small particles. The intensity and angle
of light scattered by the particles is detected and then converted by the analyzer into a
particle size distribution. Using laser diffraction analysis, particle sizes between 0.2 µm
to 2000 µm can be measured.100
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Zhao et al. used laser diffraction analysis to determine the effects of surfactants
on the degree of agglomeration of diazepam in lactose interactive mixtures. The degree of
agglomeration was obtained by dividing the area under the agglomerate distribution by
the total volume concentration of the particles. Binary diazepam-lactose interactive
mixtures added to distilled water showed a bimodal distribution with modes of
approximately 50 µm and 7 µm representing agglomerated and dispersed drug particles,
respectively. The same type of bimodal distribution was observed when ternary mixtures
of diazepam-SLS-lactose were added to distilled water. However, the modes appeared at
34 µm and 4.8 µm in the presence of a surfactant, which enhanced agglomerate
dispersion.99
Laser diffraction analysis has also been used to understand the effects of drug
loading on the deagglomeration profile.98 The following equation was used to fit the
deagglomeration profiles:

Ca  C0  C0a exp( k a t )

(1.46)

Where Ca is the percentage mass of agglomerates present in the medium at time t, C0 is
the initial mass percent of nondispersible agglomerates, and C0a is the initial mass percent
of agglomerates that undergo deagglomeration with the rate constant ka. Increased
benzodiazepine concentration in the mixture increased the values of C0, whereas adding
SLS to the mixture decreased this value. Based on this study, the authors concluded that
deagglomeration profiles can serve as useful tools during formulation as the knowledge
of parameters, such as C0 and ka, may help to adopt specific strategies for formulation
optimization.
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In conclusion, the biexponential model (Equation 1.45) representing the
dissolution of dispersed and agglomerated particles has been used to describe drug
dissolution from interactive mixtures. This model enables determination of the initial
percentages of agglomerated and dispersed particles in mixtures and the rate constants
describing dissolution. The information on the effective surface area of agglomerated and
dispersed particles, the percent total surface area of drug particles available for
dissolution and the parameters related to particle size of the agglomerated and dispersed
particles can be further determined from the biexponential model and is explained in
detail in Chapter 4 (Section 4.2.6).
1.5 Cefuroxime Axetil: Drug Profile
1.5.1 Cefuroxime Axetil (CFA) Diastereomers
Cefuroxime axetil (CFA) is an orally available ester prodrug of cefuroxime
(Figure 1.9), a second-generation injectable cephalosporin antibiotic. CFA is synthesized
by esterification of the carboxylic acid group of cefuroxime to produce the
1’-acetoxyethyl ester derivative (Figure 1.10), making the drug orally bioavailable. Upon
oral administration, CFA is absorbed from the gastrointestinal tract and hydrolyzed by
esterase enzymes in the intestinal mucosa and plasma releasing the parent drug,
cefuroxime, which has bactericidal effects against several gram-positive and gramnegative microorganisms. CFA is commonly used in the treatment of a respiratory and
urinary tract infections.101 Esterification of cefuroxime to produce CFA is carried out
using racemic (R,S)-acetoxyethyl bromide, which produces an asymmetric center at
position 1’ of the ester group. Although CFA contains three chiral carbon atoms at
positions 1’, 6, and 7 (indicated in Figure 1.10), the configuration differs only at position
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1’ indicating that the molecule exists as a pair of diastereomers. The diastereomers are
isomer A (1’S, 6R, 7R) and isomer B (1’R, 6R, 7R) as shown in Figure 1.10. Biological
studies in dogs and rats have indicated that these isomers were hydrolyzed at different
rates by esterase enzymes in the intestine and plasma. In all cases, isomer A was
hydrolyzed to nonabsorbable cefuroxime faster than isomer B.102

Figure 1.9. Chemical structure of cefuroxime (parent drug).

Figure 1.10. Chemical structure of cefuroxime axetil diastereomers.
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Because the diastereomers of CFA differ in configuration at only one chiral
carbon atom, different distances between nonbonded atoms causes changes in the overall
molecular shape and geometry. The differences in the packing of individual
diastereomers in the crystal lattice causes crystalline diastereomers to exhibit distinct
physical properties such as solubility and melting point. Previous studies have reported
the melting points of crystalline isomer A and B to be 194–196 °C and 132–134 °C,
respectively.103 In another study, two crystalline forms of the isomers A and B of CFA
were observed. These were referred to as forms AI and AII for isomer A with melting
points of 201.9 °C and 191 °C, respectively, and form BI and BII with melting points of
133.4 °C and 124.3 °C for isomer B, respectively. Form BII was found to be a
hemihydrate form, whereas all others were nonsolvated. Powder X-ray diffractometry
patterns for the different crystalline forms were distinct which permitted their
identification.104
Various crystalline solid structures can be formed between diastereomers upon
crystallization from a melt or a solution as described in Chapter 1 (Section 1.1.2). The
type of structure influences properties such as solubility and stability. In this project,
thermal analysis was to construct a phase diagram to gain insight into the solid-state
structure formed by CFA diastereomers. Further, phase solubility studies and intrinsic
dissolution rate determination on diastereomer mixtures of different compositions were
performed. These studies were conducted to understand the solution behavior of CFA
diastereomers.
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1.5.2 Cefuroxime Axetil (CFA) Dissolution Rate-Limitation
The formation of CFA, by esterification of the carboxylic acid group of
cefuroxime, is intended to improve the lipophilicity and membrane permeability of the
parent drug. Despite this, oral products of CFA exhibit a low bioavailability of 21–44 %
(after fasting) and 34–55 % (after food).105 The increased bioavailability, when
administered with food, is due to a long residence time in the upper gastrointestinal tract
during which the drug can dissolve, indicating that CFA exhibits a dissolution ratelimited bioavailability. CFA is classified as a Biopharmaceutics Classification System
(BCS) Class II drug (poor aqueous solubility, good membrane permeability). Because
dissolution rate-limited bioavailability caused by poor aqueous solubility can be partly
overcome by the use of high-energy solid forms, CFA is present as the amorphous solid
form in commercially available preparations.105
Formulation approaches, such as particle size reduction to increase surface area
have been used to improve the dissolution rate (according to Noyes-Whitney equation,
Equation 1.8). In one study by Dhumal et al. CFA particles of different sizes were
prepared and their dissolution and in vivo plasma concentration-time profile in rats were
compared (Figure 1.11). The smaller particles showed a faster dissolution rate and a
significantly high in vivo bioavailability (as represented by the area under the plasma
concentration-time curve).106
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Figure 1.11. Dissolution profile and Plasma concentration-time profile following the
administration of unprocessed CFA 20–50 μm (●); spray-dried CFA 10–100 μm (■); PPT-CFA
(precipitated CFA, 1–10 μm) (○); and SONO-CFA (sonoprecipitated CFA, 130 nm) (▲) in rats.
Reproduced from Dhumal et al. with permission from Elsevier.106

Although particle size reduction resulting in SSA increase is a commonly used
approach to enhance dissolution rate, reduced rates have been reported in some cases. For
example, one study compared the dissolution of crystalline particles with SSA of
6.24±0.03 m2/g to amorphous nanoparticles of CFA with SSA of 16.91±0.05 m2/g.
Although the initial dissolution rates (under sink conditions) for the nanoparticles were
higher (attributable to increased solubility), the dissolution rates rapidly became
indistinguishable.65 Based on high SSA and solubility, the Noyes-Whitney equation
predicted an improved dissolution profile for the nanoparticles. The anomalous result was
attributed to the propensity of nanoparticles to agglomerate causing a decrease in the
effective surface area. Agglomeration caused the dissolution rate to be lower than that
expected based on the solid’s total SSA. To take advantage of the surface area increase
afforded by particle size reduction, agglomerated drug particles must to be broken down
into dispersed drug particles or small clusters. This can be achieved by mixing
agglomerated drug particles with coarse carrier particles to form interactive mixtures
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(described in detail in Section 1.4). In this project, the interactive mixing approach was
applied to improve the dissolution rate of the model drug, CFA, which suffers from
dissolution rate-limited oral bioavailability
1.6 Research Objectives
The overall goal of this project was to understand how interactive mixing affects
the dissolution rate of the antibiotic drug, CFA. This goal required a deeper
understanding of the solid-state and the solution behavior of CFA diastereomers. The
information obtained from the diastereomer studies was combined with a formulation
approach using interactive mixing to investigate the dissolution rate of CFA from
interactive mixtures with an aqueous-soluble carrier. The following specific outcomes
were achieved:
1) A phase diagram describing the solid-state behavior of CFA diastereomers was
constructed.
2) The effects of varied diastereomer composition on the overall solubility were
determined, and an interaction between the diastereomers in solution was identified.
3) The mechanism underlying dissolution rate enhancement in interactive mixtures, as
compared to drug agglomerates and physical mixtures was determined using a model
relevant to heterogeneous particle distributions to analyze dissolution data of interactive
mixtures of amorphous CFA and milled particles of crystalline drug.
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Chapter 2: Solid-Liquid Phase Diagram of Diastereomers of Cefuroxime
Axetil

2.1 Introduction
This chapter focused on identification of the solid-state structure formed between
cefuroxime axetil (CFA) diastereomers. Diastereomers can crystallize from an equimolar
mixture as either homochiral crystals (conglomerate) or heterochiral crystals. The
crystalline forms differ in physical properties such as solubility and melting point. In
most cases, diastereomers form conglomerates The phase diagram of conglomerates
exhibits eutectic behavior. A physical mixture of eutectic composition may have different
properties than that of a fused mass of the components affecting solubility and stability of
the dosage form. As CFA is present in commercial preparations as a diastereomer
mixture (isomer A and isomer B, Figure 1.10, Chapter 1: Section 1.5.1), it is of value to
determine the eutectic composition and melting point. In this chapter, thermal analysis
utilizing differential scanning calorimetry (DSC) was used to construct a phase diagram
in order to determine the eutectic composition and melting point.
2.2 Materials and Methods
2.2.1 Materials
Commercially available amorphous CFA (Dhanuka Laboratories, Mumbai, India)
was used as the starting material. Methanol (Alfa Aesar, Ward Hill, MA, HPLC grade)
was used for separation and crystallization of the diastereomers. All proton NMR (1HNMR) spectra were recorded in dimethylsulfoxide-d6 (99.9 atom % D) (Sigma-Aldrich,
St. Louis, MO).
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2.2.2 Separation and Crystallization of Diastereomers
The diastereomers were separated from the commercially available amorphous
CFA (equimolar mixture of diastereomers). Methanol was used to selectively crystallize
the two diastereomers because they have very different solubilities in methanol.
Approximately 5 g of amorphous CFA was added to 100 ml of methanol, heated to 60 °C
and held at this temperature for 30 min with constant stirring. The slurry obtained was
filtered, and as the filtrate was allowed to cool to room temperature the initial batch of
crystals obtained were collected, dried and subjected to 1H-NMR spectroscopy analysis to
determine their identity and diastereomeric purity. The first batch of crystals was named
Lot1 crystals. The mother liquor remaining was then completely evaporated and the
deposited crystals were also dried and subjected to 1H-NMR spectroscopy (Lot 2
crystals). Proton NMR spectra (1H NMR) of the crystalline materials obtained from
methanol were recorded on a Bruker WH-400 (400 MHz) spectrometer in
dimethylsulfoxide-d6. The chemical shift values are expressed in parts per million (ppm)
relative to tetramethylsilane as an internal standard. The diastereomers were
distinguished using the chemical shift of the proton at the 1’ position of the molecule
(indicated in Chapter 1: Figure 1.10). The reported chemical shift values are 6.89 ppm
(for isomer A) and 7.01 ppm (for isomer B) and the peaks appear as a quartet. The
relative diastereomeric purities of the samples were determined by integrating the areas
under the peaks.
2.2.3 Solid State Characterization of the Diastereomers of Cefuroxime Axetil
In addition to diastereomeric purity, the solid phase of each batch of crystals was
characterized using thermal analysis and powder X-ray diffraction. Melting points and

58

diffraction patterns were compared to those previously reported in order to ascertain the
polymorphic forms of the diastereomers.
Differential scanning calorimetry (DSC) analyses were performed on a Model
Q100 DSC (TA Instruments, New Castle, DE) under a constant nitrogen purge
(50 ml/min). A three-point temperature and enthalpy calibration was performed using
o-terphenyl, indium and tin standards. The cell constant calibration was performed using
indium. Samples (3.5–4.5 mg) were hermetically sealed in aluminum pans and heated at
10 °C/min up to 210 °C. Experimental melting point values were determined as the onset
melting temperature and compared with reported values in literature that were determined
under similar conditions of heating rate.
PXRD patterns were recorded at room temperature on an X’Pert Pro MPD system
(P’Analytical B.V., Almelo, the Netherlands) equipped with a copper anode
(λ=1.54016 Å) and an X’Celerator™ detector. The operational voltage and amperage
were set to 45 kV and 40 mA, respectively. Samples were thoroughly ground and
mounted on a back-filled, aluminum sample holder and were analyzed in continuous
mode with a step size of 0.0170 °2θ and a step time of 31.75 s over the range of 2–60 °2θ.
The samples were spun at 16 rpm during the measurements. Diffractograms were plotted
as diffraction intensity vs. scattering angle (° 2θ) using X’Pert HighScore Plus software.
2.2.4 Construction of the Phase Diagram (T-χ diagram) for Diastereomers of
Cefuroxime Axetil
Diastereomer mixtures were prepared for DSC analysis by accurately weighing
appropriate quantities of the crystalline diastereomers to produce various mixtures in
10 % increments. The mixtures were then thoroughly ground, by hand in a mortar to
promote intimate contact between the different crystals. Samples (3.5–4.5 mg) were
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hermetically sealed in aluminum DSC pans. The various melting peaks of CFA overlap
with each other obscuring the individual onset temperatures. Therefore, the peak
temperature of each endotherm was used. As peak temperature is sensitive to variations
in heating rate, individual samples of each composition were heated at 1, 2 and 3 °C/min
up to 210 °C (n=2 replicates or more at each rate). The peak temperatures of the melting
endotherms were then plotted against the heating rate, and linear regression was used to
obtain the peak temperature at zero heating rate (Tpeak, 0). The phase diagram was
constructed by plotting the Tpeak, 0 values obtained from the thermograms for each
composition against the % of isomer B in the mixture.
2.3 Results and Discussion
2.3.1 Spectroscopic, Thermal and Diffraction Analyses of Crystalline Diastereomers
The 1H-NMR spectra for commercially available amorphous CFA, the first batch
of crystals obtained from methanol (named as Lot 1 crystals) and the crystalline material
deposited from the mother liquor (named as Lot 2 crystals) are shown in Figures 2.1a,
2.1b and 2.1c, respectively. The chemical shift values (in ppm) of the proton on the
1’ carbon, which appear as quartet peaks, were used to distinguish between the
diastereomers. This peak was specifically used for distinction, as the diastereomers differ
in configuration at only this asymmetric carbon atom.107 In Figure 2.1a both sets of
quartet peaks were present and the ratio of their integrated areas was found to be 1:1
indicating that commercial amorphous CFA is an equimolar mixture of diastereomers.
Lot 1 crystals obtained from the methanol filtrate showed only one set of quartet peaks at
a chemical shift of 6.89 ppm indicating the presence of only isomer A (Figure 2.1b).
Therefore isomer A could be isolated with a purity approaching 100 %. Although both
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sets of quartet peaks were present in the 1H-NMR spectrum of Lot 2 crystals (Figure
2.1c), the ratio of the two, quartet peak areas at chemical shift values of 7.01 ppm and
6.89 ppm were 1:0.18, indicating that this batch of crystals contained 85 % of isomer B
and 15 % of isomer A. Further efforts to isolate isomer B did not significantly improve
the diastereomeric purity. This was attributed to the slight solubility of isomer A in
methanol such that it could not be completely removed from the methanol filtrate. In
order to determine the sensitivity of the NMR method, 2 % w/w increments of isomer B
were added to Lot 1 crystals (form AI). The area under the peaks appearing at chemical
shift values of 6.89 ppm and 7.01 ppm were integrated. There was a proportional
increase in area under the peak at 7.01 ppm (corresponding to isomer B) as the amount of
isomer B in the mixtures increased. This enabled quantification of small percentages of
isomer B (< 2 % w/w) in a matrix of isomer A.
Thermal analysis and PXRD were used to confirm the diastereomeric identity as
well as the solid form of each material obtained upon crystallization from methanol. The
DSC thermogram of Lot 1 crystals obtained from methanol (1H-NMR spectra shown in
Figure 2.1b) is shown in Figure 2.2a. A single endotherm with an onset temperature of
202.9 °C was seen. This value was compared with the melting temperatures for the
reported solid forms of each diastereomer of CFA, and it was found to correspond with
that for form AI of isomer A (reported melting temperature is 201.9 °C). The PXRD
pattern for these crystals (Figure 2.2b) showed characteristic peaks for form AI.104 Based
on this data, the crystals from Lot 1 were confirmed as form AI. It is expected that the
first batch of crystalline material deposited from methanol to be isomer A based on its
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lower solubility in methanol compared to isomer B, creating a higher level of
supersaturation and consequently a greater driving force for crystallization.

Figure 2.1.1H-NMR spectra (in d6-dmso) (a) Commercially available CFA (b) First batch of
crystals from methanol (Lot 1 crystals) (c) Crystalline material deposited from mother liquor (Lot
2 crystals). Peaks shown correspond to the proton highlighted in bold of the CH3-CH group.
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Figure 2.2. (a) DSC thermogram of first batch of crystals from methanol (Lot 1 crystals) obtained
at heating rate of 10 °C/min (b) Powder diffractogram of first batch of crystals from methanol
(Lot 1 crystals). The reported pattern is that of form AI.104

The PXRD pattern of Lot 2 crystals is shown in Figure 2.3. As the 1H-NMR
spectra of this material (Figure 2.1c) showed the presence of both sets of quartet peaks it
was concluded that this material was a mixture of diastereomers. The powder diffraction
pattern of the crystalline material showed characteristic crystalline peaks for both form BI
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and form AI (Figure 2.3). The peak positions of the individual crystalline diastereomers
were preserved in the crystalline mixture, suggesting the absence of crystal modification
or formation of a racemate. This indicates that the diastereomers crystallized separately to
form a mixture of homochiral crystals. Purification of Lot 2 crystals in order to improve
the content of isomer B was attempted using solvents such as ethyl acetate, acetone and
hexane. Despite this the maximum purity of isomer B that could be achieved was 85 % in
a diastereomer mixture.

Figure 2.3. PXRD patterns (a) Mixture containing isomer A and isomer B (0.18:1 ratio) (b)
Reported pattern of form AI (c) Reported pattern of form BI.104
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2.3.2 Differential Scanning Calorimetry (DSC) Thermograms of Diastereomer
Mixtures
Representative DSC thermograms of mixtures containing 0 % to 85 % isomer B
at three different heating rates are shown in the Appendix Section.
Selected DSC thermograms of mixtures with containing 0 % to 85 % isomer are
shown in Figure 2.4. All thermograms shown were obtained at a heating rate of 2 °C/min
to illustrate the overall characteristics of the thermal behavior. Based on Figure 2.4,
isomer A showed a single, sharp melting peak in the absence of isomer B (0 % isomer B)
with Tpeak, 0=183 °C. As the concentration of isomer B in the mixtures increased, a second
endothermic peak appeared with Tpeak, 0 of approximately 125 °C and this peak
overlapped with the melting peak of isomer A. Melting peaks of the diastereomer
mixtures were broader than that observed in the pure isomer A sample. The peak
temperature of the lower melting peak remained consistent even as the ratio of the
isomers in the mixtures was varied. In addition, the peak temperature and size of the
original isomer A melting endotherm both decreased as the amount of isomer B present
increased up to a concentration of 70 % isomer B. The depression in the peak melting
temperature of isomer A with an increase in concentration of isomer B in the mixture
indicated that the isomers were miscible. A single endotherm was observed in the mixture
containing 75 % isomer B with a Tpeak,0 of 125.1 °C. Further increasing the isomer B
concentration above 75 % caused the second endotherm to reappear. Since the peak
temperature of the lower melting endotherm remained consistent even as the
concentration of the isomers was varied, the peak was attributed with melting of the
isomer A/isomer B eutectic mixture. Formation of a eutectic mixture can be explained by
localized melting between the diastereomers upon application of mechanical stress and
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their miscibility in the liquid state (caused by chemical similarity between the molecules).
As the diastereomers melt together, the net entropy change is greater than if they were to
melt separately. This causes the mixture to exhibit a melting point that is lower than
either pure component, assuming that the heat of fusion is relatively constant and is a
weighted sum of the individual constituents.9
The dependence of melting temperature on heating rate was clearly observed for
all diastereomer mixture compositions (Appendix Section). For the same mixture
composition at different heating rates, the peak shape looked similar, but the peak
position was different. As the heating rate increased, the peak shifted to a higher
temperature due to thermal lag which is inherent in a DSC measurement.
The possibility of polymorphic transformation upon grinding of crystalline
diastereomers to obtain the various mixtures was ruled out using PXRD analysis. The
PXRD pattern of the ground mixture containing 85 % isomer B is shown in Figure 2.3.
The peak positions of form AI and form BI were retained suggesting the absence of any
crystalline modification upon grinding.
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Figure 2.4. DSC thermograms of diastereomer mixtures of CFA with various compositions. All
thermograms were obtained at a heating rate of 2 °C/min.

2.3.3 Phase Diagram (T-χ) of Diastereomers
The phase diagram of the diastereomer mixtures of CFA was constructed by
plotting the peak temperatures extrapolated to zero heating rate (Tpeak, 0) values against
the % isomer B. At all mixture compositions, except for 75 % isomer B, there were two
endotherms, corresponding to eutectic mixture melting and liquidus temperature. The
composition of the eutectic mixture was 75 % isomer B and the eutectic melting
temperature was 124.8±0.5 °C. Below the eutectic composition (χe) or 75 % isomer B,
the higher melting endotherm corresponds to the depressed melting of excess isomer A in
the mixture. The higher melting endotherm in compositions above χe represents the
depressed melting of isomer B. At 75 % isomer B composition, the single melting
endotherm represents the eutectic composition.
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Table 2.1 summarizes the peak melting temperatures obtained at the different
heating rates as well as the peak temperature extrapolated to zero heating rate (Tpeak,0) for
mixtures ranging in concentration from 0 % to 85 % isomer B.

Figure 2.5. Phase diagram of diastereomers of CFA. The y-axis represents the peak melting
temperature extrapolated to zero heating rate (Tpeak,0) and the error bars represent the standard
error of the intercept obtained by linear regression of the peak melting temperature versus heating
rate (n=2 replicates at each heating rate).

68

Table 2.1. Thermal data for disatereomer mixtures containing 0 % to 85 % isomer B.

%
isomer Heating
B
rate
(°C/min)

0

10

20

1
2
3
1
2
3
1
2
3
1

30

40

50

60
70

75
80

85

3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3

Eutectic peak
Liquidus peak
temperature(°C)* temperature
(°C)*
127.1 (1.5)
128.6 (1.4)
130.9 (1.3)
127.9 (0.2)
130.6 (1.3)
133.2 (0.8)
126.9 (1.3)
129.9 (1.2)
131.9 (0.3)
126.6 (0.4)
129.4 (1.4)
131.3 (0.5)
127.6 (0.4)
131.7 (0.6)
134.9 (1.1)
128.0 (1.3)
129.8 (1.5)
133.7 (2.1)
127.7 (0.3)
130.3 (1.7)
134.0 (0.7)
127.3 (0.7)
129.2 (0.1)
131.6 (0.1)
127.3 (0.8)
128.8 (1.1)
130.8 (0.9)
127.2 (0.7)
128.9 (0.4)
131.9 (0.7)

187.2 (0.9)
192.3 (0.2)
196.1 (0.3)
184.9 (0.9)
187.4 (0.4)
192 (0.1)
179.1 (1.2)
181.2(1)
185.6 (0.9)
176.1(1.1)
180.6 (1.2)
185.3 (1.4)
171.2 (0.2)
174.4 (0.8)
177.3 (0.7)
167.9 (0.7)
174.9 (1.2)
177.9 (0.9)
164.5 (1.9)
169.5 (0.8)
174.1 (2.2)
159.3 (1.2)
165.8 (1.7)
169.6 (1.4)
134.1 (0.5)
137.1 (0.8)
139.3 (0.8)
134.7 (0.2)
136.0 (0.3)
138.0 (0.9)

Eutectic peak
temperature
extrapolated
to zero heating
rate (°C)**
-

Liquidus peak
temperature
extrapolated to
zero heating
rate (°C)**
183 (0.8)

125.0 (1.3)

181.1 (0.9)

125.3 (0.6)

175.8 (1.4)

124.6 (1.0)

171.4 (1.5)

123.7 (0.8)

168.6 (0.5)

124.8 (0.9)

163.9 (1.4)

124.8 (2.1)

159.7 (1.6)

124.4 (0.9)

154.6 (1.3)

125.1 (0.4)

-

125.5 (0.7)

131.5 (0.6)

124.5 (0.7)

132.9 (0.5)

*Values represent Average (±SD) of at least n=2 replicates at each heating rate.
**Values represent the y-intercept (±SE) of the plot of peak melting temperature vs.
heating rate
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2.4 Conclusion
Diastereomers of CFA were separated and crystallized from an equimolar mixture
using methanol as the solvent. Differential scanning calorimetry (DSC) analysis was used
to observe the melting behavior of different diastereomer mixture compositions. The
binary solid-liquid phase diagram of mixture compositions ranging from 0 to 85 %
isomer B indicated formation of a eutectic mixture with a melting point of 124.8±0.5 °C
and a composition of 75 % isomer B. PXRD supported the conclusion that the
diastereomers formed a eutectic mixture, based on preservation of crystalline peaks of
both components in the mixture. A physical mixture of eutectic composition may have
different properties than that of a fused mass of the components affecting solubility and
stability of the dosage form and therefore it is important to determine if the components
used together in a formulation form a eutectic mixture.
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Chapter 3: Solubility and Dissolution Studies on Diastereomers of
Cefuroxime Axetil
3.1 Introduction
Cefuroxime axetil (CFA) is present in commercial preparations as an equimolar
mixture of diastereomers assigned as isomer A (1’S, 6R, 7R) and isomer B (1’R, 6R, 7R)
(Figure 1.10, Chapter 1). In the previous chapter (Chapter 2) it was observed that the
crystalline diastereomers formed a eutectic mixture with a composition of 75 % isomer B
and a melting temperature of 124.8±0.5 °C. Pharmaceutical operations such as milling
and tableting causes contact between components of a formulation, and can lead to
contact induced melting point depression and formation of eutectic mixtures. Although
CFA is present in commercial products in the amorphous form, traces of crystalline
diastereomers may remain in solid CFA which may cause formation of eutectic. Eutectic
formation can affect the solubility and stability of the final dosage form104, 106 In addition
to the studying the nature of the solid-state structure of the diastereomers, it is also
equally important to understand the behavior of the diastereomers in solution, as
commercial preparations contain both diastereomers. Any interaction, such as formation
of a soluble or insoluble complex, can impact the solubility of CFA products.
This chapter focused on performing phase solubility studies to ascertain solution
behavior of CFA diastereomers, that is, possible formation of a complex between the
diastereomers.10 In order to further confirm or rule out the possibility of an interaction
between the diastereomers in solution, intrinsic dissolution rate (IDR) studies on
diastereomer mixtures of different compositions was carried out. A diffusion layer model
developed by Higuchi et al. that describes the dissolution of compressed binary mixtures
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containing interacting and non-interacting components was applied to the solubility
data.11, 12 Experimentally obtained IDR values for diastereomer mixtures of three
different compositions were compared to the theoretical values obtained from the
Higuchi model. The main purpose of this investigation was to study the behavior of
diastereomers in solution and calculate the diastereomer ratio that demonstrates the
highest dissolution rate based on the Higuchi model.11, 12
3.2 Materials and Methods
3.2.1 Materials
Form AI of isomer A (Lot 1 crystals) obtained by methanol crystallization as
described in Chapter 2 (Section 2.2.2) and a diastereomer mixture containing 75 %
isomer B (present as form BI and form AI, named as Lot 3 crystals) were used for phase
solubility and intrinsic dissolution rate studies. Concentrated hydrochloric acid (36 %
w/w aqueous solution, Lot No. A25X018, Alfa Aesar, Shore Road, Lancashire) and
deionized water were used to prepare 0.07 N hydrochloric as the medium for solubility
and dissolution studies. This medium was degassed prior to use. Cefuroxime axetil
reference standard (1:1 diastereomer ratio) available from the United States
Pharmacopiea (Category No. 1098220) was used for comparison with the bulk drug and
development of a calibration curve for quantification.
3.2.2 Ultraviolet (UV) spectroscopic analysis
Instrumentation
UV spectroscopic analysis was used to determine the concentration of dissolved
cefuroxime axetil. Analysis was performed using a UV-Vis spectrophotometer (HP
Agilent 8453) equipped with Chemstation software (Rev. A.10.01, Agilent
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Technologies). Samples were scanned between 190 and 400 nm and quantification of the
dissolved drug was carried out at the wavelength of maximum absorbance (λmax) which
was 281 nm.
Preparation of solutions
Standard stock solutions of 1.96×10-4 M of cefuroxime axetil (CFA) (n=3
replicates) were prepared by dissolving accurately weighed amount of the commercially
available drug (equimolar diastereomer mixture) in 0.07 N hydrochloric acid. The
solution was filtered through a 0.22 μm polypropylene membrane filter (VWR
International, Radnor, Pennsylvania). Calibration standards were then prepared at
concentrations of ranging from 1.99×10-6 M to 4.80×10-5 M from the stock solution by
appropriate dilutions with 0.07 N hydrochloric acid. The UV analytical method for
quantification of CFA was validated as per ICH Q2A guidelines for linearity and range,
accuracy, precision, limit of detection (LOD) and limit of quantitation (LOQ).108
Calibration curves were also prepared with Lot 1 crystals (form AI) and Lot 3 crystals
(75 % isomer B and 25 % isomer A) in 0.07 N hydrochloric acid. This was done to
ascertain the influence of various compositions of diastereomers on the absorption
spectrum. A calibration curve was also made in a lower concentration range from
1.99×10-8 to 4.80×10-7 M in order to ensure that the linear relationship between
absorbance and concentration was still maintained at lower concentrations. This was
necessary to quantify lower concentrations of dissolved drug.
Linearity and Range
The linear relationship was evaluated across the range of the analytical procedure.
The calibration curves were constructed with 13 concentrations ranging from
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1.99×10-6 M to 4.80×10-5 M (n=3 replicates each). The absorbance of the drug solution
was considered for plotting the linearity graph. The average value of absorbance at each
concentration was plotted against the concentration (M). The linearity was evaluated by
linear regression analysis, which was calculated by linear least square regression method
using Microsoft Excel®. The correlation coefficient and residual sum of squares was
used to evaluate linearity.
Accuracy and Precision
Accuracy and precision of the of the assay method were evaluated for both intraday and inter-day variations at three different concentrations, 1.18×10-5 M, 2.35×-10-5 M
and 3.92×10-5 M, representing low, medium and high concentrations, respectively, for
three days. Accuracy and precision were expressed in terms of percent mean recovery
and percent relative standard deviation (% RSD). Intra-day precision refers to variations
in the recovery values obtained upon analyzing the samples within the laboratory over a
short period of time during the day. Intermediate precision represents intra-assay
variations measured across three different days.
Limit of detection and quantitation
Limit of detection (LOD) and limit of quantitation (LOQ) were calculated from
the standard deviation of the response (σ) and slope (s) of the calibration curve obtained
from multiple calibration curves. The response (σ) was measured as the standard
deviation of the intercepts and the slope (s) was the mean slope of multiple calibration
curves ranging in concentration from 3.99×10-6 to 3.99×10-5 M. LOD was calculated as
3.3σ/S and LOQ as 10σ/S.
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3.2.3 Solubility Studies of Diastereomers
Solubility measurements Lot 1 crystals (form AI) crystals were carried out in
0.07 N hydrochloric acid medium. Excess Lot 1 crystals were added to medium
maintained at 37±1 °C in a temperature controlled water-bath shaker. Samples (3 ml)
were withdrawn, filtered using a 0.22 µm polypropylene filter, diluted with blank
medium and analyzed for dissolved drug content using a validated ultraviolet
spectroscopic assay method. The study was continued until the concentration of dissolved
drug remained constant with time and the plateau concentration was taken to be the
equilibrium solubility of form AI. This study was performed in triplicate.
As crystalline isomer B (form BI, confirmed by PXRD analysis, Figure 2.3,
Chapter 2) could not be isolated with purity greater than 85 %, solubility determination
of isomer B crystals involved a phase solubility technique. Phase solubility studies of
isomer B in the presence of Lot 1 crystals (form AI) were performed at 37±1 °C
according to the method of Higuchi et al.10 In this method, excess Lot 1 crystals were
added to 20 ml of pre-equilibrated 0.07 N hydrochloric acid in scintillation vials. A
known amount of crystalline diastereomer mixture containing 75 % isomer B (Lot 3
crystals) was added to the vials, and the vials were placed in a temperature-controlled
water bath shaker. Samples were withdrawn after a suitable equilibration period (usually
24 h) in order for the system to attain equilibrium. The samples were filtered using a
0.22 µm polypropylene filter, diluted with blank medium and analyzed for the total
dissolved isomer concentration (both diastereomers) using a validated UV assay method.
Additional quantities of Lot 3 crystals were added to the vials and the total isomer
concentration was measured. In all cases, Lot 1 crystals were added in excess such that
they were always maintained at their equilibrium solubility. The total isomer
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concentration (mg/ml) was plotted against the amount of isomer B added (mg). The
observed value of total isomer concentration was compared with the theoretical
concentration of the isomers to ascertain the possibility of interaction or formation of a
complex.10
3.2.4 Intrinsic Dissolution Rate Studies of Diastereomer Mixtures
Intrinsic dissolution rate (IDR) is defined as the dissolution rate of a substance
under the condition of constant surface area. IDR is dependent on solid state properties,
and extrinsic factors such as hydrodynamic conditions, pH, temperature and fluid
viscosity and is independent of particle size and shape frequently encountered in
traditional dissolution experiments. In order to measure IDR, a compact of constant
surface area of the material under study is prepared by compression and exposed to the
dissolution medium while maintaining a constant temperature, pH and stirring rate.109
Noyes-Whitney equation (Equation 1.8, Chapter 1) under sink conditions can be
rearranged to give an expression for IDR (Equation 3.1) as follows:
dW / dt DCs

S
h

(3.1)

where the term dW / dt is the IDR. In order to calculate IDR, the cumulative amount of
S

drug dissolved at each time point (mg or moles) normalized by the area of the compact
(cm2) is plotted against time and linear regression analysis is performed. The slope of this
line is the IDR and is most often reported as mg/cm2/min or moles/cm2/min. Therefore
when surface area is held constant, IDR is directly related to the solubility of the drug.
For this study, the IDR of diastereomer mixtures of three compositions was
measured. These mixtures were prepared by physically mixing appropriate quantities of
76

Lot 2 crystals (85 % isomer B) and Lot 1 crystals (form AI) to obtain the appropriate
compositions. The ratio of isomer B to isomer A, that is, NisomerB/NisomerA in the tested
compositions was 0.25, 1 and 3, where N represents the molar amount of each isomer in
the mixture. Approximately 120 mg of each diastereomer mixture was placed in a
stainless steel tablet die (sample holder) and compressed using Instron universal material
testing system (Model 5869, Norwood, MA) at a speed of 10 mm/min to a maximum
load of 5 kN to produce a compact of constant area. This particular compression force
was found to be optimal. Lower compression forces resulted in the formation of compacts
that showed an initial burst release of drug as they were not well formed, whereas higher
forces produced fragile disks that fragmented. After compression, the die cavity was
filled with paraffin wax, such that only one surface of the compact was accessible to the
dissolution medium. Figure 3.1 shows the experimental set-up used for IDR
determination. Powder X-ray diffraction analysis of the compacts prior to dissolution was
carried out and this ensured that the solid form was not altered as a result of compaction.
The sample holder was then carefully placed in 300 ml of 0.07 N hydrochloric acid
dissolution medium maintained at 37±0.5 °C. A constant surface area of the compact was
exposed to the dissolution medium. The surface area of the compacts exposed to the
dissolution medium were between 0.833–0.836 cm2. The dissolution medium was stirred
with a paddle placed at a distance of 2.5 cm directly above the compact surface at a
rotation speed of 55 rpm. Dissolution studies were carried out using a VanderKamp 600
dissolution apparatus (VanKel Industries, USA). Samples (4 ml) were withdrawn at predetermined time intervals, filtered using a 0.2 µm polypropylene syringe filter and
analyzed using the validated UV spectroscopic assay method. The test for adsorption of
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drug to the filters revealed no significant loss of drug. The volume of sample withdrawn
was replaced with an equal volume of pre-equilibrated medium to maintain sink
conditions. The IDR was determined from the slope of the linear portion of the amount
dissolved per unit area (moles/cm2) vs. time plot and is reported as the mean of the slope
of three replicate determinations

Paddle speed: 55 rpm
Dissolution medium:
0.07N aqueous
hydrochloric acid
Compact of constant surface area

Figure 3.1. Experimental IDR set-up.

The observed IDR values for the three diastereomer mixtures with NisomerB/NisomerA
ratios of 0.25, 1 and 3 were compared to the dissolution rate values obtained by
application of the Higuchi model for a binary mixture of interacting solids.11, 12
Calculation of dissolution rate by the Higuchi model requires knowledge of the
solubilities of both crystalline diastereomers, which were measured by solubility studies
(Section 3.2.3), and diffusion coefficient of the drug molecule. The calculation of
diffusion coefficient requires knowledge of the radius of the drug molecule. The twodimensional chemical structure of the molecule was drawn using ChemDraw® (version
13.0, PerkinElmer. Massachusetts). The radius of the molecule was determined using
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Molecular operating environment (MOE 2013.08, Chemical Computing Group) software.
The diffusion coefficient was calculated using the Stokes–Einstein equation assuming
that the CFA molecule is spherical (Equation 3.2)110:

D

kT
6r

(3.2)

where D is the diffusion coefficient of the molecule (cm2/min), k is the Boltzmann
constant, T is the absolute temperature, η is the viscosity of the medium and r is the
radius of the molecule.
3.3 Results and Discussion
3.3.1 Ultraviolet (UV) spectroscopic analysis
The UV assay method was found to be suitable for the quantification of dissolved
cefuroxime axetil in 0.07 N hydrochloric acid. The calibration curve of absorbance vs.
concentration (M) is shown in Figure 3.2 at a maximum wavelength (λmax) of 281 nm.
The developed analytical method was validated according to ICH Q2 (R1) guidelines as
explained in Section 3.2.2. The results of the validation study are showed in Table 3.1.
The standard error for the slope and intercept of the linear regression line were
2.02×10-2 M-1 and 5.01×10-3, respectively. Figure 3.3 shows the calibration curves
prepared using the commercially available amorphous drug (equimolar mixture of
diastereomers), Lot 1 crystals and Lot 3 crystals. There was no significant difference
between the molar absorptivities as determined from slope of the plots indicating no
significant effect of diastereomer mixture composition upon the absorption spectrum.
Table 3.2 shows the linear regression lines and the molar absorptivities determined from
the calibration curves of the various diastereomer mixture compositions
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Figure 3.2. Regression plot of cefuroxime axetil (CFA) calibration standards.

Table 3.1. Validation parameters of ultraviolet (UV) spectroscopic assay method.

Validation parameters
Linearity and Range

Values
3.99×10 to 3.99×10-5 M (R2 ≥ 0.999)
-6

CFA conc.
(M)

Accuracy and Precision

Intra-day
%
Precision

Inter-day
%
Precision

Recovery±SD (% RSD) Recovery±SD (% RSD)
1.18×10-5

99.05±1.17

1.26

99.26±0.36

2.41

2.35×10-5

98.89±1.17

1.11

98.90±0.78

2.46

3.92×10-5

99.54±0.50

0.5

99.61±0.62

1.79

LOD

4.49×10-7 M

LOQ

1.36×10-6 M
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Figure 3.3. Regression plot of amorphous CFA, Lot 1 crystals and Lot 3 crystals calibration
standards.

Table 3.2. Equation of linear regression line and molar absorptivities of standard solutions of
diastereomer mixtures.

Sample

% Isomer B

Equation*

Molar absorptivity
(L mol-1cm-1)**

Lot 1 crystals

0

2.21x+0.0063

2.21×104

Amorphous CFA

50

2.20x+0.0061

2.20×104

Lot 3 crystals

75

2.21x+0.0078

2.21×104

*Obtained by linear regression of the absorbance vs. concentration (×104 M) plot
** Calculated from the slope of the linear regression plot
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Figure 3.4 shows the regression plot of CFA calibrations standards made in a
lower concentration range from 1.99×10-8 to 4.80×10-7 M. The correlation coefficient
(R2) was 0.9992 indicating a linear relationship between absorbance and concentration.
This calibration curve was then used to quantify lower concentrations of dissolved drug
in the dissolution medium.

Figure 3.4. Regression plot of cefuroxime axetil (CFA) calibration standards in a lower
concentration range.

3.3.2 Solubility Studies and Phase Solubility Analysis of Diastereomer Mixtures
The experimentally determined concentration versus time profile for Lot 1
crystals is shown in Figure 3.5. The concentration reached a constant value after about
11 h. As the concentration remained constant, that is, there was no decrease in
concentration following approach of a steady level, it was concluded that form AI of
isomer A did not convert to a more stable form during the experiment. A decrease in
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concentration following a peak or steady concentration level suggests a solvent-mediated
conversion to a stable crystalline form upon dissolution, indicating that the solid form is
metastable. PXRD analysis of the solid residue remaining after the solubility study
showed characteristic crystalline peaks for form AI without the presence of any
additional peaks. This further confirmed that form AI was stable in the time frame of the
experiment. The equilibrium solubility of Lot 1 crystals was 2.22×10-4 M (±7.76×10-6 M)
(average± SD of n=3 replicates).

Figure 3.5. Solubility profile of Lot 1 crystals (form AI) crystals of CFA in 0.07 N hydrochloric
acid at 37±1 °C. The plotted concentrations are an average value of n=3 replicates and the error
bars represent standard deviation.

The phase solubility diagram plotted as the total isomer concentration, that is sum
of concentration of isomer A and isomer B as a function of the amount (mg) of isomer B
added to the solution at 37±1 °C is shown in Figure 3.6. The theoretical isomer
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concentration (as shown in Figure 3.6) was calculated from knowledge of the amount of
isomer B added as a 75 % isomer B mixture plus the equilibrium solubility of Lot 1
crystals (2.22×10-4 M). As a solid phase consisting of Lot 1 crystals is always present in
the system, the thermodynamic activity of dissolved isomer A is constant and its
concentration is equal to equilibrium solubility.

Figure 3.6. Phase solubility diagram of isomer B with isomer A (Lot 1, form AI crystals) of CFA
in 0.07 N hydrochloric acid at 37±1 °C. Segment b-c represents the plateau region.

With reference to Figure 3.6, it was initially observed that as the amount of
isomer B added increased from point a to point b, the total isomer concentration also
increased. This increase occurred up to a certain point (point b), that is, until the total
measured isomer concentration was 1.39 mg/ml. Further increase in amount of isomer B
did not produce a corresponding increase in the total measured isomer concentration as
represented by the plateau level of Figure 3.6 (segment b–c). Therefore, from the
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ascending portion of the experimental plot in Figure 3.6, it was concluded that isomer B
added to the system entered the solution phase resulting in an increase in measured
concentration. Finally, a plateau phase was reached where an increase in amount of
isomer B did not result in an increase in measured isomer concentration. The solid
residue remaining was analyzed by 1H-NMR spectroscopy. The NMR spectra showed an
increase in the area under the quartet peak at a chemical shift value of 7.01 ppm
(representing isomer B) as increasing amount of isomer B was added, which indicated
that the solution was saturated with isomer B.107
Another important feature of the phase solubility diagram of the diastereomers of
CFA was that the measured concentration (observed concentration plot in Figure 3.6)
was greater than the calculated theoretical concentration. This indicated the presence of
an interaction, possibly formation of a soluble complex between the diastereomers in
solution. The following scheme was proposed for the observed phenomenon of solubility
increase:

A(s ) ⇄ A(aq)

(3.3)

A( aq)  B( aq) ⇄ AB(aq)

(3.4)

 

(3.5)

K A0  A( aq)
K AB 

AB 
A B 
aq

aq

(3.6)

aq

where A(s ) and A(aq) represent solid phase and solution phase isomer A, respectively.

K A0

is the equilibrium solubility of isomer A in the absence of isomer B. Baq and AB(aq) are
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the isomer B and AB complex in solution, respectively. If the total isomer concentration
at point b is represented by S, then:



S  A0   B0   ABaq
where



(3.7)

B0  is the equilibrium solubility of isomer B and ABaq is the concentration of the

complex (assuming formation of a 1:1 complex between the diastereomers).
The ratio of the diastereomers in the solution saturated with both isomer A and
isomer B was determined by 1H-NMR spectroscopy. The areas of the peaks occurring at
chemical shift values of 6.89 ppm and 7.01 ppm were integrated and their relative ratio is
expressed in Equation 3.8 (details of 1H-NMR spectroscopy explained in Chapter 2,
Section 2.2.2).

B0   ABaq  3

A0   ABaq  2

(3.8)

Rearranging Equation 3.8 and substituting in Equation 3.7 gives the following:
S  2.5A0 
 ABaq
1.5





As the values of S and

(3.9)

A0  are known, the value of ABaq was calculated and was

found to be 0.737 mg/ml or 7.23×10-4 M.

A0 

is the equilibrium solubility of Lot 1

crystals (form AI) (Figure 3.3). Further Equation 3.10 was used to calculate

B0   1.5A0   0.5ABaq 
The value of

B0  :
(3.10)

B0  was calculated to be 0.536 mg/ml or 1.05×10-3 M.
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The values of solubilities of isomer A, isomer B and the resulting concentration of
the proposed AB complex were then used to calculate the equilibrium constant for the
formation of the complex using Equation 3.6.
3.3.3 Intrinsic Dissolution Rate Studies of Diastereomer Mixtures and Application of
Higuchi Model
Based on the results of phase solubility analysis of CFA diastereomers it was
ascertained that the diastereomers interacted in solution (Section 3.3.2). The intrinsic
dissolution rate (IDR) of Lot 1 crystals (form AI) as well as diastereomer mixtures of
three different compositions, with NisomerB/NisomerA ratios of 0.25, 1 and 3 were measured
using the stationary disk set-up as shown in Figure 3.1. Figure 3.7 shows a
representative IDR plot of Lot 1 crystals which also represents NisomerB/NisomerA ratio of 0.
Representative IDR plots of diastereomer mixtures are shown in Figure 3.8. The linear
regression equations of the plot of amount dissolved per unit area (moles/cm2) versus
time (min) for Lot 1 crystals and diastereomer mixtures is shown in Table 3.3.
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Figure 3.7. Representative intrinsic dissolution rate (IDR) plot of the amount dissolved per unit
area (moles/cm2) versus time (min) of Lot 1 crystal compacts with a fixed surface area of
0.836 cm2 in 0.07 N hydrochloric acid at 37±1 °C.
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Figure 3.8. Representative intrinsic dissolution rate (IDR) plot of the amount dissolved per unit
area (mole/cm2) versus time (min) of diastereomer mixtures of different compositions with a
fixed surface area of 0.836 cm2 in 0.07 N hydrochloric acid at 37±1 °C.
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Table 3.3. Regression equations of the amount dissolved per unit area (moles/cm2) versus time
(min) plot of Lot A1 crystals and various diastereomer mixtures.

Composition of
mixture
(NisomerB/NisomerA)

Regression equation*
1.32×10-8x-2.39×10-8

0 (Lot 1 crystals)

0.25

1

3 (Lot 3 crystals)

Correlation
coefficient
(R2)
> 0.999

1.28×10-8x+2.61×10-8

0.999

1.30×10-8x+2.06×10-8

>0.999

1.80×10-8x-1.17×10-8

>0.999

1.79×10-8x-7.60×10-9

0.999

1.80×10-8x-4.19×10-8

0.994

3.83×10-8x-1.33×10-7

>0.999

3.94×10-8x+1.94×10-8

>0.999

1.06×10-7x-6.15×10-9

0.999

1.06×10-7x+1.49×10-8

0.998

1.04×10-7x-8.49×10-8

0.999

IDR (moles/cm2/min)**

1.30×10-8 (±2×10-10)

1.80×10-8 (±1.20×10-10)

3.89×10-8 (±8.04×10-10)
1.05×10-7 (±1.28×10-5)

*Equation obtained by linear regression of the plot of amount dissolved (moles/cm2) versus time
(min)
**IDR is the slope of the plot of amount dissolved per unit area (moles/cm2) versus time (min)
and is represented as average (±S.D.) of at least n=2 replicates at each diastereomer composition

The plots of amount dissolved per unit area versus time were linear with
correlation coefficients of R2≥ 0.994 for all the runs (Table 3.3). The linearity of the plots
(Figure 3.7 and Figure 3.8) indicated that the crystalline diastereomers were physically
stable during the time frame of the experiment. Solvent-mediated phase conversion to
crystalline forms with greater stability (and lower solubility) or saturation of the
dissolution media (absence of sink condition) would be indicated by a curvature in the
IDR plot. PXRD analysis of the compacts after the dissolution study showed that the
crystalline peaks corresponding to form AI and form BI were preserved. Therefore
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PXRD analysis provided further confirmation of the absence of any solvent-mediated
conversion of the crystalline diastereomers.
The Higuchi model describing dissolution of interacting components, that is,
components that interact in solution to form a complex (discussed in detail in Chapter 1:
Section 1.2.3) was used to calculate the theoretical dissolution rates of diastereomer
mixtures of different compositions. The model was chosen based on evidence of
interaction between the diastereomers in solution from the phase solubility study (Section
3.3.2).
The calculation of theoretical dissolution rate of mixtures using Higuchi model
requires knowledge of the diffusion coefficients of the molecule and complex as well as
thickness of the diffusion layer (h term) (Equations 1.22–1.27, Chapter 1: Section
1.2.3).11, 12 The diffusion coefficient of CFA molecule was calculated using the StokesEinstein equation (Equation 3.2). The radius of a single CFA molecule was measured to
be 8.32 Å using MOE software. The diffusion coefficient of the complex was calculated
by assuming that the radius of the complex is twice that of a single molecule or 16.64 Å.
The viscosity value of 0.07 N hydrochloric acid was assumed to be the same as that for
water at 37 °C which is 7.19×10-4 Pas.111 Based on these values, the diffusion coefficient
for CFA and the CFA complex at 37 °C were 2.28×10-4 cm2/min and 1.14×10-4 cm2/min,
respectively.
The theoretical thickness of the diffusion layer (h term), was calculated by
rearranging Equation 3.1 to solve for h. The data from the IDR study of Lot 1 crystals
(Table 3.2) was used to calculate the h value, as the equilibrium solubility (Cs) of Lot 1
crystals was measured to be 2.22×10-4 M (Section 3.3.2) and the diffusion coefficient of
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CFA was calculated as 2.28×10-4 cm2/min. The thickness of the diffusion layer was
calculated to be 39 µm. In previous studies, the thickness of the diffusion layer was found
to be 30 µm under similar conditions.12,112
A knowledge of values of solubilities of Lot 1 crystals (form AI), isomer B as
well as the complex as determined from the phase solubility studies, the diffusion
coefficients of CFA and the complex and the thickness of the diffusion layer enabled
calculation of the critical ratio. The critical ratio is the particular mixture composition at
which both diasteromers coexist on the compact surface (explained in detail in Chapter
1: Section 1.2.2). The critical ratio was calculated for NisomerB/NisomerA to be 2.44, where
NisomerB and NisomerA are the respective amounts of isomer B and isomer A in the mixture.
Therefore at the critical ratio, NisomerB was 0.71 and Nisomer A was 0.29. For mixture
compositions of NisomerB> 0.71, isomer B forms the surface phase represented by Case 2
in Figure 1.5, Chapter 1. The dissolution rate of isomer B (RB) was calculated using
Equation 1.24 (Chapter 1) where isomer B is component B and isomer A is component
A. Accordingly the intrinsic dissolution rate of isomer A (RA) was calculated using
Equation 1.25 for compositions of NisomerB> 0.71. Similarly for compositions where
NisomerB< 0.71which is represented by Case 3 in Figure 1.5, Chapter 1, isomer A forms
the surface phase. The intrinsic dissolution rate of isomer A (RA) was calculated using
Equation 1.22 and that of isomer B (RB) was calculated using Equation 1.23.11, 12
Figure 3.9 shows the intrinsic dissolution rates of diastereomer mixtures with
values of NisomerB from 0 to 1. These values were calculated as described above using the
Higuchi model for components that interact in solution.11, 12 The values for the theoretical

92

intrinsic dissolution rates for various diastereomer compositions according to Higuchi
model for interacting components are listed in Table 3.4.

Figure 3.9. Theoretical intrinsic dissolution rates of isomer A and isomer B from diastereomer
mixtures of various compositions. Values obtained by application of Higuchi model for binary
mixtures of interacting components. The (*) indicates the critical mixture ratio where NisomerB
0.71and NisomerA is 0.29.11, 12
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Table 3.4.Theoretical dissolution rate values of isomer A and isomer B from diastereomer
mixtures. Values were obtained by application of Higuchi model for components exhibiting
solution interaction.11, 12

NisomerB/NisomerA

NisomerB

IDR of isomer B
(RisomerB×108)
(moles/cm2/min)

IDR of isomer A
(RisomerA ×108)
(moles/cm2/min)

0

0

-

1.30

0.11

0.1

0.148

1.33

0.25

0.2

0.346

1.38

0.43

0.3

0.623

1.46

0.67

0.4

1.04

1.56

1

0.5

1.74

1.74

1.5

0.6

3.14

2.09

2.33

0.7

7.41

3.18

2.44 *

0.71

8.31

3.41

3

0.75

7.82

2.61

4

0.8

7.34

1.84

9

0.9

6.66

0.740

*indicates critical ratio
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The observed IDR values of the diastereomer mixtures of compositions
represented by NisomerB/NisomerA values of 0.25, 1 and 3 (Table 3.3) were compared with
the theoretical values for mixtures (calculated using the Higuchi model) given in Table
3.4. Figure 3.10 shows the comparison of the theoretical and observed IDR of
diastereomer mixtures of the above mentioned compositions. Based on these results it
was concluded that the Higuchi model describing the dissolution rate of interacting
components provided a reasonable fit to the observed IDR data, with the difference in the
experimental and theoretical rates being less than 10 % for each mixture composition.

Figure 3.10. Comparison of IDR values calculated using the Higuchi model for interacting
components (theoretical) and observed values for diastereomer mixtures. The observed values
represent the average value of IDR from at least n=2 replicates at each diastereomer mixture
composition and error bars are the standard deviations.
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3.4 Conclusion
Phase solubility analysis on diastereomers of CFA showed evidence of interaction
or complexation between the diastereomers in solution. The measured concentration of
the dissolved diastereomers was greater than the theoretical concentration indicating
formation of a soluble complex. A scheme was proposed for formation of a soluble
complex between the diastereomers. The results of the phase solubility study were further
confirmed by intrinsic dissolution rate measurements on compacts of diastereomer
mixtures. The dissolution rates of the diastereomers from the mixtures were in good
agreement with the Higuchi model for dissolution of binary mixtures of components that
form a 1:1 complex in solution. As CFA suffers from solubility problems, interaction or
complexation between the diastereomers is an important finding as it implies that using a
combination of the diastereomers is beneficial over use of a single isomer. Further the
ratio of the diastereomers expressed as NisomerB/NisomerA that shows the maximum
dissolution rate when calculated using the Higuchi model for interacting components was
2.44. Using this composition in formulations may limit dissolution rate-limited
bioavailability problems of the drug.
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Chapter 4: Interactive Mixtures for Dissolution Rate Enhancement of
Cefuroxime Axetil
4.1 Introduction
This work involved preparation of mechanically stable interactive mixtures of
amorphous CFA with an aqueous soluble carrier material and investigation of the
mechanism of dissolution rate enhancement from interactive mixtures relative to physical
mixtures and drug agglomerates. To this end, a dissolution model relevant to
heterogeneous particle distributions was applied to mixture dissolution data (explained in
detail in Chapter 1: Section 1.4.5). As amorphous drugs can potentially convert to
stable crystalline forms during dissolution resulting in variable dissolution profiles, a
stable crystalline form of CFA was micronized and formulated into an interactive
mixture. Modeling the dissolution data enabled calculation of the surface area of drug
that was available for contact with the dissolution medium or the effective surface area
and the weight-fraction of agglomerated particles in the mixtures. Parameters related to
particle size of agglomerated and dispersed particles in interactive and physical mixtures
were also calculated in order to understand the mechanism of dissolution rate
enhancement upon interactive mixing.
4.2 Materials and Methods
4.2.1 Materials
Commercially available (as received) cefuroxime axetil (Dhanuka Laboratories,
Mumbai, India) and Lot 3 crystals which is a diastereomer mixture containing 75 %
isomer B (present as form AI and form BI, Chapter 3: Section 3.2.1) were formulated
separately as mixtures with sucrose carrier particles. Crystalline sucrose (Lot no. 08189,
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Fisher Scientific, Fair Lawn, New Jersey) was used as a carrier material. Sucrose was
chosen as a carrier based on its high aqueous solubility such that it would dissolve rapidly
in the dissolution medium. Hydrophilic polymers were avoided based on their effect on
solution viscosity that would further cause a barrier for dissolution. Specific size fractions
of the drug agglomerates and carrier material were obtained by sieve classification using
a set of standard sieves (Gilson Company, Inc.). Hydrochloric acid (36 % w/w aqueous
solution, Lot no. A25X018, Alfa Aesar, Shore Road, Lancashire) and deionized water
were used to prepare 0.07 N hydrochloric acid as the dissolution medium which was
degassed prior to use.
4.2.2 Characterization of CFA and Carriers
Commercially available CFA was analyzed by powder X-ray diffraction (PXRD)
and differential scanning calorimetry (DSC) techniques in order to characterize the solid
form. PXRD patterns were recorded at room temperature on a X’Pert Pro MPD system
(P’Analytical B.V., Almelo, the Netherlands) equipped with a with a copper anode
(λ = 1.5406 Å) and an X’Celerator™ detector. The operational voltage and amperage
were set to 45 kV and 40 mA, respectively. The radiation was passed through a nickel
filter. The incident and diffracted beam optics consisted of a divergence slit, antiscatter
slit (2 °), and soller slit (0.1 mm). Samples were mounted on a back-filled, aluminum
sample holder and were analyzed in continuous mode with a step size of 0.0170 °2θ and a
step time of 31.75 s over the range of 2-60 °2θ. The samples were rotated on a vertical
stage at 16 rpm during the measurements. Diffractograms were analyzed by X’Pert
HighScore Plus software. DSC measurements were performed using a TA Q100
differential scanning calorimeter (TA Instruments, Newcastle, DE). Approximately 4 mg
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samples were placed in aluminum sample pans and hermetically sealed. The
measurements were made between 0 °C and 250 °C at a scan rate of 20 °C/minute under
a constant nitrogen purge (50 ml/min). Data were analyzed using TA Instruments
Universal Analysis software (version 4.5A). Lot 3 crystals were characterized using
PXRD analysis as described in Chapter 2: Section 2.2.3.
Particle size distributions of the commercially available drug and carrier materials
were determined using sieve analysis as per USP 32/NF 27 chapter <786> using
approximately 10 g of each material for the test.113A light microscope (Model BX-51,
Olympus) was used to visualize primary drug particles within agglomerates, and the
particle sizes were based on the Feret diameters (ImageJ software, version 1.41o). Lot 3
crystals were milled using a ball mixer mill (Retsch mill, MM200, Haan, Germany).
Approximately 1 g of material was sealed in the milling vessel and the material was
ground at an impact frequency of 15 Hz for 30 min. Particle size analysis was carried out
on the milled material using optical microscopy and the particle sizes were based on the
Feret diameters.
The true volumes of commercially available CFA and Lot 3 crystals were
determined using a stereopycnometer (Model SPY-6DC, Quantachrome Instruments,
Boynton Beach, FL) using helium as the displaced gas. Samples weighing approximately
5 g were purged with nitrogen for 20 min before measurement. True density was
calculated as the ratio of the sample weight to the true volume.
Specific surface areas of the drug materials used to prepare the mixtures were
measured by multi-point BET (Brunauer, Emmett and Teller) analysis of nitrogen vapor
adsorption (FlowSorb II 2300, Micromeritics Instrument Corporation, Norcross, GA).
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Powder samples were dried under vacuum at 50 °C for 48 h. Each dried powder was then
filled into a clean, dry sample tube and degassed under a helium purge at 50 °C for 6 h.
Measurements were made at a series of relative nitrogen pressures (p/p0) of 0.05, 0.10,
0.15, 0.20 and 0.25 by taking two adsorbed volume () measurements per sample at each
relative pressure. The BET equation (Equation 4.1) was used to compute the volume of
gas required to form a monolayer ( vm ):

p / p0
c 1
1

( p / p0 ) 
v(1  p / p0 ) vm c
vm c

(4.1)

Linear regression analysis was used to estimate

vm and the affinity constant, c .

The total surface area of the sample ( S ) was computed using the following equation:
S

vm AN
M

(4.2)

where A is Avogadro’s number, N is the area of each adsorbed nitrogen gas molecule
(16.2 Å2) and M is the molar volume of the gas. The total surface area was divided by the
mass of the sample to obtain the specific surface area (SSA) of each sample.114
4.2.3 Intrinsic Dissolution Rate (IDR) Measurement
Intrinsic dissolution rate (IDR) of commercially available CFA was measured
using the experimental set-up and the method as described in Chapter 3: Section 3.2.4.
The value for IDR of Lot 3 crystals is reported in Chapter 3: Table 3.2 and this value
was used for further calculation in this study.
4.2.4 Drug-Carrier Mixture Preparation
Mixtures of CFA drug agglomerates (< 53 µm size fraction) and Lot 3 crystal
milled particles were prepared separately with a specific size fraction of the carrier
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material, sucrose in the 500–1000 µm size range, using a centrifugal planetary mixer
(Thinky Mixer ARM-310, Thinky USA, Inc.). Briefly, 5 g of each 10 % w/w CFAcarrier material mixture was prepared by weighing out appropriate quantities of each
component, followed by mixing at a rotational speed of 2000 rpm for 5 min. All materials
were stored at 33 % RH in a humidity chamber for 72 h prior to use. Mechanical stability
of the mixtures was assessed by sieving them until a constant weight (less than 2 %
weight difference) remained on a sieve whose size opening was smaller than the carrier
particles but was larger than the original drug particles. Figure 4.1 shows the
experimental set-up of the sieves used for mechanical stability determination of mixtures.
Mixtures were also evaluated using microscopy to visualize the mixtures. The content of
drug retained in each mixture was determined by analyzing 6 × 20 mg samples with the
validated UV assay method (Chapter 3: Section 3.3.1). Mixtures using the same size
fractions of the drug and carrier material were also prepared using a laboratory scale Vblender and were similarly examined by optical microscopy.
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Figure 4.1. Experimental set-up of sieves for mechanical stability determination of mixtures; light
blue-carrier particles, dark blue-drug particles.

4.2.5 Dissolution Studies
Dissolution studies were carried out on pure drug, physical mixtures and
interactive mixtures of the drug with sucrose carrier particles. The amount of mixture
used for the dissolution study contained the equivalent of approximately 90 mg of drug
and each mixture sample was analyzed in triplicate. Mixture samples were placed in the
basket assembly and were immersed in 900 ml of 0.07 N hydrochloric acid as the
dissolution medium. The choice of the dissolution medium was based on USP
specifications for dissolution medium for CFA tablets.115 The rotation speed and bath
temperature were maintained at 50 rpm and 37±0.5 °C, respectively (Vanderkamp 600
dissolution tester, VanKel Industries, Inc.). Samples (5 ml) were withdrawn at predetermined time intervals, filtered through 0.2 µm polypropylene filter, appropriately
diluted if necessary and analyzed for CFA content by a validated UV spectroscopic assay
method at a λmax of 281 nm (Chapter 3: Section 3.3.1). The volume of sample
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withdrawn at each time point was replaced with an equal volume of blank dissolution
media.
4.2.6 Modeling of Dissolution Data
Drug dissolution from interactive mixtures has been modeled using the
biexponential equation derived from Wagner’s model assuming exponential surface area
changes as dissolution proceeds.96 This model treats dissolution from interactive mixtures
as a two-stage process involving rapid dissolution of dispersed particles in parallel with
slower dissolution of agglomerated particles as illustrated in Figure 4.2.

Carrier is dissolved in
dissolution medium

Agglomerated particles Wa

Dispersed particles Wd
kd

ka

Drug in solution
Drug in solution

Figure 4.2.Schematic representation of drug dissolution from interactive mixtures; light bluecarrier particles, dark blue-drug particles.

The biexponential dissolution model (Equation 1.45, Chapter 1: Section 1.4.5)
was used to model drug dissolution from pure drug agglomerates, interactive and
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physical mixtures with sucrose. This model has shown utility in studying dissolution
from drug particles that have bimodal size distributions in numerous studies.91-94 The
method of residuals was used to determine the various parameters, such as ka, kd, Wa and
Wd that describe the dissolution of the dispersed and agglomerated particles. This model
assumes a five-fold difference between the rate constants.116
The parameters obtained through application of the biexponential model to
dissolution data enabled calculation of the effective surface area of the agglomerated and
dispersed particles, namely, Sa and Sd respectively. Equation 1.41 (Chapter 1: Section
1.4.5) is an expression for the amount of drug dissolved at t=∞. Therefore W∞ is the
amount of drug dissolved at infinite time or the initial amount of drug. In case of the
biexponential model, Wa is the initial amount (or weight) of drug present as agglomerates
in the mixture and can be expressed by Equation 4.3 which enabled calculation of the
effective surface area of the agglomerated particles in the mixture (Sa):

Sa 

Wa k a
kCs

(4.3)

In Equation 4.3, the term kCs is the intrinsic dissolution rate which was measured
experimentally using the stationary disk method (Section 4.2.3), and Wa and ka were
calculated following application of the method of residuals to the amount remaining to
dissolve versus time data. The effective surface area of the dispersed particles in the
mixtures, Sd was calculated using Equation 4.4:

Sd 

Wd k d
kCs

(4.4)

Therefore Equation 4.3 and Equation 4.4 allowed the effect of interactive
mixing on the amount of interface between the particles and the dissolution medium to be
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determined and allowed comparisons to be made between the effective surface areas
contributing to dissolution from the various samples.
Further modeling also involved development of a relationship between the rate
constants, ka and kd describing the surface area changes of the agglomerated and
dispersed particles and a parameter related to particle size. Assuming that the
agglomerated particles are spherical, the initial weight of ‘n’ number of agglomerated
particles can be expressed as:
Wa 

4 3
ra   a  n
3

(4.5)

where is ra the radius of the agglomerated particles, ρa is the density of the agglomerated
particles. The surface area of ‘n’ number of agglomerated particles is given by:

S a  4ra2  n

(4.6)

Substitution of Equation 4.5 and Equation 4.6 in Equation 4.3 gives the following

ra  a 

3kCs
ka

(4.7)

where raρa is a parameter related to the particle size of the agglomerated particles.
Similarly for dispersed particles, the relationship between the parameter related to
particle size and rate constant is as follows:

rd  d 

3kCs
kd

(4.8)

4.2.7 Statistical Analyses
Dissolution profiles of drug agglomerates, physical and interactive mixtures were
compared using the similarity factor (f2). The similarity factor is a logarithmic reciprocal
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square root transformation of the sum of the squared error and is a measurement of the
‘sameness or equivalence” of two dissolution profiles (Equation 4.9).117
 1 n

f 2  50  log 1    ( Rt  Tt ) 2 
  n  t 1


0.5

 100

(4.9)

where Rt is the mean percent drug dissolved of a reference product and Tt is the mean
percent drug dissolved of a test product and n is the number of time points. f2 values of
50–100 indicate that the dissolution profiles are similar. An f2 value of 50 indicates an
average difference between mean dissolution profiles of up to 10 %.117 In order to
calculate the f2 value, the mean cumulative percent dissolved value was used from n=3
measurements for each mixture sample. Calculation of similarity factor (f2) value allows
an appropriate weighting to be given to certain time points of the dissolution profile.
One-way analysis of variance (ANOVA) with Tukey’s multiple comparison test
was employed to evaluate the statistical significance between the various parameters
calculated by application of the method of residuals to amount remaining to dissolve
versus time data for the mixture samples (α = 0.05). Two-way ANOVA with Tukey’s
multiple comparison tests was used to evaluate statistical significance between
parameters and well as any statistically significant interactions calculated for the mixture
samples containing two different coating materials. In two-way ANOVA, the factors
were the coating material (Amorphous CFA vs. Lot 3 crystals (milled)) and mixture type
(pure drug, physical mixtures and interactive mixtures).
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4.3 Results and Discussion
4.3.1 Solid State, Particle Size and Surface Area Analysis of CFA
The PXRD pattern of commercially received CFA (Figure 4.3) revealed a broad
diffuse pattern characteristic of amorphous solids The DSC thermogram for the drug
exhibited a glass transition (Tg) event at 78.1 °C (Figure 4.4) which indicated that the
supplied drug material was the amorphous solid form. The reported Tg for amorphous
CFA is 77.5 °C.118

Figure 4.3. PXRD pattern of commercially available CFA.
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Figure

4.4. DSC thermogram of commercially available CFA at a heating rate of 20 °C/min.

Lot 3 crystals mixture (75 % isomer B) was prepared by physically mixing
appropriate quantities of Lot 2 crystals containing 85 % wt. isomer B and Lot 1 crystals.
The solid forms of CFA diastereomers present in Lot 3 crystals were form AI and form
BI.
The particle size distribution of sucrose was determined using a set of standard
sieves. The largest size fraction (32 % w/w) of the sucrose particles was the
500–1000 µm size range. Figure 4.5 is an optical microscopy image of sucrose carrier
particles that were used to prepare physical and interactive mixtures.
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Figure 4.5. Optical microscopy image of sucrose carrier particle (500–1000 µm). Images obtained
under 10  magnification.

Figure 4.6a is the histogram for particle size analysis of commercially available
CFA by sieve analysis. Optical microscopy of CFA particles (< 53 µm size range
collected by sieve analysis) revealed the presence of the drug agglomerates (Figure
4.6b). In order to obtain information on the particle size of the dispersed particles in the
< 53 µm agglomerate size fraction, the agglomerates were dispersed in oil and the
particles visualized by optical microscopy. Figure 4.6c is the image of the material
dispersed in oil. The d30, d50 and d90 values found using image analysis were 10 μm,
20 μm and 40 μm, respectively, by measuring the Feret diameter of approximately 1200
particles. Drug particles in the < 53 µm size range (using sieve analysis) were used to
form interactive and physical mixtures with both carrier particles.
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b

c
b

Figure 4.6. (a) Particle size analysis of commercially available CFA obtained by sieve analysis as
per USP 32/NF 27 <786> method (b) Optical microscopy image of fine particles (< 53 µm size
fraction) from the commercially available CFA showing the presence of agglomerates (c) Optical
microscopy image of fine particles (< 53 µm size fraction) from the commercially available CFA
dispersed in oil showing primary particles. Images obtained under 10  magnification.

Figure 4.7a and Figure 4.7b are the optical microscopy images for milled
particles of Lot 3 crystals before and after dispersion in oil, respectively. The Feret d30,
d50 and d90 values were found to be 3.8 μm, 5.7 μm and 28 μm for the milled particles and
1.6 μm, 4 μm and 15 μm for the milled particles following dispersion in oil. PXRD
analysis of the milled particles showed preservation of crystalline peaks of form AI and
form BI indicating absence of phase conversion upon milling (Figure 4.8).103
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Figure 4.7. Optical microscopy images of Lot 3 crystals (75 % isomer B) (a) without dispersion in
oil (b) after dispersion in oil. Images obtained under 10  magnification.

Figure 4.8. PXRD pattern (a) Milled particles of Lot 3 crystals (75 % isomer B) (b) Reported
pattern of form AI (c) Reported pattern of form BI.104
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The true density of commercially available CFA (< 53 μm) size fraction was
1.04 g/cm3 and that of Lot 3 crystals (milled) was 1.44 g/cm3.
Figure 4.9 and Figure 4.10 are the BET plots used to measure the specific
surface area (SSA) of the drug materials used. The value of specific surface area, as
determined by nitrogen vapor adsorption, represents the theoretical maximum surface
area of the drug particles that is available for contact with solvent during dissolution. The
total surface area was calculated using Equation 4.2 (Section 4.2.2) following
application of the BET equation for each sample and this value was divided by the
sample mass to obtain the specific surface area (SSA). Table 4.1 shows the SSA values
in m2/g for each CFA sample.

Figure 4.9. Representative BET plot of commercially available CFA (< 53 µm) size fraction.
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Figure 4.10. Representative BET plot of milled particles of Lot 3 crystals.

Table 4.1. Specific surface area values of drug materials used to coat carrier particles. Values
represent average (± SD) of n=2 measurements.

Sample

Specific surface area (m2/g)

Commercially available amorphous CFA (< 53 μm) size

0.167 (±5×10-4)

fraction
Milled particles of Lot 3 crystals (75 % isomer B)

0.881 (±3.50×10-3)

4.3.2 Intrinsic Dissolution Rate (IDR) Profile of Amorphous CFA
The entire dissolution profile of commercially available amorphous CFA in
0.07 N hydrochloric acid solution at 37 °C expressed as amount dissolved per unit area
(mg/cm2) vs. time (min) is shown in Figure 4.11a. It was observed that the initial portion
of the plot was linear, followed by a gradual curvature or decrease in slope. The decrease
in slope could be attributed to phase transformation of amorphous CFA to a more stable,
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less soluble solid form during dissolution. In order to determine the linear portion for
determination of IDR, the first derivative was calculated and the data were considered
linear when this value showed less than 15 % variation. A residuals plot was also
constructed and the residuals were found to be random up to 60 min time point followed
by a pattern which is indicative of non-linearity in the data. The IDR of amorphous CFA
was taken as the slope of the initial linear segment of the amount dissolved per unit area
vs time plot as shown Figure 4.11b. Table 4.2 shows the regression equations of the
initial linear segment of the amount dissolved per unit area (mg/cm2) versus time (min)
plot of amorphous CFA.
Non-linear IDR profiles as shown in Figure 4.11a are typical for amorphous
solids and metastable polymorphs that undergo solvent-mediated transformations to more
stable and less soluble crystalline forms during dissolution.119-121 PXRD analysis was
used to confirm that the non-linearity in the IDR plot was caused by phase conversion of
amorphous CFA during the dissolution experiment. PXRD analysis of the compacts was
performed both prior to and after the IDR measurement. Figure 4.12a is the powder
diffractogram of the compact before the dissolution experiment which shows a diffuse
pattern characteristic of amorphous solids. The PXRD pattern of the compact after the
dissolution experiment shows the presence of Bragg peaks indicating that a crystalline
material had deposited on the compact surface (Figure 4.12b). These data supported the
fact that amorphous CFA underwent a solvent-mediated phase transformation to a stable
crystalline form during dissolution.
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Figure 4.11. Representative intrinsic dissolution rate (IDR) profile of commercially available
amorphous CFA (a) entire profile showing curvature (b) initial linear segment up to 60 min used
to calculate IDR.
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Table 4.2. Regression equations of the amount dissolved per unit area (mg/cm2) versus
time (min) plot of amorphous CFA.

Sample

Amorphous CFA

Regression equation*

Correlation
coefficient (R2)

7.67×10-2x+2.27×10-2

> 0.999

7.56×10-2x+2.92×10-2

>0.999

7.73×10-2x-2.24×10-2

>0.999

IDR (mg/cm2/min)**

7.65×10-2 (±8.62×10-4)

*Equation obtained by linear regression of the initial linear segment of the plot of amount
dissolved (mg/cm2) versus time (min) (Figure 4.11b)
**IDR is the slope of the plot of amount dissolved per unit area (mg/cm2) versus time (min) and
is represented as average (±S.D.) of at least n=2 replicates.

A representative IDR plot for Lot 3 crystals mixture (75 % isomer B: 25 % isomer
A present as solid form BI and form AI) is shown in Figure 3.8, Chapter 3. The IDR
plots were linear indicating that form AI and form BI were physically stable in the
dissolution medium during the time frame of the experiment. The IDR values of Lot 3
crystals (NisomerB/NisomerA = 3) was 5.38×10-2 (±6.53×10-4) mg/cm2/min, this value
represents the average (±S.D.) of n=3 replicate measurements.
Amorphous CFA has a higher IDR and a higher solubility based on the direct
relationship between IDR and solubility (Equation 3.1, Chapter 3) as compared to Lot 3
crystals. Therefore, commercial products contain the amorphous solid form of CFA based
on its higher apparent solubility in an effort to improve dissolution rate. However, the
results from the IDR study on amorphous CFA compacts showed evidence of solventmediated conversion to a less soluble crystalline form during dissolution. Solvent-
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mediated phase transformations can potentially result in non-reproducible dissolution
profiles from formulations containing the metastable solid form of a drug. Since the
crystalline forms (form AI and form BI) were physically stable in the dissolution medium
during the time frame of the study, this work also involved preparation and evaluation of
interactive mixtures of micronized particles of the stable crystalline form of CFA as a
means of circumventing the problem of phase conversion during dissolution.

Figure 4.12. PXRD plots of commercially available CFA compacts (a) prior to dissolution study
(b) after dissolution study showing presence of crystalline diffraction peaks.
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4.3.3 Evaluation of Interactive and Physical Mixtures: Mechanical Stability, Optical
Microscopy and Drug Content Analyses
Table 4.3 shows the drug content in the various mixtures measured using a
validated UV spectroscopic assay. The values for drug content in mixtures prepared using
the laboratory scale V-blender represents the drug content of these mixtures prior to
sieving. This was because a small fraction, less than 1 % wt. of drug was retained on
carrier following sieve analysis. Since sieving almost completely separated the mixture
into its components, the mixtures prepared using the V-blender were used in dissolution
studies without sieving. The mixture samples prepared using the centrifugal planetary
mixer (Thinky® mixer) were sieved using the set-up shown in Figure 4.1 prior to
measurement of drug content.
Optical microscopy was used in order to visualize the presence of any interactions
between the drug and carrier particles. Figure 4.13a and Figure 4.13b are the optical
micrographs of the mixtures of the drug-sucrose mixtures prepared using the Thinky®
mixer. Figure 4.13c and Figure 4.13d are the optical micrographs of the drug-sucrose
mixtures prepared using the V-blender. Figure 4.13a and Figure 4.13b clearly showed
that the drug particles were adhered to the carrier surface supporting evidence for
formation of mechanically stable interactive mixtures. Figures 4.13c and Figure 4.13d
showed the presence of agglomerated CFA particles both adhered to, and separate from
the carrier surface representative of physical mixtures. Thus, sieving and microscopy
both qualitatively indicated a greater degree of deagglomeration and greater drug-carrier
interactions in the interactive mixtures compared to the physical mixtures. This can be
attributed to the high-speed, centrifugal-planetary mixer, which provided much more
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energy to break down the agglomerates and cause them to adhere to the carrier surface
than the low intensity, laboratory-scale V-blender.
Table 4.3. Drug content in prepared mixtures. Targeted drug content was 10 % wt. drug. Values
represent average (% RSD) obtained from 6 samples.

Mixture sample

Drug content
(% wt.)

Amorphous CFA-sucrose interactive mixture*

8.01 (0.99)

Lot 3 crystals-sucrose interactive mixture*

8.92 (0.86)

Amorphous CFA-sucrose physical mixture**

8.27 (1.21)

Lot 3 crystals-sucrose physical mixture**

8.74 (1.22)

*indicates mixtures prepared using Thinky® mixer. Drug content determined after sieving.
**indicates mixtures prepared using laboratory scale V-blender. Drug content determined prior to
mechanical sieving.

Figure 4.13. Optical micrographs of prepared mixtures (a) amorphous CFA-sucrose interactive
mixture (b) Lot 3 crystals (milled)-sucrose interactive mixture (c) amorphous CFA-sucrose
physical mixture (d) Lot 3 crystals (milled) -sucrose physical mixture. All images obtained under
10  magnification.
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4.3.4 Dissolution Profiles and Modeling Results
Dissolution profiles of amorphous CFA agglomerates and mixtures were obtained
by adding mixture samples containing approximately 90 mg of drug to 900 ml of 0.07 N
hydrochloric acid. Figure 4.14 shows the cumulative amount dissolved vs. time for all
the mixtures and for drug agglomerates.

Figure 4.14. Representative cumulative percent dissolved versus time profiles for amorphous
CFA agglomerates (< 53 µm), interactive and physical mixtures, thereof, prepared with sucrose
(500–1000 µm) carrier particles.

The dissolution profiles for the amorphous CFA agglomerates and the physical
mixtures with both carriers were similar to each other with approximately 90 % of the
drug dissolved after about 48 h. In sharp contrast, the interactive mixtures were almost
completely dissolved in 6 h (Figure 4.14). The calculated similarity factor (f2) values
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between the dissolution profiles of amorphous CFA agglomerates, physical and
interactive mixtures with sucrose are given in Table 4.4.
Table 4.4. Similarity factor (f2) values for amorphous mixture samples.
Comparison

f2 statistic value*

Inference

Amorphous agglomerates and

92.52

Dissolution profiles similar

15.9

Dissolution profiles not

physical mixture
Amorphous agglomerates and
interactive mixture
Physical mixture and

similar
16.3

interactive mixture

Dissolution profiles not
similar

*f2 value calculated using Equation 4.9 (Section 4.2.7). f2 values between 50–100 indicate
similarity between dissolution profiles.116

In order to understand the improvement in dissolution rate of drug from
interactive mixtures relative to amorphous drug agglomerates and physical mixtures, the
biexponential model (Equation 1.45, Chapter 1: Section 1.4.5) was applied to the
amount remaining to dissolve vs. time data. Figure 4.15a is a representative amount
remaining to dissolve (mg) vs time plot for amorphous CFA-sucrose interactive mixture
and the biexponential model fit to the data. The method of residuals was used to
determine Wa and ka from the terminal portion of the plot and the residuals were used to
calculate Wd and kd as shown in Figure 4.15b. Table 4.5 shows the equations following
application of the biexponential model to amount remaining to dissolve vs time data for
the amorphous CFA mixture samples and the correlation coefficients of the model fitting.
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The correlation coefficients are greater than 0.994 indicating that the biexponential model
fit the dissolution data.

Figure 4.15. (a) Representative amount remaining to dissolve vs time plot of amorphous CFAsucrose interactive mixture (b) Application of method of residuals to amount remaining to
dissolve vs time plot.
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Table 4.5. Biexponential model fit to amount remaining to dissolve vs time data for amorphous
CFA mixture samples.
Sample

78.44e-0.00062t+11.33e-0.039t

Correlation
coefficient (R2)
0.999

78.35e-0.00062t+11.93e-0.041t

0.999

78.48e-0.00064t+10.97e-0.040t

0.997

79.45e-0.00085t+11.83e-0.038t

0.996

79.45e-0.00085t+11.81e-0.039t

0.996

80.11e-0.00088t+12.38e-0.041t

0.994

31.36e-0.0088t+57.58e-0.041t

0.999

29.08e-0.0087t+60.54e-0.039t

0.999

28.79e-0.0087t+63.61e-0.040t

0.999

Biexponential model equation*

Amorphous CFA agglomerates

Amorphous CFA-sucrose physical
mixture

Amorphous CFA-sucrose
interactive mixture

*Biexponential model is of the form Wae-kat+Wde-kdt

The initial weights of agglomerated and dispersed particles, Wa and Wd were
determined which enabled calculation of the weight-fraction of agglomerated particles
represented by Wa

Wa  Wd

for each mixture sample. Results are shown in Figure 4.16.

One-way ANOVA with Tukey’s multiple comparison tests were used to evaluate
statistical significance between the mixtures.
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Figure 4.16. Comparison of weight–fraction of agglomerated particles for amorphous CFA
agglomerates (< 53 µm size fraction), interactive and physical mixtures, thereof, prepared with
sucrose carrier particles based on modeling of dissolution data (Equation 1.45). * # represents
statistical significant comparisons. Each data point represents the average of n=3 replicates,
where the error bars are the standard deviation (SD).

The weight-fraction of agglomerated particles was significantly lower for the
interactive mixture compared to that of drug agglomerates and the physical mixture
(p<0.05). The weight-fraction of agglomerated particles in the interactive mixture was
0.33 (±2.10×10-2) as compared to 0.873 (±4.75×10-3) and 0.869 (±2.48×10-3) for CFA
agglomerates and physical mixture, respectively. These data indicate that interactive
mixing was able to decrease agglomeration of drug particles. In contrast, low-intensity
physical mixing was not able to effectively break up drug agglomerates causing the
weight-fraction of agglomerated particles to be significantly higher in physical mixtures
and comparable to that of the pure drug agglomerates.
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The effective surface area of the agglomerated and dispersed particles, Sa and Sd,
were calculated from Equation 4.3 and Equation 4.4, respectively. Figure 4.17 shows
the sum of the Sa and Sd term for amorphous CFA agglomerates and interactive and
physical mixtures. The sum of the effective surface area of the agglomerated and
dispersed particles from the interactive mixture was significantly higher compared to that
of drug agglomerates and the physical mixture (p<0.05). The effective surface area of the
drug particles from the interactive mixture was 35.3 (±1.40) cm2 as compared to
6.58 (±0.218) cm2 and 7.08 (±0.353) cm2 for CFA agglomerates and physical mixture,
respectively. Interactive mixing was able to effectively break up the agglomerated drug
particles such that a larger fraction of the total surface area was available for dissolution.

Figure 4.17. Comparison of the effective surface areas of agglomerated particles and dispersed
particles, for amorphous CFA agglomerates (< 53µm size fraction), interactive and physical
mixtures, thereof, prepared with sucrose carrier particles. Values calculated using Equation 4.3
and Equation 4.4. * # represents statistical significant comparisons. Each data point represents
the average of n=3 replicates, where the error bars are the standard deviation (SD).
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The sum of the effective surface areas of the agglomerated and dispersed
particles, calculated using Equation 4.3 and Equation 4.4 for the various samples were
calculated as a fraction of the theoretical maximum surface area available for dissolution.
The theoretical maximum surface area for each sample was calculated from knowledge of
the specific surface area (SSA) of CFA agglomerates measured by nitrogen vapor
adsorption (< 53 μm size fraction, Table 4.1) and the amount of drug used in the
dissolution experiment. The values of the percent total surface area of the different
samples are given in Table 4.6.

Table 4.6. Percent total surface area of CFA agglomerates and mixture samples based on
dissolution data. Theoretical maximum surface area determined using nitrogen vapor adsorption
analysis. Values represent average (±SD) of n=3 replicates for each sample.

Sample

% Total surface area

CFA agglomerates

4.45 (±0.127)

CFA-sucrose physical mixture

4.69 (±0.197)

CFA-sucrose interactive mixture

2.37E+01 (±0.494)*#

*# represents statistical significant comparisons; *vs CFA agglomerates and #vs physical mixture

Based on Figure 4.17 and Table 4.6, it was concluded that interactive mixing was
able to deagglomerate the particles such that a significantly higher fraction of the total
surface area of the drug particles were available for dissolution. The mechanism of
dissolution rate enhancement from interactive mixtures can be attributed to surface area
increase afforded by high-intensity mixing of the carrier particles with the drug
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agglomerates causing break down of agglomerated drug particles into dispersed drug
particles or smaller agglomerates with a larger surface area exposed to the solvent.
The relationship between the rate constants describing the surface area change
and a parameter related to particle size was developed using Equation 4.7 and Equation
4.8 for the agglomerated and dispersed particles, respectively. The values for the
parameter related to particle size for the agglomerated particles (raρa) for CFA
agglomerates and a mixture is shown in Figure 4.18 whereas that for the dispersed
particles (rdρd) is shown in Figure 4.19. The parameter related to particle size for the
agglomerated particles was significantly lower for the interactive mixtures compared to
the CFA agglomerates and the physical mixture. The value of the raρa term for the
interactive mixture was 26.4 (±0.155) mg/cm2 as compared to 366 (±6.68) mg/cm2 and
267 (±5.31) mg/cm2 for CFA agglomerates and physical mixture, respectively.
Comparison of the value for the rdρd term across the mixtures revealed that this
term was not significantly different for any of the samples (p=0.184).
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Figure 4.18. Comparison of parameter related to agglomerate particle size ( ra  a ) for amorphous
CFA agglomerates (< 53µm size fraction), interactive and physical mixtures, thereof, prepared
with sucrose carrier particles based on particle dissolution data. Values calculated using
Equation 4.7.* # represents statistical significant comparisons. Each data point represents the
average of n=3 replicates, where the error bars are the standard deviation (SD).
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Figure 4.19. Comparison of parameter related to dispersed particle size ( rd  d ) for amorphous
CFA agglomerates (< 53µm size fraction), interactive and physical mixtures, thereof, prepared
with sucrose carrier particles based on particle dissolution data. Values calculated using
Equation 4.8. Each data point represents the average of n=3 replicates, where the error bars are
the standard deviation (SD).

The data in Figure 4.18 and Figure 4.19 can be understood as follows: the size of
the agglomerated particles (described by radius, ra and represented by the raρa term) was
significantly lower in interactive mixtures as compared to physical mixture and CFA
agglomerates, caused by break down of the agglomerated drug particles upon impaction
with the sucrose carrier. In this case, physical mixing also decreased the particle size of
the agglomerates, although not to the same degree as interactive mixing. The density of
the agglomerates (represented by the ρa term) would also affect the raρa term; as the
density of agglomerates with a larger particle size is expected to be lower than those with
a smaller particle size based on less efficient packing of larger size particles. However the
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density term is not expected to be significantly different between particles of different
sizes and as a result particle size would play a more important role in determining the
value of the raρa term.
The parameter related to particle size of dispersed particles, rdρd term was not
significantly different across the samples (Figure 4.19) indicating that interactive mixing
did not appear to affect the size of the dispersed particles. This indicated that there was
no milling or particle size reduction of the drug during mixing. The concepts relating the
parameter related to particle size of agglomerated and dispersed particles in the samples
are depicted in Figure 4.20.
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Figure 4.20. Schematic representation of parameter related particle size (rρ term) in CFA drug
agglomerates, physical and interactive mixtures: pink-carrier particles; blue-micronized drug
particles. The black circles represent the particle size.

Equation 4.7 and Equation 4.8 were used to calculate the radius of the
agglomerated and dispersed particles, respectively. The density value used in these
equations was the true density of the material as measured by helium pycnometry. The
radius of the agglomerated particles for the amorphous CFA-sucrose interactive mixture
was calculated as 254 (±1.49) μm and that of the dispersed particles was
54.76 (±1.37) μm. These values were compared to the radius of the particles calculated
using the specific surface area (SSA) of amorphous CFA (< 53 μm) size fraction and the
true density of the material. The value of the radius using the vapor adsorption analysis
method was 17.06 μm which represents the size of the dispersed particles. The
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significantly lower value of particle size of the dispersed particles calculated using vapor
adsorption analysis as compared to that calculated from the dissolution data may be
attributed to the surface roughness of amorphous CFA particles. An increase in surface
roughness may have increased the value of SSA leading to an underestimation of particle
size.
The results of modeling of the dissolution data for CFA agglomerates and the
mixtures prepared with sucrose carrier particles, showed that interactive mixing was able
to decrease the weight-fraction of agglomerated particles. The dissolution rate
enhancement upon interactive mixing was attributed to an increase in effective surface
area of the drug exposed to the solvent when formulated as an interactive mixture. The
increase in effective surface area was caused by a decrease in agglomerate particle size
by break down of the agglomerates upon impaction with the carrier particles during
mixing. Based on dissolution rate enhancement of amorphous CFA following
formulation as an interactive mixture, this work was extended to include preparation of
interactive mixtures of crystalline forms of CFA.
As amorphous CFA is prone to solvent-mediated phase transformation to stable
crystalline forms during dissolution, milled particles Lot 3 crystals (diastereomer eutectic
mixture containing 75 % isomer B: 25 % isomer A) were formulated as interactive
mixtures with sucrose carrier particles. It was hypothesized that formation of interactive
mixtures of micronized particles of these more physically stable solid forms would
enhance the dissolution rate enough to compensate for their lower solubility relative to
amorphous CFA and avoid the problem of solvent-mediated phase transformation. This
particular diastereomer ratio containing 75 % isomer B and 25 % isomer A was chosen,
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as the ratio of NisomerB/NisomerA in this mixture is close to the critical mixture ratio of 2.44
which shows the highest dissolution rate (Figure 3.9, Chapter 3). Figure 4.21 is the
cumulative amount dissolved vs. time plot for milled Lot 3 crystals and various mixtures
prepared using the same. The dissolution profile for amorphous CFA-sucrose interactive
mixture is also shown in Figure 4.21, as it was the mixture that showed the highest
dissolution rate (Figure 4.14) and is used as a comparison profile. The similarity factor
(f2) values of the mixtures formulated with Lot 3 crystals (milled) and amorphous CFAsucrose interactive mixture are shown in Table 4.7. The dissolution profiles of Lot 3
crystals (milled)-sucrose interactive mixture was significantly different from the
interactive mixture containing amorphous CFA.
Table 4.8 shows the equations following application of the biexponential model
to amount remaining to dissolve vs time data for the Lot 3 crystals (milled) mixture
samples and the correlation coefficients of the model fitting. The correlation coefficients
are greater than 0.991 indicating that the biexponential model fit the dissolution data.
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Figure 4.21. Representative cumulative percent dissolved versus time profiles for Lot 3 crystals
(milled), interactive and physical mixtures, thereof, prepared with sucrose (500–1000 µm) carrier
particles. The dissolution profile of amorphous CFA-sucrose interactive mixture is shown for
comparison.
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Table 4.7. Similarity factor (f2) values for mixture samples.
Comparison

f2 statistic value*

Inference

Amorphous CFA-sucrose
interactive mixture and Lot 3

70.91

Dissolution profiles are similar

58.45

Dissolution profiles are similar

crystals (milled)
Amorphous CFA-sucrose
interactive mixture and Lot 3
crystals (milled)-sucrose
physical mixture
Amorphous CFA-sucrose
interactive mixture and Lot 3
crystals (milled)-sucrose

19.98

Dissolution profiles are not
similar

interactive mixture

*f2 value calculated using Equation 4.9 (Section 4.2.7). f2 values between 50–100 indicate
similarity between dissolution profiles.116
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Table 4.8. Biexponential model fit to amount remaining to dissolve vs time data for Lot 3
crystals (milled) samples.

Sample

Biexponential model equation*

Lot 3 crystals (milled)

Lot 3 crystals (milled)-sucrose

Correlation
coefficient (R2)

76.12e-0.016t+16.99e-0.322t

0.992

78.37e-0.015t+16.66e-0.322t

0.995

79.22e-0.012t+15.40e-0.319t

0.994

76.23e-0.017t+15.71e-0.336t

0.994

77.38e-0.016t+13.10e-0.324t

0.992

75.29e-0.016t+15.99e-0.311t

0.995

61.12e-0.053t+28.25e-0.311t

0.991

62.44e-0.052t+30.49e-0.328t

0.998

60.23e-0.054t+31.55e-0.321t

0.997

physical mixture

Lot 3 crystals (milled)-sucrose
interactive mixture

*Biexponential model is of the form Wae-kat+Wde-kdt

The initial weights of agglomerated and dispersed particles, Wa and Wd were
determined which enabled calculation of the weight-fraction of agglomerated particles
represented by Wa

Wa  Wd

for each mixture sample prepared with milled Lot 3 crystals.

Results for the weight–fraction of agglomerated particles are shown in Figure 4.22. Twoway ANOVA with Tukey’s multiple comparison tests was used to evaluate statistical
significance between the mixtures. The weight-fraction of agglomerated particles was
significantly lower for the interactive mixture prepared with either coating material, that
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is, amorphous CFA or Lot 3 crystals (milled) as compared to pure drug and physical
mixtures. These data indicate that interactive mixing with sucrose carrier was able to
effectively break down agglomerated particles of amorphous CFA or Lot 3 crystals.
However the weight-fraction of agglomerated particles in amorphous CFA-sucrose
interactive mixtures was significantly lower as compared to that in interactive mixtures
containing Lot 3 crystals. The increased deagglomeration tendency of amorphous
agglomerates as compared to crystalline agglomerates may be related to the packing
nature of the amorphous particles which may have formed a more porous agglomerate
structure as compared to crystalline particles. There was no significant difference in the
weight-fraction of agglomerated particles in Lot 3 crystals (milled) and physical mixture
prepared with the same, indicating that low-intensity physical mixing was not able to
effectively break up drug agglomerates.
The effective surface area of the agglomerated and dispersed particles, Sa and Sd,
were calculated from Equation 4.3 and Equation 4.4, respectively. Figure 4.23 shows
the sum of the Sa and Sd term for the amorphous CFA-sucrose interactive mixture, Lot 3
crystals (milled), interactive and physical mixtures of Lot 3 crystals (milled). The sum of
the effective surface area of the agglomerated and dispersed particles from all samples
containing Lot 3 crystals (milled) were significantly higher than those formulated with
amorphous CFA. The effective surface area of the drug from interactive mixtures of Lot
3 crystals was significantly higher compared to that of Lot 3 crystals (milled) and the
physical mixture. The effective surface area of the drug particles from the interactive
mixture containing Lot 3 crystals (milled) was 239 (±14) cm2 and was significantly
higher as compared to 118 (±8.10) cm2 and 113 (±11) cm2 for Lot 3 crystals (milled) and
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physical mixture, respectively. The higher effective surface of the drug from interactive
mixtures containing milled crystalline particles as compared to those containing
amorphous CFA resulted in their faster dissolution rate (Figure 4.21).

Figure 4.22. Comparison of weight-fraction of agglomerated particles for amorphous CFAsucrose interactive mixture, Lot 3 crystals (milled) and interactive and physical mixtures, thereof,
prepared with sucrose carrier particles based on modeling of dissolution data (Equation 1.45). *
# ** represents statistical significant comparisons. Each data point represents the average of n=3
replicates, where the error bars are the standard deviation (SD).
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Figure 4.23. Comparison of the effective surface areas of agglomerated particles and dispersed
particles, for amorphous CFA-sucrose interactive mixture, Lot 3 crystals (milled) and interactive
and physical mixtures, thereof, prepared with sucrose carrier particles. Values calculated using
Equation 4.3 and Equation 4.4. * # ** represents statistical significant comparisons. Each data
point represents the average of n=3 replicates, where the error bars are the standard deviation
(SD).

The sum of the effective surface areas of the agglomerated and dispersed
particles, calculated using Equation 4.3 and Equation 4.4 for the various samples were
calculated as a fraction of the theoretical maximum surface area available for dissolution.
The theoretical maximum surface area for each sample was calculated from knowledge of
the specific surface area (SSA) of Lot 3 crystals (milled) measured by nitrogen vapor
adsorption (Table 4.1) and the amount of drug used in the dissolution experiment. The
values of the percent total surface area of the different samples are given in Table 4.9.
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Table 4.9. Percent total surface area Lot 3 crystals (milled) and mixture samples based on
dissolution data. Theoretical maximum surface area determined using nitrogen vapor adsorption
analysis. Values represent average (±SD) of n=3 replicates for each sample.

Sample

% Total surface area

Lot 3 crystals (milled)

14.2 (±1.06)

Lot 3 crystals (milled)-sucrose physical

14.0 (±1.15)

mixture
Lot 3 crystals (milled)-sucrose interactive

29.7 (±0.124)* #

mixture

*# represents statistical significant comparisons; *vs Lot 3 crystals (milled) and #vs physical
mixture.

Based on Figure 4.23 and Table 4.9, it was concluded that interactive mixing
resulted in availability of a larger fraction of the total surface area of the drug particles for
dissolution. The effective surface area of the drug from milled Lot 3 crystal samples was
higher than that of drug from amorphous CFA-sucrose interactive mixtures. Interactive
mixing of milled crystalline particles with sucrose carrier further contributed to the
effective surface area increase and dissolution rate enhancement.
The parameter related to particle size of the agglomerated and dispersed particles
was calculated for Lot 3 crystal (milled) samples and compared to that obtained for
amorphous CFA-sucrose interactive mixture. Figure 4.24 shows the values for the
parameter related to agglomerate particle size (raρa) term. The raρa term was significantly
lower for samples formulated with Lot 3 crystal (milled) as compared to those prepared
with amorphous CFA due to milling of crystalline material that caused particle size
reduction. The value for the raρa was 3.06 (±5.55×10-2) mg/cm2 for the interactive
mixtures prepared with Lot 3 crystals (milled) as compared to 11.5 (±1.84) mg/cm2 and
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9.99 (±0.288) mg/cm2 for the milled crystals and physical mixture, respectively. Similar
to the results of amorphous CFA mixtures discussed above and shown in Figure 4.17,
interactive mixing was able to cause size reduction of the agglomerated particles.

Figure 4.24. Comparison of parameter related to agglomerate particle size ( ra  a ) for amorphous
CFA-sucrose interactive mixture, Lot 3 crystals (milled) and interactive and physical mixtures,
thereof, prepared with sucrose carrier particles. Values calculated using Equation 4.7.
* # ** represents statistical significant comparisons. Each data point represents the average of
n=3 replicates, where the error bars are the standard deviation (SD).

The parameter related to particle size of dispersed particles, rdρd term was not
significantly different across the samples prepared using milled Lot 3 crystals (Figure
4.25) indicating that interactive mixing did not appear to significantly affect the size of
the dispersed particles. This indicates that there is no milling or particle size reduction of
the drug during mixing. In contrast, the rdρd term for the samples made with Lot 3
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crystals was significantly lower than that for amorphous CFA-sucrose interactive
mixtures. For example, the rdρd term for Lot 3 crystals (milled)-sucrose interactive
mixture was 0.505 (±1.35×10-2) mg/cm2 and that of amorphous CFA-sucrose interactive
mixture was 5.70 (±0.143) mg/cm2. Therefore milling of crystalline particles caused a
decrease in primary particle size and an increase in effective surface area which was able
to compensate for the lower solubility of the crystalline form relative to amorphous CFA.
The radius of milled particles of Lot 3 crystals was calculated from the SSA value
using vapor adsorption analysis and was found to be 2.36 μm representing the size of the
dispersed particles. The radius of the agglomerated and dispersed particles in Lot 3
crystals (milled)-sucrose interactive mixtures was calculated by Equation 4.7 and
Equation 4.8, respectively. The values were found to be 21.25 (±0.39) μm and 3.50
(±0.09) μm, respectively. There was good accordance between the size of the dispersed
particles by vapor adsorption analysis and modeling.
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Figure 4.25. Comparison of parameter related to dispersed particle size ( rd  d ) for amorphous
CFA-sucrose interactive mixture, Lot 3 crystals (milled) and interactive and physical mixtures,
thereof, prepared with sucrose carrier particles. Values calculated using Equation 4.8.*
represents statistical significant comparisons. Each data point represents the average of n=3
replicates, where the error bars are the standard deviation (SD).

4.4 Conclusion
The dissolution rate of CFA was dramatically improved through the use of
interactive mixtures. The mechanism underlying the improvement in dissolution rate
upon interactive mixing was investigated by application of a dissolution model relevant
to heterogeneous particle distributions. It was demonstrated that the improvement was
due a lower weight-fraction of agglomerated particles in the interactive mixtures as
compared to physical mixtures and the pure drug itself. This further increased availability
of the drug’s surface area to the dissolution medium. Interactive mixtures had larger
effective surface areas because the drug agglomerates had been broken down to dispersed
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drug particles and agglomerate size had been reduced. This effect could not be achieved
with simple physical mixing. Modeling enabled development of a relationship between
the rate constants describing surface area change of the agglomerated and dispersed
particles and a parameter related to particle size. It was concluded that interactive mixing
did not affect the particle size of dispersed drug particles but decreased the size and
number of the agglomerated particles making a larger surface area accessible to the
solvent for dissolution.
Interactive mixtures were formulated with milled particles of Lot 3 crystals in
order to avoid phase transformation during dissolution which was observed with
amorphous CFA. Interactive mixtures formulated with Lot 3 crystals (75 % wt. isomer B)
exhibited a higher dissolution rate as compared to that made with amorphous drug.
Milling of the crystalline particles to increase surface area compensated for the lower
solubility of the crystalline form relative to amorphous CFA. As a result, interactive
mixing may allow the crystalline material to be used as an alternative to the metastable
amorphous solid, which was shown to undergo solvent-mediated conversion during
dissolution.
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Chapter 5: Summary
Solid-state and solubility studies on the diastereomers of cefuroxime axetil (CFA)
helped to understand their behavior relevant to pharmaceutical processing and
dissolution. Thermal analysis utilizing differential scanning calorimetry (DSC) enabled
construction of a temperature-composition diagram of various compositions of the
diastereomers, namely, isomer A and isomer B of CFA. The diastereomers were found to
form a eutectic mixture with a composition of 75 % isomer B and melting point of 124.8
±0.5 °C. As properties of the drug can vary depending upon the solid phase, construction
of the phase diagram was important in identifying the eutectic composition. This
information is important for CFA as it is present in commercial preparations in form of a
diastereomer mixture and eutectic formation is likely to occur during solid processing
when diastereomer crystals are brought into intimate contact.
Phase solubility studies on diastereomer mixtures revealed that the
diastereomers form a soluble complex. These results were further confirmed by intrinsic
dissolution rate (IDR) measurements on diastereomer mixtures of various compositions.
The results of the IDR studies were in good agreement with the Higuchi dissolution
model for binary mixtures of interacting components. As a result it was concluded that
the diastereomers interact or complex in solution, which results in a higher solubility than
would be predicted by the behavior of the individual diastereomer. Furthermore, this
means the solubility of CFA is depends upon the diastereomer composition in a nontrivial
way. Given that CFA suffers from dissolution rate limitations, an optimum diastereomer
ratio (71 % isomer B: 29 % isomer A) has been identified that can maximize the drug’s
poor solubility.
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In this project, interactive mixtures of commercially available amorphous CFA
and milled particles of the diastereomer eutectic mixture (75 % isomer B) were prepared
with sucrose carrier particles. Interactive mixtures exhibited a marked improvement in
dissolution rate when compared with both the physical mixtures and the pure drug. The
mechanism of dissolution rate enhancement following interactive mixing was attributed
to a decreased fraction of agglomerated drug particles and smaller sized agglomerates
leading to an increase in the surface area available for dissolution. Milling of crystalline
drug and subsequent formulation of the milled particles as interactive mixtures was able
to result in an increase in effective surface area and compensate for the poor solubility of
the crystalline forms relative to the amorphous drug. Formulation of crystalline form of
CFA is a significant advantage as compared to use of amorphous CFA which undergoes a
solvent-mediated conversion to more stable crystalline forms. It is possible this strategy
of interactive mixing can be extended to other drugs that exhibit dissolution rate-limited
bioavailability and for which maximum dissolution is critical.
The major factor that limits the widespread us of interactive mixtures is the drug
dose that can be incorporated into the formulation. Drug loading is dictated by the
amount of carrier surface available for interaction. The carrier-to-drug ratio in interactive
mixture formulations ranges from 5:1 to 10 such that for high dose drugs such as CFA,
large amounts of carrier are necessary to avoid formation of multiple drug layers that can
impede drug dissolution. This in turn leads to administration of impractical amounts of
formulation to deliver the required drug dose. Despite this problem, if the dissolution rate
can be improved upon formulation of interactive mixtures, the necessity to deliver large
drug doses to produce an equivalent oral bioavailability may be avoided. Another
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important factor that needs consideration is the effect that added excipients may have on
the stability of drug-carrier interactive mixtures. In one study, addition of magnesium
stearate resulted in segregation of aspirin-lactose mixtures. Alteration of electrostatic
attraction between the drug and carrier caused drug displacement from the carrier
surface.122 Therefore the effect of excipient such as surfactants, lubricants and
disintegrants that are commonly added to solid dosage forms requires assessment when
considering formulation of interactive mixtures in tablet or capsule dosage forms.
Despite the problems associated with interactive mixture formulation, it is a
suitable option for dissolution rate enhancement of CFA. Thermal degradation of CFA
can limit the feasibility of developing a solid dispersion formulation and the lack of
ionizable functional groups on the CFA molecule precludes the possibility of developing
a salt form. Therefore further development of a binary drug-carrier interactive mixture
with excipients such as surfactants and disintegrants which can aid in dissolution rate
enhancement is a viable formulation approach to improve the dissolution rate of CFA.

147

Bibliography
1. Li ZJ, Grant DJW. 1997. Relationship between physical properties and crystal
structures of chiral drugs. Journal of Pharmaceutical Sciences. 86(10): 1073-1078.
2. Herman C, Haut B, Aerts L, Leyssens T. 2012. Solid-liquid phase diagrams for the
determination of the solid state nature of both polymorphs of (RS)-2-(2-oxopyrrolidin-1yl)-butyramide. International Journal of Pharmaceutics. 437: 156-161.
3. Carey FA. 2000. Organic Chemistry, 4th edition, Boston (MA): McGraw-Hill.
4. Hutt AJ, O’Grady J. 1996. Drug chirality: a consideration of the significance of the
stereochemistry of antimicrobial agents. Journal of Antimicrobial Chemotherapy. 37: 732.
5. Gu C, Grant DJW. 2004. Effects of crystal structure and physical properties on the
release of chiral drugs. In: Chirality in Drug Design and Development. New York (NY):
Marcel-Dekker, Inc. p 1-33.
6. Brittain HG. 1990. Crystallographic consequences of molecular dissymmetry.
Pharmaceutical Research. 7(7): 683-690.
7. Sanster J. 1999. Phase diagram and thermodynamic properties of binary systems of
drugs. Journal of Physical Chemistry Reference Data. 28(4): 889-930.
8. Li ZJ, Zell MT, Munson EJ, Grant DJW. 1999. Characterization of racemic species of
chiral drugs using thermal analysis, thermodynamic calculation, and structural studies.
Journal of Pharmaceutical Sciences. 88(3): 337-346.
9. Bi M, Hwang S-J, Morris KR. 2003. Mechanism of eutectic formation upon
compaction and its effects on tablet properties. Thermochimica Acta. 404: 213-226.
10. Higuchi T, Connors KA. 1965. Phase-solubility techniques. In: Advances in
Analytical Chemistry and Instrumentation. Volume 4. New York (NY): WileyInterscience. p. 117-212. Copyright 1965 by John Wiley & Sons, Inc.
11. Higuchi WI, Mir NA, Desai. SJ 1965. Dissolution rates of polyphase mixtures.
Journal of Pharmaceutical Sciences. 54: 1405-1410.
12. Shah SA, Parrott EL. 1976. Dissolution of Two-Component Solids. Journal of
Pharmaceutical Sciences. 65(12): 1784-1790.
13. Brouwers J, Brewster ME, Augustijns P. 2009. Supersaturating drug delivery
systems: the answer to solubility-limited oral bioavailability? Journal of Pharmaceutical
Sciences. 98: 2549-2572.
14. Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S. 2011. Formulation design
for poorly water-soluble drugs based on biopharmaceutics classification system: basic
approaches and practical applications. International Journal of Pharmaceutics. 420: 1-10.
15. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 2001. Experimental and
computational approaches to estimate solubility and permeability in drug discovery and
development settings. Advanced Drug Delivery Reviews. 46: 3-26.
16. Kesisoglou K, Panmai S, Wu Y. 2007. Nanosizing-oral formulation development and
biopharmaceutical evaluation. Advanced Drug Delivery Reviews 59: 631-644.
17. Takagi T, Ramachandran C, Bermejo M, Yamashita S, Yu LX, Amidon GL. 2006. A
provisional biopharmaceutical classification of the top 200 oral drug products in the
United States, Great Britain, Spain, and Japan. Molecular Pharmaceutics 3: 631-643.

148

18. Horter D, Dressman JB. 2001. Influence of physicochemical properties on dissolution
of drugs in the gastrointestinal tract. Advanced Drug Delivery Reviews. 46: 75-87.
19. Yu L. 2001. Amorphous pharmaceutical solids: preparation, characterization and
stabilization. Advanced Drug Delivery Reviews. 48: 27-42.
20. Takano R, Furumoto K, Shiraki K, Takata N, Hayashi Y, Aso Y, Yamashita S. 2008.
Rate-limiting steps of oral absorption for poorly water-soluble drugs in dogs; prediction
from a miniscale dissolution test and a physiologically-based computer simulation.
Pharmaceutical Research. 25: 2334-2344.
21. Butler JM, Dressman JB. 2010. The developability classification system: application
of biopharmaceutics concepts to formulation development. Journal of Pharmaceutical
Sciences. 99: 4940-4953.
22. Noyes A, Whitney W. 1897. The rate of solution of solid substances in their own
solutions. Journal of American Chemical Society. 19: 930-934.
23. Dokoumetzidis A, Macheras P. 2006. A century of dissolution research: from NoyesWhitney to the biopharmaceutics classification system. International Journal of
Pharmaceutics. 321: 1-11.
24. Leuner C, Dressman J. 2000. Improving drug solubility for oral delivery using solid
dispersions. European Journal of Pharmaceutics and Biopharmaceutics. 50: 47-60.
25. Bladgen N, de Matas M, Gavan PT, York P. 2007. Crystal engineering of active
pharmaceutical ingredients to improve solubility and dissolution rates. Advanced Drug
Delivery Reviews. 59: 617-630.
26. Pudipeddi M, Serajuddin ATM. 2005. Trends in solubility of polymorphs. Journal of
Pharmaceutical Sciences. 94: 929-939.
27. Hancock BC, Parks M. 2000. What is the true solubility advantage for amorphous
pharmaceuticals? Pharmaceutical Research. 17: 397-404.
28. Vasconcelos T, Sarmento B, Costa P 2007. Solid dispersions as strategy to improve
oral bioavailability of poor water soluble drugs. Drug Discovery Today. 12: 1068-1075.
29. Serajuddin ATM. 1999. Solid dispersion of poorly water-soluble drugs: early
promises, subsequent problems, and recent breakthroughs. Journal of Pharmaceutical
Sciences. 88: 1058-1066.
30. Kushida I, Ichikawa M, Asakawa N. 2002. Improvement of dissolution and oral
absorption of ER-34122, a poorly water-soluble dual 5-lipooxygenase/cyclooxygenase
inhibitor with anti-inflammatory activity by preparing solid dispersion Journal of
Pharmaceutical Sciences. 91: 258-266.
31. Serajuddin ATM. 2007. Salt formation to improve drug solubility. Advanced Drug
Delivery Reviews. 59: 603-616.
32. Engel GL, Farid NA, Faul MM, Richardson LA, Winneroski LL. 2000. Salt form
selection and characterization of LY333531 mesylate monohydrate. International Journal
of Pharmaceutics. 198: 239-247.
33. Babu NJ, Nangia A. 2011. Solubility advantage of amorphous drugs and
pharmaceutical cocrystals. Crystal Growth and Design. 11: 2662-2679.
34. Stanton MK, Tufekcic S, Morgan C, Bak A. 2009. Drug substance and former
structure property relationships in 15 diverse pharmaceutical co-crystals. Crystal Growth
and Design. 9: 1344-1352.

149

35. Fleisher D, Bong R, Stewart BH. 1996. Improved oral drug delivery: solubility
limitations overcome by the use of prodrugs. Advanced Drug Delivery Reviews. 19: 115130.
36. Shah JC, Chen JR, Chow D. 1992. Oral bioavailability and in situ absorption of
etoposide in rat. International Journal of Pharmaceutics. 84: 223-232.
37. Doyle TW, Vyas DM. 1990. Second generation analogs of etoposide and mitomycin
C. Cancer Treatment Reviews. 17: 127-131.
38. Anderberg EK, Nystrom C, Bisrat M. 1988. Physicochemical aspects of drug release:
VII. The effect of surfactant concentration and drug particle size on solubility and
dissolution rate of felodipine, a sparingly soluble drug. International Journal of
Pharmaceutics. 47: 67-77.
39. Mosharraf M, Nystrom C. 1995. The effect of particle size and shape on the surface
specific dissolution rate of microsized practically insoluble drugs. International Journal of
Pharmaceutics. 122: 35-47.
40. Patravale VB, Date AA, Kulkarni RM. 2004. Nanosuspensions: a promising drug
delivery strategy. Journal of Pharmacy and Pharmacology. 56: 827-840.
41. Junghanns JAH, Muller RH. 2008. Nanocrystal technology, drug delivery and clinical
applications. International Journal of Nanomedicine. 3(3): 295-310.
42. Rasenack N, Muller BW. 2002. Dissolution rate enhancement by in situ
micronization of poorly water-soluble drugs. Pharmaceutical Research. 19: 1894-1900.
43. Muller RH, Peters K. 1998. Nanosuspensions for the formulation of poorly soluble
drugs I. preparation by a size-reduction technique. International Journal of
Pharmaceutics. 160: 229-237.
44. Keck CA, Muller RH. 2006. Drug nanocrystals of poorly soluble drugs produced by
high pressure homogenization. European Journal of Pharmaceutics and
Biopharmaceutics. 62: 3-16.
45. Wu W, Nancollas GH. 1999. Determination of interfacial tension from crystallization
and dissolution data: a comparison with other methods. Advances in Colloid and
Interface Science. 79: 229-279.
46. Descamps M, Willart JF, Dudognon E, Caron V. 2007. Transformation of
Pharmaceutical Compounds upon Millin and Comilling: The Role of Tg. Journal of
Pharmaceutical Sciences. 96(5): 1398-1407.
47. Nakach M, Authelin J-R, Chamayou A, Dodds J. 2004. Comparison of various
milling techniques for grinding pharmaceutical powders. International Journal of Mineral
Processing. 74S: S173-S181.
48. Van Eedenbrugh B, Van den Mooter G, Augustijns P. 2008. Top-down production of
drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into
solid products. International Journal of Pharmaceutics. 364: 64-75.
49. Merisko-Liversidge E, Liversidge GG, Cooper ER. 2003. Nanosizing: a formulation
approach for poorly-water-soluble compounds. European Journal of Pharmaceutical
Sciences. 18: 113-120.
50. Merisko-Liversidge E, Liversidge GG. 2011. Nanosizing for oral and parenteral drug
delivery: A perspective on formulating poorly-water soluble compounds using wet media
milling technology. Advanced Drug Delivery Reviews. 63: 427-440.

150

51. Keck CM, Muller RH. 2006. Drug nanocrystals of poorly soluble drugs produced by
high pressure homogenization. European Journal of Pharmaceutics and
Biopharmaceutics. 62: 3-16.
52. Muller RH, Gohla S, Keck CM. 2011. State of the art nanocrystals - Special features,
production, nanotoxicology aspects and intracellular delivery. European Journal of
Pharmaceutics and Biopharmaceutics. 78: 1-9.
53. D’Addio SM, Prud’homme RK. 2011. Controlling drug nanoparticle formation by
rapid precipitation. Advanced Drug Delivery Reviews. 63: 417-426.
54. Chan H-K, Kwok PCL. 2011. Production methods for nanodrug particles using the
bottom-up approach. Advanced Drug Delivery Reviews. 63: 406-416.
55. Pasquali I, Bettini R, Giordano F. 2006. Solid-state chemistry and particle
engineering with supercritical fluids in pharmaceutics. European Journal of
Pharmaceutical Sciences. 27: 299-310.
56. Vehring R. 2008. Pharmaceutical Particle Engineering via Spray Drying.
Pharmaceutical Research. 25(5): 999-1022.
57. Jinno J, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M, Toguchi H,
Liversidge GG, Higaki K, Kimura T. 2006. Effect of particle size reduction on
dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs.
Journal of Controlled Release. 111: 56-64.
58. Wu Y, Loper A, Landis E, Hettrick L, Novak L, Lynn K, Chen C, Thompson K,
Higgins R, Batra U, Shelukar S, Kwei G, Storey D. 2004. The role of biopharmaceutics
in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog
model predicts improved bioavailability and diminished food effect on absorption in
human. International Journal of Pharmaceutics. 285(1-2): 135-146.
59. Nystrom C, Westerberg M. 1986. The use of ordered mixtures for improving the
dissolution rate of low solubility compounds. Journal of Pharmacy and Pharmacology.
38: 161-165.
60. Seville J, Tuzun U, Clift R. 1997. Processing of particulate solids. London (UK):
Blackie Academic and Professional.
61. Alonso M, Alguacil FJ. 1999. Dry mixing and coating of powders. Revista de
Metalurgia (Madrid). 35: 315-328.
62. Massimilla L, Donsi G. 1976. Cohesive forces between particles of fluid-bed
catalysts. Powder Technology. 15: 253-260.
63. Israelachvili JN. 1991. Intermolecular and surface forces. 2nd edition. London (UK):
Academic.
64. Perrut M, Leboeuf JJF. 2005. Enhancement of dissolution rate of poorly-soluble
active ingredients by supercritical fluid processes, Part I: micronization of neat particles.
International Journal of Pharmaceutics. 288: 3-10.
65. Heng D, Cutler DJ, Chan H, Yun J, Raper JA. 2008. What is a suitable dissolution
method for drug nanopartices? Pharmaceutical Research. 25: 1696-1701.
66. de Villiers MM, Van der Watt JG. 1994. The measurement of mixture homogeneity
and dissolution to predict the degree of drug agglomerate breakdown achieved through
powder mixing. Pharmaceutical Research. 11: 1557-1561.
67. Pfeffer R, Dave RN, Wei D, Ramlakhan. M 2001.Synthesis of engineered particulates
with tailored properties using dry particle coating. Powder Technology. 117: 40-67.

151

68. Hersey JA. 1977. Preparation and properties of ordered mixtures. Australian Journal
of Pharmaceutical Sciences. 6: 29-31.
69. Hersey JA. 1975. Ordered mixing: a new concept in powder mixing practice. Powder
Technology.11: 41-44.
70. Egermann H. 1983.Ordered mixtures-interactive mixtures. Powder Technology. 36:
117-118.
71. Egermann H. 1980. Suggestions on the nomenclature of powder mixtures. Powder
Technology. 26: 235-237.
72. Yueng CC, Hersey JA. 1979. Criteria for ordered mixtures. Powder Technology. 24:
106-107.
73. Bannister P, Harnby N. 1983. A colorimetric technique for assessing the mixture
quality of fine particle mixtures. Powder Technology. 36: 275-279.
74. Ouabbas Y, Dodds J, Galet L, Chamayou A, Baron M. 2009. Particle-particle coating
in a cyclomix impact mixer. Powder Technology. 189: 245-252.
75. Saharan VA, Kukkur V, Kataria M, Kharb V, Choudhury PK. 2008. Ordered mixing:
mechanism, process and applications in pharmaceutical formulations. Asian Journal of
Pharmaceutical Sciences. 3(6): 240-259.
76. Watanabe H, Ghadiri M, Matsuyama T, Ding YL, Pitt KG, Maruyama H, Matsusaka
S, Masuda H. 2007. Triboelectrification of pharmaceutical powders by particle impact.
International Journal of Pharmaceutics. 334: 149-155.
77. Rowley G. 2001. Quantifying electrostatic interactions in pharmaceutical solid
systems. International Journal of Pharmaceutics. 227: 47-55.
78. Ouabbas Y, Dodds J, Galet L, Chamayou A, Baron M. 2009. Particle-particle coating
in a cyclomix impact mixer. Powder Technology. 189: 245-252.
79. Ramlakhan M, Wu CY, Watano S, Dave RN, Pfeffer R. 2000. Dry particle coating
using magnetically assisted impaction coating: modification of surface properties and
optimization of system and operating parameters. Powder Technology. 112: 137-148.
80. Staniforth JN. 1985. Ordered mixing or spontaneous granulation? Powder
Technology. 45: 72-81.
81. Podczeck F, Newton JM, James MB. 1997. Variations in the adhesion force between
a drug and carrier particles as a result of changes in the relative humidity of the air.
International Journal of Pharmaceutics. 149: 151-160.
82. Podczeck F, Newton JM, James MB. 1997. Influence of relative humidity of storage
air on the adhesion and autoadhesion of micronized particles to particulate and
compacted powder surfaces. Journal of Colloid and Interface Science. 187: 484-491.
83. Gauthier M, Regnier S, Rougeot P, Challiet N. 2006. Force analysis for
micromanipulations in dry and liquid media. Journal of Mechanometrics. 3-4: 389-413.
84. Nystrom C, Mazur J, Sjorgen J. 1982. Studies on the direct compression of tablets II.
The influence of the particle size of dry binder on the mechanical strength of tablets.
International Journal of Pharmaceutics. 10: 209-218.
85. Visser J. 1989. Van der Waals and other cohesive forces affecting powder
fluidization. Powder Technology. 58: 1-10.
86. Westerberg M, Nystrom C. 1993. Physicochemical aspects of drug release XVII. The
effect of drug surface area coverage to carrier materials on drug dissolution from ordered
mixtures. International Journal of Pharmaceutics. 90: 1-17.

152

87. Westerberg M, Jonsson B, Nystrom C. 1986. Physicochemical aspects of drug
release. IV. The effect of carrier particle properties on the dissolution rate from ordered
mixtures. International Journal of Pharmaceutics. 28: 23-31.
88. Ibrahim H, Sallam E, Takieddin M, Abu Shamat M. 1988. Dissolution characteristics
of interactive powder mixtures. Part one. Effect of solubility and particle size of
excipients. Drug Development and Industrial Pharmacy. 14: 1249-1276.
89. Nilsson P, Westerberg M, Nyström C. 1988. Physicochemical aspects of drug release.
V. The importance of surface coverage and compaction on drug dissolution from ordered
mixtures. International Journal of Pharmaceutics. 45: 111-121.
90. Westerberg M, Nyström C. 1991. Physicochemical aspects of drug release. XII. The
effect of some carrier particle properties and lubricant admixture on drug dissolution
from tableted ordered mixtures. International Journal of Pharmaceutics. 69: 129-141.
91. Ibrahim H, Sallam E, Takieddin M, Abu Shamat M. 1988. Dissolution characteristics
of interactive powder mixtures. Part one. Effect of solubility and particle size of
excipients. Drug Development and Industrial Pharmacy. 14: 1249-1276.
91. Liu J, Stewart PJ. 1998. Deaggregation during the dissolution of benzodiazepines in
interactive mixtures. Journal of Pharmaceutical Sciences. 87: 1632-1638.
92. Bolhuis GK, Zuurman K, te Wierik GHP. 1997. Improvement of dissolution of poorly
soluble drugs by solid deposition on a super disintegrant. II. The choice of super
disintegrants and effect of granulation. European Journal of Pharmaceutical Sciences.
5(2): 63-69.
93. Tay T, Allahham A, Morton DAV, Stewart PJ. 2011. Understanding improved
dissolution of indomethacin through the use of cohesive poorly water-soluble aluminium
hydroxide: effects of concentration and particle size distribution. Journal of
Pharmaceutical Sciences. 100: 4269-4280.
94. Tay T, Allahham A, Morton DAV, Stewart PJ. 2011. Counter-intuitive enhancement
in the dissolution of indomethacin with the incorporation of cohesive poorly watersoluble inorganic salt additives. European Journal of Pharmaceutics and
Biopharmaceutics. 79: 674-682.
95. Anderberg EK, Nystrom C. 1990. Physicochemical aspects of drug release X.
Investigation of the applicability of the cube root law for characterization of the
dissolution rate of fine particulate materials. International Journal of Pharmaceutics. 62:
143-151.
96. Wagner JG. 1969. Interpretation of percent dissolved-time plots derived from in vitro
testing of conventional tablets and capsules. Journal of Pharmaceutical Sciences. 58:
1253-1257.
96. Alway B, Sangchantra R, Stewart PJ. 1996. Modeling the dissolution of diazepam in
lactose interactive mixtures. International Journal of Pharmaceutics. 130: 213-224.
97. de Villiers MM, Lotter AP. 1993. Influence of surfactants and interactive mixing on
the cohesive properties of a poorly wettable solid. Powder Technology. 75: 159-165.
98. Zhao F-Y, Stewart PJ. 2004. Modeling the deagglomeration of micronized
benzodiazepines from powder mixtures added to dissolution media. Journal of
Pharmaceutical Sciences. 93: 1618-1627.
99. Zhao, F-Y, Stewart, PJ. 2003. De-agglomeration of micronized benzodiazepines in
dissolution media measured by laser diffraction particle sizing. Journal of Pharmacy and
Pharmacology. 55: 749-755.
153

99. Mosharraf M, Nystrom C. 1999. The effect of dry mixing on the apparent solubility
of hydrophobic, sparingly soluble drugs. European Journal of Pharmaceutical Sciences.
9: 145-156.
100. Stonajović Z, Marković S. 2012. Determinations of particle size distributions by
laser diffraction. Technics-New Materials. 21: 11-20.
101. Kees F, Lukassek U, Naber KG, Grobecker H. 1991. Comparative Investigation on
the Bioavailability of Cefuroxime Axetil. Drug Research. 41(11): 843-846.
102. Mosher GL, McBee J, Shaw DB. 1992. Esterase activity toward diastereomers of
cefuroxime axetil in the rat and dog. Pharmaceutical Research. 9(5): 687-689.
103. Oszczapowicz I, Malafiej E, Horoszewicz-Malafiej A, Szelachowska M, Kuklewicz
C, Sieranska E. 1995. Esters of cephalosporins. Part III. Separation and properties of the
R and S isomers of the 1-acetoxyethyl ester of cefuroxime. Acta Poloniae Pharmaceutica.
52(6): 471-476.
104. Park A, Chyall LJ, Byrn S. 2000. Characterization of cefuroxime axetil. Glaxo
Wellcome, SR-5597.01. West Lafayette (IN): SSCI Inc.
105. Ceftin® package insert. 2009. Research Triangle Park (NC): GlaxoSmithKline LLC.
106. Reprinted from European Journal of Pharmaceutics and Biopharmaceutics,
70(1), Dhumal RS, Biradar SV, Yamamura S, Paradkar AR, York P. Preparation of
amorphous cefuroxime axetil nanoparticles by sonoprecipitation for enhancement of
bioavailability, 109-115, (2008), with permission from Elsevier.
107. Kansal VK, Bhat SG, Marutikumar TV, Chava YA, Sankaran R. 2004 Apr 21. An
improved method for preparation of cefuroxime axetil. European patent EP 1 409 492
B1.
108. ICH Harmonised Tripartite Guideline, Validation of Analytical Procedures: Text
and Methodology 2(R1). 1994 Oct.
109. Intrinsic dissolution rate. Chapter <1087>. In: United States Pharmacopeia and
National Formulary. USP 29-NF 24. 30(6). Rockville (MD): United States
Pharmacopeial Convention. p. 2130.
110. Miller CC. 1924. The Stokes-Einstein law for diffusion in solution. Proceedings of
the Royal Society of London. Series A, Containing Papers of a Mathematical and
Physical Character. 106 (740): 724-749.
111. Kestin J, Sokolov M, Wakeham WA. 1978. Viscosity of liquid water in the range of
-8 °C to 150 °C. Journal of Physical Chemistry Reference Data. 7(3): 941-948.
112. Braun RJ, Parrott EL. 1972. Effect of various parameters upon diffusion-controlled
dissolution of benzoic acid. Journal of Pharmaceutical Sciences. 61(4): 592-597.
113. Particle size distribution estimation by analytical sieving. Chapter <786>. In: United
States Pharmacopeia and National Formulary. USP 29-NF 24. 30(6). Rockville (MD):
United States Pharmacopeial Convention. p. 2219.
114. FlowSorb II 2300 Operator’s Manual. Norcross (GA): Micromeritics Corporation.
115. Cefuroxime axetil tablets. 2006. In: United States Pharmacopeia and National
Formulary. USP 29-NF 24. Rockville (MD): Unired States Pharmacopeial Convention. p
442.
116. Shargel L, Wu-Pong S, Yu A. 2005. Applied Biopharmaceutics and
Pharmacokinetics. 5th ed. New York (NY): McGraw-Hill.

154

117. U.S. Department of Health and Human Services, Food and Drug Administration,
Center for Drug Evaluation and Research. 1997 Aug. Guidance for Industry: Dissolution
testing of immediate release solid oral dosage forms.
118. Graeser KA, Patterson JE, Zeitler JA, Gordon KC, Rades T. 2009. Correlating
thermodynamic and kinetic parameters with amorphous stability. European Journal of
Pharmaceutical Sciences. 37: 492-498.
119. Ruetzel-Edens SM, Kleemann RL, Lewellen PL, Borghese AL, Antoine LJ. 2003.
Crystal forms of LY334370 HCl: isolation, solid-state characterization, and
physicochemical properties. Journal of Pharmaceutical Sciences. 92(6): 1196-1205.
120. Sehic S, Betz G, Hadzidedic S, El-Arini SK, Leuenberger H. 2010. Investigation of
intrinsic dissolution behavior of different carbamazepine samples. International Journal
of Pharmaceutics. 386: 77-90.
121. Betigeri S, Thakur A, Shukla R, Raghavan K. 2008. Effect of polymer additives on
the transformation of BMS-566394 anhydrate to the dihydrate form. Pharmaceutical
Research. 25(5): 1043-1051.
122. Swaminathan V, Kildsig D. 2000. The effect of particle morphology on the physical
stability of pharmaceutical powder mixtures: the effect of surface roughness of the carrier
on the stability of ordered mixtures. Drug Development and Industrial Pharmacy. 26(4):
365-373.

155

Appendix: DSC Analyses of Diastereomer Mixtures
A.1. Sample Preparation
The samples for DSC analyses were prepared and analyzed as described in
Section 2.2.4 (Chapter 2).
A.2. Results
The following figures (Figure A.1–A.11) show the DSC thermograms obtained at
each heating rate: 1, 2 and 3 °C/min (n=1 replicate is shown at each heating rate) and plot
of peak melting temperature versus heating rate for diastereomer mixture samples
ranging in composition from 0 % to 85 % isomer B.
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Figure A.1. (a) DSC thermogram of Lot 1 crystals (form AI) at three heating rates: 1, 2 and 3 °C/min (b) Plot of peak melting temperature versus
heating rate. Values represent average of n=2 replicates at each heating rate and error bars are standard deviation.
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Figure A.2. (a) DSC thermogram of diastereomer mixture containing 10 % isomer B at three heating rates: 1, 2 and 3 °C/min (b) Plot of peak
melting temperature versus heating rate for eutectic endotherm (c) Plot of peak melting temperature versus heating rate for liquidus endotherm.
Values represent average of n=2 replicates at each heating rate and error bars are standard deviations.
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Figure A.3. (a) DSC thermogram of diastereomer mixture containing 20 % isomer B at three heating rates: 1, 2 and 3 °C/min (b) Plot of peak
melting temperature versus heating rate for eutectic endotherm (c) Plot of peak melting temperature versus heating rate for liquidus endotherm.
Values represent average of n=2 replicates at each heating rate and error bars are standard deviations.
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Figure A.4. (a) DSC thermogram of diastereomer mixture containing 30 % isomer B at three heating rates: 1, 2 and 3 °C/min (b) Plot of peak
melting temperature versus heating rate for eutectic endotherm (c) Plot of peak melting temperature versus heating rate for liquidus endotherm
Values represent average of n=2 replicates at each heating rate and error bars are standard deviations.
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Figure A.5. (a) DSC thermogram of diastereomer mixture containing 40 % isomer B at three heating rates: 1, 2 and 3 °C/min (b) Plot of peak
melting temperature versus heating rate for eutectic endotherm (c) Plot of peak melting temperature versus heating rate for liquidus endotherm
Values represent average of n=2 replicates at each heating rate and error bars are standard deviations.

162
Figure A.6. (a) DSC thermogram of diastereomer mixture containing 50 % isomer B at three heating rates: 1, 2 and 3 °C/min (b) Plot of peak
melting temperature versus heating rate for eutectic endotherm (c) Plot of peak melting temperature versus heating rate for liquidus endotherm
Values represent average of n=2 replicates at each heating rate and error bars are standard deviations.
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Figure A.7. (a) DSC thermogram of diastereomer mixture containing 60 % isomer B at three heating rates: 1, 2 and 3 °C/min (b) Plot of peak
melting temperature versus heating rate for eutectic endotherm (c) Plot of peak melting temperature versus heating rate for liquidus endotherm.
Values represent average of n=2 replicates at each heating rate and error bars are standard deviations.
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Figure A.8. (a) DSC thermogram of diastereomer mixture containing 70 % isomer B at three heating rates: 1, 2 and 3 °C/min (b) Plot of peak
melting temperature versus heating rate for eutectic endotherm (c) Plot of peak melting temperature versus heating rate for liquidus endotherm.
Values represent average of n=2 replicates at each heating rate and error bars are standard deviations.
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Figure A.9. (a) DSC thermogram of diastereomer mixture containing 75 % isomer B (b) Plot of peak melting temperature versus heating rate for
eutectic endotherm Values represent average of n=2 replicates at each heating rate and error bars are standard deviation.

166
Figure A.10. (a) DSC thermogram of diastereomer mixture containing 80 % isomer B at three heating rates: 1, 2 and 3 °C/min (b) Plot of peak
melting temperature versus heating rate for eutectic endotherm (c) Plot of peak melting temperature versus heating rate for liquidus endotherm.
Values represent average of n=2 replicates at each heating rate and error bars are standard deviations.
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Figure A.11 (a) DSC thermogram of diastereomer mixture containing 85 % isomer B at three heating rates: 1, 2 and 3 °C/min (b) Plot of peak
melting temperature versus heating rate for eutectic endotherm (c) Plot of peak melting temperature versus heating rate for liquidus endotherm.
Values represent average of n=2 replicates at each heating rate and error bars are standard deviations.

